The California Health Benefits Review Program (CHBRP) responds to requests from the State Legislature to provide independent analyses of the medical, financial, and public health impacts of proposed health insurance benefit mandates and proposed repeals of health insurance benefit mandates. In 2002, CHBRP was established to implement the provisions of Assembly Bill 1996 (California Health and Safety Code, Section 127660, et seq.) and was reauthorized by Senate Bill 1704 in 2006 (Chapter 684, Statutes of 2006). The statute defines a health insurance benefit mandate as a requirement that a health insurer or managed care health plan (1) permit covered individuals to obtain health care treatment or services from a particular type of health care provider; (2) offer or provide coverage for the screening, diagnosis, or treatment of a particular disease or condition; or (3) offer or provide coverage of a particular type of health care treatment or service, or of medical equipment, medical supplies, or drugs used in connection with a health care treatment or service.

A small analytic staff in the University of California’s Office of the President supports a task force of faculty from several campuses of the University of California, as well as Loma Linda University, the University of Southern California, and Stanford University, to complete each analysis within a 60-day period, usually before the Legislature begins formal consideration of a mandate bill. A certified, independent actuary helps estimate the financial impacts, and a strict conflict-of-interest policy ensures that the analyses are undertaken without financial or other interests that could bias the results. A National Advisory Council, drawn from experts from outside the state of California and designed to provide balanced representation among groups with an interest in health insurance benefit mandates, reviews draft studies to ensure their quality before they are transmitted to the Legislature. Each report summarizes scientific evidence relevant to the proposed mandate, or proposed mandate repeal, but does not make recommendations, deferring policy decision making to the Legislature. The State funds this work through a small annual assessment on health plans and insurers in California. All CHBRP reports and information about current requests from the California Legislature are available at the CHBRP Web site, www.chbrp.org.
A Report to the 2009-2010 California State Legislature

Analysis of Assembly Bill 98:
Maternity Services

March 16, 2009

California Health Benefits Review Program
1111 Franklin Street, 11th Floor
Oakland, CA 94607
Tel: 510-287-3876
Fax: 510-763-4253
www.chbrp.org

Additional free copies of this and other CHBRP bill analyses and publications may be obtained by visiting the CHBRP Web site at www.chbrp.org.

Suggested Citation:
PREFACE

This report provides an analysis of the medical, financial, and public health impacts of Assembly Bill 98, which would require health insurance products regulated under the California Department of Insurance to cover maternity services. The bill defines “maternity services” to include prenatal care, ambulatory care maternity services, involuntary complications of pregnancy, neonatal care, and inpatient hospital maternity care including labor and delivery and postpartum care. In response to a request from the California Assembly Committee on Health on January 15, 2009, the California Health Benefits Review Program (CHBRP) undertook this analysis pursuant to the provisions of Senate Bill 1704 (Chapter 684, Statutes of 2006) as charted in Section 127600, et seq. of the California Health and Safety Code.

Edward Yelin, PhD, Janet Coffman, MPP, PhD, and Wade Aubry, MD, all of the University of California, San Francisco, prepared the medical effectiveness analysis section. Min-Lin Fang, MLIS, of the University of California, San Francisco, conducted the literature search. Aaron B. Caughey, MD, PhD, of the University of California, San Francisco, and Alina Salganicoff, PhD, of the Henry J. Kaiser Family Foundation, provided technical assistance with the literature review and expert input on the analytic approach. Helen Halpin, ScM, PhD, and Sara McMenamin, MPH, PhD, of the University of California, Berkeley, prepared the public health impact analysis and related portions of the Introduction. Susan Ettner, PhD, and Gerald Kominski, PhD, of the University of California, Los Angeles, prepared the cost impact analysis. Robert Cosway, FSA, MAAA, of Milliman, provided actuarial analysis. Susan Philip, MPP, of CHBRP staff prepared the background section and synthesized the individual sections into a single report. Sarah Ordódy, BA, provided editing services. A subcommittee of CHBRP’s National Advisory Council (see final pages of this report) and a member of the CHBRP Faculty Task Force, Sheldon Greenfield of the University of California, Irvine, reviewed the analysis for its accuracy, completeness, clarity, and responsiveness to the Legislature’s request.

CHBRP gratefully acknowledges all of these contributions but assumes full responsibility for all of the report and its contents. Please direct any questions concerning this report to:

California Health Benefits Review Program
1111 Franklin Street, 11th Floor
Oakland, CA 94607
Tel: 510-287-3876
Fax: 510-763-4253
www.chbrp.org

All CHBRP bill analyses and other publications are available on the CHBRP Web site, www.chbrp.org.

Susan Philip, MPP
Director
# TABLE OF CONTENTS

LIST OF TABLES .......................................................................................................................... 4

EXECUTIVE SUMMARY ............................................................................................................. 5

INTRODUCTION ........................................................................................................................ 14
  Background of Disease or Condition ................................................................. 14
  Background of AB 98 ......................................................................................... 15

MEDICAL EFFECTIVENESS .................................................................................................... 20
  Literature Review Methods ........................................................................... 20
  Outcomes Assessed .......................................................................................... 21
  Study Findings ..................................................................................................... 22

UTILIZATION, COST, AND COVERAGE IMPACTS ............................................................. 40
  Present Baseline Cost and Coverage ................................................................. 40
  Impacts of Mandated Coverage ......................................................................... 45

PUBLIC HEALTH IMPACTS ..................................................................................................... 54
  The Impact of the Proposed Mandate on the Health of the Community .......... 54
  The Impact on the Health of the Community Where Gender and Racial Disparities Exist ... 56
  The Extent to Which the Proposed Service Reduces Premature Death and the Economic Loss Associated with Disease ................................................................. 57
  Long-Term Public Health Impacts ....................................................................... 58

APPENDICES .............................................................................................................................. 59
  Appendix A: Text of Bill Analyzed ................................................................. 59
  Appendix B: Literature Review Methods ............................................................. 61
  Appendix C: Summary of Studies on Medical Effectiveness of Prenatal Care Services ................................................................. 65
  Appendix D: Cost Impact Analysis: Data Sources, Caveats, and Assumptions ........ 86
  Appendix E: Information Submitted by Outside Parties ......................................... 91

REFERENCES ............................................................................................................................. 92
### LIST OF TABLES

**Table 1.** Summary of Coverage, Utilization, and Cost Impacts of AB 98..........................12

**Table 2.** Medically Effective Prenatal Care Services.................................................................33

**Table 3.** Percentage of Members Enrolled in Individual CDI-Regulated Policies with Maternity Coverage .................................................................41

**Table 4.** Baseline (Pre-mandate) Per Member Per Month Premium and Expenditures by Insurance Plan Type, California, 2008 .................................................................51

**Table 5.** Post-mandate Impacts on Per Member Per Month and Total Expenditures by Insurance Plan Type, California, 2008 .................................................................52

**Table 6.** Estimated Impact on Individual Premiums .................................................................53

**Table 7.** Upper Bound Estimates of Public Health Impacts of AB 98.................................55

**Table 8.** Births in California by Race/Ethnicity of Mother, 2006 ........................................56

**Table 9.** Births Characteristics in California by Race/Ethnicity of Mother, 2006 .............57

**Table C-1.** Studies that Examined the Effectiveness of Different Numbers of Prenatal Visits...65

**Table C-2.** Summary of Findings from Studies of the Effectiveness of Prenatal Care Services ..................................................................................................................73
EXECUTIVE SUMMARY

California Health Benefits Review Program Analysis of Assembly Bill 98: Maternity Services

The California Health Benefits Review Program (CHBRP) undertook the analysis of Assembly Bill (AB) 98 in response to a request from the California Assembly Committee on Health on January 15, 2009, pursuant to the provisions of Senate Bill 1704 (Chapter 684, Statutes of 2006) as chaptered in Section 127600, et seq. of the California Health and Safety Code. This report provides an analysis of the medical, financial, and public health impacts of AB 98.

AB 98, introduced by Assembly Member Hector De La Torre, would require health insurance products regulated under the California Department of Insurance (CDI) to cover maternity services. AB 98 defines maternity services to include prenatal care, ambulatory care maternity services, involuntary complications of pregnancy, neonatal care, and inpatient hospital maternity care including labor and delivery and postpartum care. AB 98 is similar to legislation introduced in prior sessions: AB 1962 (2008), Senate Bill (SB) 1555 (2004), and SB 897 (2003). Both AB 1962 and SB 1555 passed the Legislature during their respective sessions and were vetoed by the Governor.

AB 98 would apply only to CDI-regulated policies (mostly including preferred provider organizations) and represent approximately 13.7% of the privately insured market in California. Health care service plans (including health maintenance organizations, point-of-service plans, and some preferred provider organizations), which are regulated by the Department of Managed Health Care (DMHC), make up the remaining portion of the privately insured market. However, although DMHC-regulated plans make up the majority of the privately insured market (which contains both the group and individual market segments), CDI-regulated policies represent a substantial portion of the individual market—about 51.8%.

Current laws and regulations governing DMHC-regulated health care service plans require coverage for maternity services under provisions related to “basic health care services.” DMHC-regulated plans are required to cover maternity and pregnancy-related care under laws governing emergency and urgent care. Regulations defining basic health care services specifically include prenatal care as preventive care that must be covered. CDI-regulated plans currently have no such requirements.

The Federal Civil Rights Act requires employers that offer health insurance and have 15 or more employees to cover maternity services benefits at the same level as other health care benefits. Complications of pregnancy are generally covered regardless of whether the health insurance

---

1 AB 98 would add Section 10123.865 to the California Insurance Code.
2 The legislative history of AB 1962, SB 1555, and SB 897 are available at www.leginfo.ca.gov. CHBRP conducted analyses of these bills and those reports are available at www.chbrp.org/analyses/html.
3 Section 1317.1 of the California Health and Safety Code
4 Section 1300.67 of the California Code of Regulations, Title 28
5 The Pregnancy Discrimination Act under Title VII of the Civil Rights Act of 1964
policy provides coverage for maternity benefits. Insurers are also required to cover newborns for the first 30 days of life regardless of whether the health insurance policy covers maternity services.  

The bill’s definition of maternity services is generally consistent with the definitions of maternity services under health insurance: prenatal care (such as office visits and screening tests), labor and delivery services (including hospitalization), care resulting from complications related to a pregnancy; and postpartum/postnatal care.

In 2006, the birth rate in California was 71.3 births per 1,000 women of childbearing age, or more than 562,000 births (CDPH, 2009). The majority (85.9%) of births were to mothers who initiated prenatal care in the first trimester, with only 0.6% of women receiving no prenatal care (CDPH, 2009). Overall in California, there are approximately 75 maternal pregnancy-related deaths and 3,000 infant deaths per year (CDPH, 2007; MOD 2003-2005). Infant mortality is most frequently caused by birth defects (23.5% of deaths), followed by prematurity and low birth weight (15.6% of deaths), maternal complications of pregnancy (6.0% of deaths), and SIDS (5.2% of deaths) (CDPH, 2005). As will be discussed in further detail in the Medical Effectiveness section, specific prenatal care services can be effective in reducing the rate of preterm births, low–birth weight babies, transmission of infectious diseases, and other related infant and maternal morbidity and mortality.

The Medical Effectiveness and Public Health Impacts sections of this report focus on the outcomes associated with prenatal care services because: (1) a majority of births occur in the hospital setting regardless of insurance status, (2) prenatal care services use would be most affected by the potential for out-of-pocket costs and thus most directly impacted by AB 98, (3) AB 98 would not affect coverage for infants, and (4) plans and policies that do not cover maternity services cover complications related to a pregnancy. The Utilization, Cost, and Coverage Impact analysis includes the full range of services that are considered to be “maternity services.”

**Medical Effectiveness**

Studies of prenatal care can be divided into two major groups:

- Studies of the impact of variation in the number of prenatal care visits that pregnant women receive; and

- Studies of the effectiveness of specific medical services provided to pregnant women (e.g., laboratory tests, medications, etc.).

Randomized controlled trials (RCTs) have consistently found no statistically significant association between the numbers of prenatal visits pregnant women receive and birth outcomes for either infants or mothers.

---

However, there is clear and convincing evidence from multiple RCTs that the following prenatal care services are effective in producing better birth outcomes for mothers and infants:

- Smoking cessation counseling
- Ultrasound to identify structural abnormalities and determine gestational age
- Folic acid to prevent neural tube defects
- Screening and treatment for asymptomatic bacteriuria
- Screening for hepatitis B
- Screening and treatment for human immunodeficiency virus
- Calcium supplements, aspirin, and anti-convulsants for treatment of hypertensive disorders
- Screening and prophylactic and therapeutic treatment for Rh(D) incompatibility
- Progestational agents to prevent preterm delivery
- Corticosteroids to promote maturation of lungs in fetuses scheduled for preterm delivery due to preeclampsia or other complications
- Magnesium sulfate to prevent neurological impairment in fetuses at risk for preterm delivery
- External cephalic version for breech presentation at term
- Membrane sweeping and induction of labor for prevention of postterm pregnancies

In addition, there is a preponderance of evidence from nonrandomized studies and/or a small number of RCTs that the following prenatal care services are effective:

- Screening for domestic violence
- Screening for Down syndrome, hemoglobinopathies, and Tay-Sachs disease
- Screening and treatment for chlamydia, gonorrhea, and syphilis
- Screening for group B streptococcus
- Screening and treatment for gestational diabetes
- Iron supplements for treatment of iron deficiency anemia
- Blood pressure monitoring for hypertensive disorders
- Screening for atypical red blood cell alloantibodies other than Rh(D) incompatibility
- Ultrasound to diagnose placenta previa
Utilization, Cost, and Coverage Impacts

Current Coverage of Maternity Benefits

Because maternity benefits are required to be provided by Knox-Keene\textsuperscript{7} licensed DMHC-regulated plans, AB 98 targets CDI-regulated policies. About 2,370,000 Californians, or 11.1\% of enrollees in plans subject to state regulation, are in the CDI-regulated market. CHBRP’s survey of the largest health insurers in the state indicates the following:

- **Entire CDI-regulated market**: Most Californians enrolled in CDI-regulated policies (66\%) currently have coverage for maternity benefits, including prenatal care and delivery services. All enrollees have coverage for complications of pregnancy.

- **CDI-regulated large- and small-group markets**: 100\% of enrollees in CDI-regulated policies in the large- and small-group markets currently have maternity benefits. Therefore, the proposed mandate would impact only the enrollees in individual (non-group) CDI-regulated policies.

- **CDI-regulated individual market**: 22\% of enrollees in CDI-regulated policies in the individual (non-group) insurance market currently have maternity benefits.
  
  - Of those who do not currently have coverage for maternity services, about one-quarter are women of childbearing age (19 to 44).
  
  - There is evidence that risk segmentation has already had a substantial impact on the CDI-regulated individual market, because in a previous analysis of SB 1555 in 2004, CHBRP estimated that approximately 82\% of those in the individual market had maternity benefits.

- **Public programs**: The Medi-Cal and Aid to Infants and Mothers (AIM) programs cover maternity services for women who qualify. Pregnant women who are in households with incomes less than or equal to 200\% of the Federal poverty level generally qualify for Medi-Cal. AIM provides coverage for both uninsured and underinsured women between 200\% and 300\% of the Federal poverty level. AIM defines underinsured women as those with private insurance who face out-of-pocket costs for maternity services greater than $500. CHBRP estimates that approximately 29\% of privately insured women who deliver babies during 2009 and have no maternity benefits when they become pregnant may qualify for Medi-Cal or AIM.
  
  - Based on data from AIM, there is evidence of current cost-shifting to that program. As of 2008, about 7\% of the women enrolled in AIM were simultaneously enrolled in private health insurance policies that did not cover maternity services. Another 10\% of AIM enrollees were enrolled in private insurance policies that did cover maternity services.
  
  - CHBRP estimates that approximately 10,400 women enrolled in CDI-regulated policies with no maternity benefits at the time of pregnancy would give birth during 2009.

\textsuperscript{7} Health maintenance organizations in California are licensed under the Knox-Keene Health Care Services Plan Act, which is part of the California Health and Safety Code.
• Of these women, approximately 2,300 would switch to Medi-Cal and another 700 would enroll in AIM following pregnancy. This is because their income eligibility would change following pregnancy (since pregnant women are considered a household of two and presumably their household income would not increase).

• Another 300 of these women may transfer to policies covering maternity that are offered by their existing carrier.

• The remaining 7,100 women would not have insurance coverage pre-mandate for their prenatal care and delivery.

Post-Mandate Coverage, Cost, and Utilization

• AB 98 would expand maternity services coverage to 805,000 enrollees with CDI-regulated individual policies, including 207,000 women aged 19 to 44 years.

• CHBRP estimates that there would not be a direct impact on Medi-Cal enrollment as a result of AB 98. Those women who currently have no maternity coverage and qualify for Medi-Cal after pregnancy would still shift to Medi-Cal post-mandate due to their income levels.

• Women enrolled in AIM who are currently enrolled in CDI-regulated individual policies that do not cover maternity services would have maternity coverage post-mandate. However, the out-of-pocket cost of maternity services in those policies would likely still be greater than $500 (adding up deductibles and copayments), so those women would still qualify for AIM. As AIM would be the secondary payer if women retain their private coverage, there may be a small shift of costs from AIM onto the private plans, depending on whether AIM plans seek reimbursement from the private plans.

• CHBRP estimates that approximately 7,100 pregnancies would be newly covered under CDI-regulated insurance policies post-mandate. The impact of expanded coverage on utilization is summarized below:

  o Overall, the mandate is estimated to have no impact on the number of deliveries, since the birth rate is not expected to change, post-mandate.

  o Most women are likely to continue to face large out-of-pocket expenditures for maternity services regardless of whether or not their insurance policy includes maternity benefits. This is because almost two-thirds of the women in CDI-regulated individual policies are currently in high-deductible health plans (HDHPs) and prenatal care is usually subject to the HDHP deductible. Even the women currently enrolled in non-HDHPs frequently face high cost-sharing requirements in the CDI-regulated individual market, and some might also choose to switch to HDHPs post-mandate in order to save on premiums.

  o Standard prenatal care is almost always bundled with delivery services and paid for as a single lump-sum fee to physicians. As women need the obstetrician’s services for delivery, they are likely to pay this fee eventually, even if they must pay out of pocket. Thus, their only pre-mandate incentive to delay or avoid receipt of prenatal care is to postpone payment. To the extent that prenatal care and delivery services are bundled as a
fixed charge and women are aware of this fee structure, it is unlikely that AB 98 would have a large impact on utilization of standard prenatal care services. Furthermore, even if use of these services increased, it would not affect expenditures because the fee does not depend on the number of prenatal care visits made.

- Certain types of screening tests are not included in the standard prenatal care fee and might be used more frequently post-mandate if they are part of the maternity benefit, thereby affecting costs. The amount of the increase is difficult to estimate, as these tests would be subject to HDHP deductibles and women may treat them as out-of-pocket costs.

Among all enrollees in state-regulated policies (both CDI-regulated and DMHC-regulated), total health expenditures are estimated to increase by $29.7 million, or 0.04%, as a result of this mandate (see row labeled “Total Annual Expenditures” in Table 1). As the total number of deliveries and average cost associated with each delivery is not expected to increase, the mandate primarily shifts costs from individuals to insurers. CHBRP assumes that the administrative expenses for health plans will increase in proportion to the increase in their covered health care costs, leading to an estimated increase in overall expenditures. Note that the increase in total expenditures is a total of:

- The increase in premium expenditures in the individual market: $89.3 million (see row labeled “Premium expenditures for individually purchased insurance” in Table 1).
- The increase in out-of-pocket expenditures for maternity benefits covered by insurance (e.g., copayments and deductibles): $21.5 million (see row labeled “Individual out-of-pocket expenditures for covered benefits”).
- The reduction in out-of-pocket expenditures for maternity benefits not currently covered by insurance: $81.1 million (see row labeled “Out-of-pocket expenditures for noncovered benefits”).

All of the costs of the mandate would be concentrated in the CDI-regulated individual market, where total expenditures are estimated to increase by 1.10% and premiums by 4.24%. Per member per month (PMPM) premiums are estimated to increase by an average of $7.17 in this market.

- Insurance premiums in the individual market are stratified by age bands, so premiums are likely to increase more for younger individuals (particularly ages 19 to 29) than for older individuals. CHBRP estimates that for the majority of individuals in the CDI-regulated individual market who do not currently have maternity benefits, AB 98 would increase average premiums by 2.01% to 27.47% among those 20 to 44 years old, depending on the age of the enrollee. Among the minority of individuals in the CDI-regulated individual market who currently have maternity benefits, AB 98 is expected to decrease average premiums by 1.30% to 19.46%.

- Premiums are currently gender-rated for 59% of individually purchased CDI-regulated health insurance products in California. Under gender rating, the premium increases resulting from the mandate could be greater for women than men.
In addition to varying with age and gender, premium changes could vary across policies, depending on how women of a given age self-select into different policies based on their likelihood of getting pregnant.

- The estimated premium increases may result in approximately 7,600 newly uninsured. It is likely that these newly uninsured would disproportionately consist of younger individuals and women, if they experience the greatest premium increases.

**Public Health Impacts**

- An increase in the utilization of effective prenatal care services by pregnant women could lead to a reduction in infant and maternal mortality and improve health outcomes, such as the rates of low birth weight or preterm births, infectious disease transmissions, and respiratory distress syndrome.

- CHBRP is unable to estimate what the impact of AB 98 will be on the utilization of prenatal care. A lower bound estimate would assume that there will be no increase in the utilization of effective prenatal care services because these pregnant women will likely still face high out-of-pocket costs. An upper bound estimate would assume that all 7,100 newly covered pregnancies would have financial barriers to prenatal care removed and thus an increase in the utilization of effective prenatal care services, and corresponding health outcomes would be expected.

- Despite poorer health outcomes for babies born to black women, such as increased rates of preterm birth, low birth weight, and infant mortality, there is no evidence that AB 98 would have an impact on prenatal care utilization rates among black women specifically, or reduce these disparities in health outcomes.

- The passage of AB 98 could disproportionately impact women because, to the extent that insurance premiums are gender-rated, women would experience relatively higher premium increases than men.

- In California, 10.9% of babies are born preterm and there are 3,000 infant deaths each year. It is estimated that each premature birth costs society approximately $51,600. To the extent that AB 98 increases the utilization of effective prenatal care that can reduce outcomes such as preterm births and related infant mortality, there is a potential to reduce morbidity and mortality and the associated societal costs.
Table 1. Summary of Coverage, Utilization, and Cost Impacts of AB 98

<table>
<thead>
<tr>
<th>Coverage</th>
<th>Before Mandate</th>
<th>After Mandate</th>
<th>Increase/Decrease</th>
<th>Change After Mandate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population in plans subject to state regulation (a)</td>
<td>21,340,000</td>
<td>21,340,000</td>
<td>0</td>
<td>0.00%</td>
</tr>
<tr>
<td>Total population subject to AB 98</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In large- and small-group plans</td>
<td>1,332,000</td>
<td>1,332,000</td>
<td>0</td>
<td>0.00%</td>
</tr>
<tr>
<td>In individual plans</td>
<td>1,038,000</td>
<td>1,038,000</td>
<td>0</td>
<td>0.00%</td>
</tr>
<tr>
<td>Total</td>
<td>2,370,000</td>
<td>2,370,000</td>
<td>0</td>
<td>0.00%</td>
</tr>
<tr>
<td>Percentage of individuals in CDI-regulated policies with maternity coverage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In large- and small-group plans</td>
<td>100%</td>
<td>100%</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>In individual plans</td>
<td>22%</td>
<td>100%</td>
<td>77.55%</td>
<td>345.49%</td>
</tr>
<tr>
<td>Total</td>
<td>66%</td>
<td>100%</td>
<td>33.97%</td>
<td>51.44%</td>
</tr>
<tr>
<td>Number of individuals in CDI-regulated policies with maternity coverage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In large- and small-group plans</td>
<td>1,332,000</td>
<td>1,332,000</td>
<td>0</td>
<td>0.00%</td>
</tr>
<tr>
<td>In individual plans</td>
<td>233,000</td>
<td>1,038,000</td>
<td>805,000</td>
<td>345.49%</td>
</tr>
<tr>
<td>Total</td>
<td>1,565,000</td>
<td>2,370,000</td>
<td>805,000</td>
<td>51.44%</td>
</tr>
</tbody>
</table>

Utilization and Cost

<table>
<thead>
<tr>
<th>Number of individuals in CDI-regulated policies with uncomplicated pregnancies</th>
<th>Before Mandate</th>
<th>After Mandate</th>
<th>Increase/Decrease</th>
<th>Change After Mandate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnancy covered by private insurance</td>
<td>20,000</td>
<td>27,100</td>
<td>7,100</td>
<td>35.43%</td>
</tr>
<tr>
<td>Pregnancy covered by AIM or Medi-Cal</td>
<td>3,000</td>
<td>3,000</td>
<td>0</td>
<td>0.00%</td>
</tr>
<tr>
<td>Pregnancy not covered by insurance</td>
<td>7,100</td>
<td>0</td>
<td>-7,100</td>
<td>-100.00%</td>
</tr>
<tr>
<td>Total</td>
<td>30,100</td>
<td>30,100</td>
<td>0</td>
<td>0.00%</td>
</tr>
<tr>
<td>Average cost per uncomplicated pregnancy</td>
<td>$11,300</td>
<td>$11,300</td>
<td>$0</td>
<td>0.00%</td>
</tr>
</tbody>
</table>

Expenditures

| Premium expenditures by private employers for group insurance                  | $50,546,207,000 | $50,546,207,000 | $0                  | 0.00%                |
| Premium expenditures for individually purchased insurance (b)                 | $5,944,229,000  | $6,033,527,000  | $89,298,000         | 1.50%                |
| Premium expenditures by individuals with group insurance, CalPERS, Healthy Families, AIM, or MRMIP (c) | $13,475,994,000 | $13,475,994,000 | $0                  | 0.00%                |
Notes: (a) This population includes privately insured (group and individual) and publicly insured (e.g., CalPERS, Medi-Cal, Healthy Families, AIM, MRMIP) individuals enrolled in health insurance products regulated by DMHC or CDI. Population includes enrollees aged 0 to 64 years and enrollees 65 years or older covered by employer-sponsored insurance.  
(b) Premium expenditures by individuals include employee contributions to employer-sponsored health insurance and member contributions to public insurance.  
(c) Of the CalPERS employer expenditures, about 59% are state expenditures for CalPERS members who are state employees.  
(d) Medi-Cal state expenditures for members under 65 years of age include expenditures for individuals covered by the Major Risk Medical Insurance Program (MRMIP) and Access for Infants and Mothers (AIM) program.  
Key: CalPERS = California Public Employees’ Retirement System. |
INTRODUCTION

Assembly Bill (AB) 98, introduced by Assembly Member Hector De La Torre, would require health insurance products regulated by the California Department of Insurance (CDI) to cover maternity services.8 The California Health Benefits Review Program (CHBRP) undertook the analysis of AB 98 in response to a request from the California Assembly Committee on Health on January 15, 2009, pursuant to the provisions of Senate Bill (SB) 1704 (Chapter 684, Statutes of 2006) as chaptered in Section 127600, et seq. of the California Health and Safety Code.

Background of Disease or Condition

Maternity services benefits generally include prenatal care, such as office visits and screening tests; labor and delivery services, including hospitalization; care resulting from complications related to a pregnancy; and postnatal care. The vast majority of births in California are covered by some form of health insurance (RAND Corporation, 2009). In 2006, the birth rate in California was 71.3 births per 1,000 women of childbearing age, or more than 562,000 births (CDPH, 2009).

In California during 2006, the majority (85.9%) of births were to mothers who initiated prenatal care in the first trimester. Another 11.3% started prenatal care in the second trimester, with 2.2% starting care in the third trimester (defined by the March of Dimes as “late” prenatal care). Overall, 2.8% of births in California are to women receiving “late” or no prenatal care (CDPH, 2009). In addition, only 0.6% of births were to women receiving no prenatal care, 12.3% of live births were to women having 1 to 8 prenatal visits, 46.5% had 9 to 12 visits, 32.5% had 13 to 16 visits, while 8.1% had 17 or more visits (CDPH, 2009).

Three major health outcomes in relation to maternity care and utilization of prenatal services are birth weight, preterm deliveries, and infant and maternal mortality. An infant is considered low birth weight if he or she is below 2,500 grams at birth. In California, 6.9% of babies born weigh less than 2,500 grams, and 1.2% of those are considered very low birth weight (i.e., less than 1,500 grams) (CDPH, 2009). Major risk factors for low birth weight include multifetal pregnancy, history of preterm delivery, birth defects, chronic maternal health problems, smoking, alcohol and illicit drug use, maternal and fetal infections, placental problems, inadequate maternal nutrition, and socioeconomic factors (MOD, 2004).

A full-term pregnancy is defined as a gestational length of 37 to 42 weeks. Babies born before 37 weeks of gestation are classified as preterm, while babies born before 32 weeks of gestation are classified as very preterm. In California, 10.9% of births were preterm births in 2006, with approximately 1.5% being very preterm (CDPH, 2009; MOD, 2005). Preterm and particularly very preterm babies are at higher risk for death and disabilities such as cerebral palsy, mental retardation, visual impairment, and hearing loss (IOM, 2006). The causes of preterm birth are not well understood, but medical conditions such as chronic hypertension, diabetes, infections, and stress are associated with preterm birth (IOM, 2006). In addition, a family or personal history of preterm birth and multifetal pregnancy also increases the risk of preterm birth (IOM, 2006).

8 AB 98 would add Section 10123.865 to the California Insurance Code.
Overall in California, the rate of maternal pregnancy-related mortality is 13.6 deaths per 100,000 live births (CDPH, 2007). This translates into nearly 75 maternal deaths in California each year. Infant mortality rates in California are 520 deaths per 100,000 live births, resulting in close to 3,000 deaths annually (MOD, 2003-2005). Infant mortality, or death of an infant in the first year of life, is most frequently caused by birth defects (23.5% of deaths), followed by prematurity and low birth weight (15.6% of deaths), maternal complications of pregnancy (6.0% of deaths), and SIDS (5.2% of deaths) (CDPH, 2005). As will be discussed in further detail in the Medical Effectiveness section, specific prenatal care services can be effective in reducing the rate of preterm births, low–birth weight babies, transmission of infectious diseases, and other related infant and maternal morbidity and mortality.

**Background of AB 98**

According to the bill’s author, the primary goal of AB 98 is to ensure that no pregnant women find themselves unintentionally enrolled in a health insurance policy that does not cover maternity services. According to the bill’s author, AB 98 may also be seen as an anti-discriminatory bill since it prevents policies from excluding a gender-specific condition. In addition, AB 98 is also intended to level the playing field between health care service plans that are regulated by the Department of Managed Health Care (DMHC) (which are required to cover maternity services) and health insurers regulated by the CDI (which presently are not). Presumably, requiring all insurers to cover maternity services would halt the current risk segmentation of the market, which is the practice of insurers selling low-cost polices to individuals who would use fewer health care services (in this case no maternity services), and higher-cost policies to those who would use more health care services.

CHBRP has previously analyzed three bills similar to AB 98: one introduced by Assembly Member De La Torre in 2008 (AB 1962) and two introduced by Senator Jackie Speier in 2003 (SB 897) and again in 2004 (SB 1555). Both SB 1555 (2004) and AB 1962 (2008) passed the Legislature and was vetoed by Governor Arnold Schwarzenegger who stated that he was vetoing these legislative proposals because “A mandate, no matter how small, will only serve to increase the overall cost of health care. I want to decrease the number of uninsured Californians. Increasing the cost of coverage moves in the opposite direction” (Schwarzenegger, 2008).

In 2004, In CHBRP’s analyses of SB 897 and SB 1555, CHBRP estimated that approximately 82% of those in the individual market had coverage for maternity services, while the remaining 18%—192,000 individuals—did not have coverage for maternity services. As will be discussed in further detail in the Utilization, Cost, and Coverage Impacts section, the percentage of those that have coverage for maternity services in the individual market has dropped to 22%, while the remaining 78%—about 805,000 individuals—currently do not have coverage for maternity services. This indicates that risk segmentation has already had a substantial impact on the individual (non-group) insurance market.

---

9 Analyses of the three bills are available on CHBRP’s Web site at www.chbrp.org/analyses.html
Current Requirements
There are state and federal laws and regulations currently in place related to health insurance coverage of maternity services.

California laws
As mentioned, health care service plans regulated by the DMHC are required to provide coverage for maternity services under provisions related to “basic health care services.” While this coverage requirement is not explicit in statute, regulations defining basic health care services specifically include prenatal care as preventive care that must be covered. DMHC-regulated plans are also required to cover maternity and pregnancy-related care under statutes governing emergency and urgent care. 10 Thus, under existing California laws and regulations, the 86.3% of the privately insured market that is enrolled in DMHC-regulated plans have coverage for maternity services. 11

In addition to general requirements on coverage, there are existing laws and regulations related to the maternity services benefit if the health insurance product includes this benefit. Specifically:

- **Minimum length of stay for maternity services**: Health plan and policies that provide maternity coverage are prohibited from restricting “benefits for inpatient hospital care to a time period less than 48 hours following a normal vaginal delivery and less than 96 hours following a delivery by cesarean section.” 12 This is also a federal protection under the Newborns’ and Mothers’ Health Protection Act of 1996. 13

- **Limitation on copayments and deductibles for specified maternity services**: Health plans and policies that provide maternity coverage are prohibited from charging members copayments and deductibles for maternity services that “exceeds the most common amount of the copayment or deductible” for inpatient and outpatient services. 14

California law includes provisions related to accessing health insurance in the group market by pregnant women. Currently, health plans and insurers issuing group contracts or policies “may not impose a pre-existing condition exclusion to... a condition relating to benefits for pregnancy or maternity care.” However, health plans and insurers that write individual policies have the right to deny issuing policies to applicants that have certain conditions, including pregnancy, pregnancy of a spouse or covered dependent, or planned surrogacy or adoption in process. 15

---

10 Section 1300.67 of the California Code of Regulations, Title 28
11 CHBRP’s methods of calculating enrollment in private and public programs that would be affected by the mandate are described in Appendix D.
12 California Health and Safety Code, Section 1367.621; California Insurance Code, Section, 10123.87
14 California Health and Safety Code, Section 1373.4; California Insurance Code, Section 10119.5
15 California Health and Safety Code, Sections 1357.06 and 1357.51; California Insurance Code, Section 10198.7 and 10708. Also see www.dmhc.ca.gov/dmhc_consumer/hp/hp_individual.asp#rights.
Under California law, plans and insurers are required to issue health insurance to a newborn for the first 30 days of his or her life. This requirement also applies to CDI-regulated individual policies that do not cover maternity services.¹⁶

**Federal laws**
Under Title VII of the Federal Civil Rights Act, employers may not discriminate on the “basis of pregnancy, childbirth, or related medical conditions.” In terms of health insurance coverage, employers that offer health insurance and have 15 or more employees must cover maternity services benefits at the same level as other health care benefits.¹⁷ Thus, under federal law, those obtaining health insurance in the large-group market and those in the small-group market (in firms having 15 or more employees) must have coverage for maternity services. (As determined in CHBRP’s survey of the largest health insurers in California, which will be discussed in detail in the *Utilization, Cost, and Coverage Impacts* section, small-group members enrolled in firms having two or more employees also have coverage for maternity services.)

The federal Health Insurance Portability and Accountability Act, which amends the Employee Retirement Income Security Act, prohibits employer-based plans from applying pre-existing condition exclusions to pregnancy, whether or not the woman had previous coverage.

**Other California Programs**

**Medi-Cal**
Pregnant women who are at or below 200% of the Federal Poverty Level (FPL) are eligible for Medi-Cal either through Medi-Cal for Families or through Medi-Cal’s pregnancy-related programs. A pregnant woman would qualify for Medi-Cal for Families if her household income is at or below 100% of the FPL and her household meets property eligibility standards. A pregnant woman may qualify for Medi-Cal’s pregnancy-related programs if her household income is at or below 200% of the FPL and the property limits are waived. Medi-Cal’s pregnancy-related programs cover pregnancy-related services such as prenatal care, labor and delivery, complications of delivery, and postpartum care for up to 60 days.

**Access to Infants and Mothers program**
Pregnant women who are at or below 300% of the FPL may qualify for the Access for Infants and Mothers (AIM) program. To qualify, a woman must:
- be below 300% of the Federal poverty level;
- be pregnant (though no more than 30 weeks);
- be a California resident;
- not be enrolled in another publicly funded program; and
- not have maternity coverage from a private insurance policy unless that policy requires more than $500 in out-of-pocket expenses for maternity services (for example, a woman may be in a high-deductible health plan [HDHP] facing deductibles and co-insurance higher than $500). (Therefore, it is possible to be enrolled in AIM and have private insurance.)

---

¹⁷ The Pregnancy Discrimination Act under Title VII of the Civil Rights Act of 1964
AIM covers all medically necessary services from the point of enrollment until 60 days postpartum. In terms of maternity services, AIM covers prenatal care, labor and delivery, complications of pregnancy, and postpartum care. Women enrolled in AIM must pay 1.5% of their adjusted annual household income after income deductions. They do not have any copayments or cost-sharing. Babies born to women enrolled in AIM are automatically enrolled in the Healthy Families program.18

Other State Activities and Trends
There are 17 states, including California, that currently have some requirements related to the coverage of maternity services (BCBSA, 2008). Of these, four mandate that maternity services be covered in the individual market: Massachusetts, New Jersey, Oregon, and Washington. Massachusetts laws require health maintenance organizations (HMOs), medical service corporations, and nonprofit hospital service corporations to cover maternity services.19 New Jersey and Washington require all individual health policies to include maternity benefits except for “bare-bones” plans.20,21 Washington also requires carriers that sell individual health plans covering maternity services to ensure that cost-sharing levels for maternity services are the same as other health care benefits. In addition, three states, including California, Illinois, and Georgia require managed care organizations or HMOs to cover maternity benefits in the individual market. Montana’s Supreme Court held that excluding maternity services was gender-based discrimination and the Insurance Commission ordered that all insurers cover maternity benefits.22 Maine and New Hampshire require carriers selling individual health policies to offer a maternity rider if the policy does not cover maternity services in its base plan.23

Health insurance policies that cover maternity services in the individual market can be difficult to find, according to a recent survey by the National Women’s Law Center (NWLC) of over 3,500 individual policies in 47 states and the District of Columbia (NWLC, 2008). They found that 59% of the individual health insurance policies did not include coverage for maternity services and few (12%) included “comprehensive maternity services” (defined as prenatal care, labor, deliver, postpartum care, and care related to complications of pregnancy). In California, the NWLC found that there were about 106 plans with maternity coverage available in the individual market with 26 of those including comprehensive maternity services.

The NWLC survey also found that in states where carriers offered maternity services as a rider in the individual market (not including California), women faced high out-of-pocket costs for maternity services. For example, the out-of-pocket costs for labor and delivery could range from about $7,000 for a normal delivery to about $16,000 for a cesarean delivery with complications. An analysis of the out-of-pocket costs for maternity services (including prenatal and postpartum

18 Babies born to AIM enrollees who also have private insurance would be covered by private insurance for the first 30 days unless the woman submits an infant registration form to the Healthy Families program within 11 months of enrollment into AIM. In that case, babies will be covered by the Healthy Families program from the date of birth.
19 Massachusetts General Laws Chapter 176G, Section 4(c), 4I; Massachusetts General Laws Chapter 176B, Section 4H; Massachusetts General Laws Chapter 176A, Section 8H.
20 New Jersey Statue Annotated, Section 17B:26-2.1b
21 Washington Insurance Code RCW 48.43.041
22 Montana Insurance Order, February 16, 1994
23 New Hampshire Statute Section 415:6-d
care) for women enrolled in a consumer-driven health plan with maternity coverage showed that out-of-pocket costs can range from about $8,000 to $21,000 (KFF, 2007).

Bill Provisions, Key Assumptions, and Analytic Approach
AB 98 would require the entire CDI-regulated market to cover maternity services. The CDI-regulated market consists of approximately 13.7% of the privately insured market in California. CDI-regulated policies represent about 51.8% of those enrolled in privately insured individual products and 24.7% of those enrolled in the privately insured small-group market. Because all group policies are required to cover maternity services, the Utilization, Cost, and Coverage Impacts analysis focuses only on the CDI-regulated individual market. That section specifically examines the impact of adding maternity services to those CDI-regulated individual policies that do not currently cover them.

AB 98 would not directly affect populations who are enrolled in health insurance products that are not subject to benefit mandates, such as those enrolled in self-insured plans or those who are uninsured. In addition, AB 98 would not place any new requirements on publicly funded programs such as CalPERS, Medi-Cal, or AIM.

As discussed above, there are existing laws related to underwriting of policies and laws that allow carriers to deny coverage for individual health insurance policies on the basis of pregnancy. These laws would not be affected by AB 98. Accordingly, AB 98 would allow health insurance products regulated by the CDI and the DMHC to continue to apply pre-existing condition limitations for individual (non-group) insurance. Finally, AB 98 does not place new requirements on coverage of newborns.

AB 98 defines “maternity services” to include prenatal care, ambulatory care maternity services, involuntary complications of pregnancy, neonatal care, and inpatient hospital maternity care including labor and delivery and postpartum care. The Medical Effectiveness and Public Health Impacts sections of this report focus on the outcomes associated with prenatal care services because: (1) a majority of births occur in the hospital setting regardless of insurance status, (2) prenatal care services use would be most affected by the potential for out-of-pocket costs and thus most directly impacted by AB 98, (3) AB 98 would not affect coverage for infants, and (4) plans and policies that do not cover maternity services cover complications related to a pregnancy. The Utilization, Cost, and Coverage Impact analysis includes the full range of services that are considered to be “maternity services.”

---

24 SB 1704, CHBRP’s authorizing legislation, defines a benefit mandate bill as “a proposed statute that requires a health care service plan or a health insurer, or both, to ... offer or provide coverage of a particular type of health care treatment or service.” Thus, the portion of the population directly affected by a benefit mandate bill are those enrolled in a health insurance products offered by health care service plans or health insurers.
MEDICAL EFFECTIVENESS

As noted in the Introduction, AB 98 defines maternity services to include prenatal care, ambulatory care maternity services, involuntary complications of pregnancy, neonatal care, and inpatient hospital maternity care including labor and delivery and postpartum care. Each of these categories of maternity services in turn encompasses multiple screening tests, diagnostic tests, monitoring services, and treatments. Conducting a medical effectiveness analysis on the full range of maternity services is not feasible within the 60 days allotted for CHBPR analysis. In addition, because AB 98 is most likely to affect utilization of prenatal care, CHBPR focuses this review of the literature on the effectiveness of prenatal care services. Regardless of health insurance status, the vast majority of women in the United States deliver their babies in hospitals. AB 98 would not affect coverage for infants.

Literature Review Methods

Due to the large amount of literature on prenatal care services, CHBPR limited its literature search to meta-analyses, systematic reviews, and evidence-based guidelines because such syntheses of multiple studies are the strongest forms of evidence of the effectiveness of medical interventions. Syntheses of studies of the effects of prenatal care services were identified through searches of MEDLINE (PubMed), the Cochrane Database of Systematic Reviews, the Cochrane Register of Controlled Clinical Trials, Web of Science, and EconLit. In addition, Web sites maintained by the following organizations that index or publish systematic reviews and evidence-based guidelines were searched: Agency for Healthcare Research and Quality, Institute for Clinical Systems Improvement, International Network of Agencies for Health Technology Assessment, National Health Service Centre for Reviews and Dissemination, National Institutes of Health, National Guidelines Clearinghouse, National Institute of Clinical Evidence, Scottish Intercollegiate Guideline Network, the U.S. Preventive Services Task Force, and the World Health Organization.

The search was limited primarily to studies published in English from January 2008 to present. The time frame for the search was truncated because CHBPR conducted a search of the literature on the effectiveness of prenatal care services published from 1995 through 2007 for a report it issued in 2008 on AB 1962, an identical bill regarding coverage for maternity services. Older literature was searched for only a few topics that were not adequately addressed in the previous search, such as screening for congenital disorders and interventions to prevent preeclampsia and preterm birth. Sixteen additional pertinent studies were identified, retrieved, and reviewed. Findings from these studies were integrated with findings from 28 studies that were analyzed for CHBPR’s report on AB 1962. A more thorough description of the methods used to conduct the medical effectiveness review and the process used to grade the evidence for each outcome measure is presented in Appendix B: Literature Review Methods. Appendix C includes tables that describe the studies that CHBPR reviewed and their findings. A table that lists effective prenatal care services appears at the end of this section of the report (Table 2).
Outcomes Assessed

The literature search focused on the impact of prenatal care services on health outcomes for pregnant women and infants. Findings from studies of the accuracy of screening tests were examined only for purposes of determining whether accurate tests of a given disease or condition are available. Findings regarding the effectiveness of treatments were reviewed but are not summarized below because CHBRP is less interested in whether treatments cure the diseases or conditions they are intended to treat than in whether receiving treatment is associated with better birth outcomes for mothers and infants.

Maternal health outcomes assessed include:

- Maternal mortality
- Eclampsia
- Preeclampsia
- Kidney infection
- Antepartum hemorrhage
- Placental abruption
- Preterm premature rupture of membranes
- Induction of labor
- Postpartum hemorrhage

Infant health outcomes assessed include:

- Low birth weight
- Small birth weight for gestational age
- Fetal, neonatal, and infant mortality
- Admission to neonatal intensive care unit
- Transmission of infectious disease
- Alloimmune hemolytic disease
- Cerebroventricular or intraventricular hemorrhage
- Respiratory distress syndrome
- Cerebral palsy
- Gross motor dysfunction
Study Findings

Studies of prenatal care can be divided into two major groups:

- Studies of the impact of variation in the number of prenatal care visits that pregnant women receive; and
- Studies of the effectiveness of specific services provided during prenatal care visits or in conjunction with them (e.g., laboratory tests, medications).

These two sets of studies are summarized separately below.

Studies of the Impact of the Number of Prenatal Care Visits

Randomized controlled trials (RCTs) generally have found no statistically significant association between the number of prenatal visits and birth outcomes for either infants or mothers (Alexander and Korenbrot, 1995). Of the 11 RCTs included in a systematic review published in 1995, all of them found that pregnant women who had greater numbers of prenatal care visits (either office or home visits) were no less likely than women who had fewer visits to have a preterm birth or a low–birth weight infant (Fiscella, 1995). The most recent meta-analysis of studies on the effects of numbers of prenatal care visits found that the number of visits does not affect the odds of having a preterm birth, delivering a low–birth weight infant, or admission of a newborn to a neonatal intensive care unit (Villar et al., 2001). This meta-analysis also reported that the number of visits was not associated with the odds of maternal mortality, preeclampsia, and antepartum or postpartum hemorrhage.

Most studies of prenatal care do not include a control group of pregnant women who receive no prenatal care. Providing prenatal care has been an established standard of medical practice for so long that it is considered unethical to randomize pregnant women to receive no prenatal care. Thus, the effect of having no prenatal care is unlikely to ever be studied in prospective RCTs (Alexander and Kotelchuck, 2001; Fiscella, 1995). As a consequence, researchers typically study the impact of more versus fewer prenatal care visits. In several studies, the differences studied have been as small as one or two visits (Villar et al., 2001). It is more difficult to detect an effect of a small difference in the number of prenatal visits than to detect a difference between a standard number of visits and no visits.25

There is clear and convincing evidence that having more prenatal care visits is not associated with better birth outcomes for either infants or mothers, but the threshold above which there is no benefit to additional visits has not been established.

---

25 Some nonrandomized studies have found that women who obtained more prenatal care visits delivered infants with larger mean birth weights and that their infants had a lower risk of death (Alexander and Korenbrot, 1995; Fiscella, 1995). However, many of these nonrandomized studies did not adequately adjust for preterm birth or for individual and socio-economic factors associated with poor birth outcomes, such as having a low income, having a low level of education, and having a substance use disorder (Alexander and Korenbrot, 1995; Alexander and Kotelchuck, 2001; Fiscella, 1995). Nonrandomized studies that did not adequately control for these factors may have overstated the benefits of having more prenatal care visits.
Studies of the Effectiveness of Specific Prenatal Care Services

Although the number of prenatal care visits is not associated with birth outcomes, there is evidence that a number of services provided to pregnant women during or in conjunction with prenatal care visits are effective. These services include screening tests, diagnostic tests, monitoring services, and treatments for diseases or conditions associated with poorer birth outcomes. Some prenatal care services, such as blood pressure monitoring and ultrasound testing, are typically performed as part of an office visit. In other cases, samples of blood, urine, or other bodily fluids are collected in a medical office and then analyzed in a medical laboratory. In still other cases, women who have positive results on screening tests for diseases or conditions associated with poorer birth outcomes are prescribed medications to cure or mitigate these conditions. However, the impact of these services on overall rates of poor birth outcomes is likely to be small, because the percentages of pregnant women who have many of these diseases and conditions are small.

The evidence of the effectiveness of these services is discussed below. Evidence was drawn primarily from meta-analyses and systematic reviews published by the Cochrane Collaboration or in peer-reviewed journals and from systematic reviews conducted in conjunction with the preparation of evidence-based guidelines issued by the Institute for Clinical Systems Improvement (ICSI), the National Collaborating Centre for Women’s and Children’s Health (NCCWCH), the New Zealand Ministry of Health, the United States Preventive Services Task Force (USPSTF), and the United States Public Health Service. Findings from studies of these services are grouped into categories below based on the nature of the disease or condition for which screening and/or diagnostic tests are performed, and monitoring or treatment provided.

Behavioral risk factors

Smoking. Smoking during pregnancy is a major risk factor for preterm birth and low birth weight (Fiscella, 1995). Two meta-analyses and three systematic reviews of RCTs have examined the impact of brief advice to quit smoking and/or smoking cessation counseling on these birth outcomes (Lu et al., 2003; Lumley et al., 2004; NCCWCH, 2008; NZMOH, 2008; US DHHS, 2008). All five studies concluded that brief advice and/or counseling regarding smoking cessation increases the likelihood that pregnant women will stop smoking. One meta-analysis found that providing counseling and other psychosocial interventions were more effective than brief advice, self-help materials, and referral to smoking cessation programs (US DHHS, 2008). The studies also determined that smoking cessation advice and/or counseling reduces the risk of giving birth preterm or delivering a low–birth weight infant. The meta-analysis found that smoking cessation advice or counseling decreased the risk of giving birth preterm by 16% and the risk of delivering a low–birth weight infant by 19% (Lumley et al., 2004).28

---

26 The Institute for Clinical Systems Improvement is an independent, not-for-profit organization that promotes quality improvement among health plans, hospitals, and medical groups in Minnesota. This citation is to an evidence-based guideline for routine prenatal care.

27 The National Collaborating Centre for Women’s and Children’s Health is one of seven National Collaborating Centres in the United Kingdom that are funded by the National Institute for Health and Clinical Excellence (NICE) to develop the clinical guidelines for the National Health Service.

28 All risk reductions, odds, and percentage differences cited in this section of the report are statistically significant at p<0.05.
**Domestic violence.** Domestic violence during pregnancy can cause injury to both pregnant women and their fetuses. The authors of one systematic review conducted in conjunction with the preparation of an evidence-based guideline assessed evidence of the effectiveness of screening pregnant women to identify those being abused (ICSI, 2008). The systematic review identified several nonrandomized studies with comparison groups that reported findings that favored screening.

**Fetal abnormalities**
Tests are available to screen pregnant women and, in some cases, their partners, for genetic traits for disorders that are associated with poor birth outcomes and serious illness or disability among children. Diagnostic tests are conducted on fetuses whose parents have these traits or are otherwise at elevated risk for these disorders.

**Down syndrome.** Down syndrome (commonly caused by trisomy 21) is a genetic disorder that causes mental retardation, heart defects, and other major health problems. Two systematic reviews conducted in conjunction with the preparation of an evidence-based guideline have assessed evidence regarding the accuracy of screening tests for Down syndrome (ICSI, 2008; NCCWCH, 2008). Both concluded that there is sufficient evidence to recommend counseling all women about screening for Down syndrome and providing screening to those who would like to be screened using ultrasound for nuchal translucency and/or blood tests for biomarkers (ICSI, 2008; NCCWCH, 2008). Women whose results for these tests suggest they are at elevated risk for carrying a child with Down syndrome are encouraged to undergo either an amniocentesis or chorionic villus sampling test, each of which has a small risk of causing a miscarriage, to determine if their fetuses have the disorder (ICSI, 2008; NCCWCH, 2008). The purpose of this two-stage approach is to ensure that invasive diagnostic testing is targeted at women who are at high risk of carrying a fetus with Down syndrome. In the past, maternal age of 35 years or older was used as the sole criterion for determining which pregnant women should receive amniocentesis or chorionic villus sampling, even though this approach detects only one third of Down syndrome cases (ICSI, 2008).

**Hemoglobinopathies.** Two evidence-based guidelines recommend screening for hemoglobinopathies, such as sickle cell anemia and thalassemias, in populations at higher risk carrying the gene mutations associated with these disorders (ICSI, 2008; NCCWCH, 2008). When both parents have the genetic mutations that cause the disorder (i.e., are carriers), they can unwittingly pass the disorder on to their child. In the United States, parents of African ancestry are at greatest risk of being carriers for the sickle cell mutation. Parents of southeast Asian ancestry are at greater risk of being carriers of alpha thalassemia mutations, and parents of Mediterranean ancestry are at greatest risk for being carriers of beta thalassemia mutations. One guideline recommends offering complete blood count tests to all pregnant women and their partners and additional tests to pregnant women from racial/ethnic groups at increased risk of carrying a fetus with one of these disorders (ICSI, 2008). The other guideline makes two recommendations for screening depending on the prevalence of hemoglobinopathies in a population of pregnant women (NCCWCH, 2008). Where the prevalence of hemoglobinopathies is high, the guideline recommends offering blood tests to all pregnant women and their partners. Where the prevalence is low, the guideline recommends using a questionnaire about family
origin to identify pregnant women at high risk for carrying a fetus with one of these disorders and offering testing to high-risk women and their partners.

**Tay-Sachs disease.** Tay-Sachs disease is a fatal genetic disorder that causes harmful quantities of a fatty substance called ganglioside GM2 to build up in the brain. The disorder occurs where both parents are carriers of specific gene defect associated with the disease. Ashkenazi Jews have the highest risk of carrying these genetic mutations. One evidence-based guideline published in the United States recommends offering screening for this disorder to all Jewish parents because most Jews in the United States are of Ashkenazi descent (ICSI, 2008).

**Neural tube defects.** Neural tube defects are birth defects that affect the brain and spinal cord. They include spina bifida, anencephaly, and encephalocele (NCCWCH, 2008). Based on findings from a systematic review and individual studies, one evidence-based guideline recommended that all pregnant women be offered an ultrasound scan to screen for neural tube defects and other structural anomalies, ideally between 18 and 20 weeks of gestation (NCCWCH, 2008). One individual RCT cited in this guideline found that the detection rate for fetal structural abnormalities was higher for routine screening of all pregnant women than for selective screening of women at high risk for carrying a fetus with structural abnormalities. Two systematic reviews found that evidence from RCTs indicates that consumption of folic acid prior to conception is associated with a statistically significant reduction in the risk of giving birth to an infant with neural tube defects (ICSI, 2008; NCCWCH, 2008). One meta-analysis cited in these systematic reviews reported that consumption of folic acid prior to consumption was associated with a 72% lower risk of giving birth to a child with a neural tube defect. The Centers for Disease Control and Prevention (CDC) and the Institute of Medicine (IOM) recommend that women of childbearing age consume 400 micrograms of folic acid per day prior to conception and 600 micrograms per day during pregnancy from fortified foods and supplements (ICSI, 2008). The United Kingdom’s Department of Health recommends that both pregnant and non-pregnant women take 400 micrograms per day (NCCWCH, 2008). Folic acid supplements and food fortified with folic acid are not typically covered by health plans regardless of whether a woman has maternity benefits. However, a pregnant woman who does not have maternity benefits might delay obtaining prenatal care and, thus, not receive timely advice about consuming an adequate quantity of folic acid.

**Other structural anomalies.** Ultrasound can be used to determine whether a fetus has structural anomalies in other organ systems, such as the cardiovascular system, face, gastrointestinal system, pulmonary system, skeleton, or urinary system. As noted previously, one evidence-based guideline recommended that all pregnant women be offered an ultrasound scan to screen for structural anomalies (NCCWCH, 2008). Two meta-analyses have assessed the accuracy of providing an ultrasound including a nuchal translucency measurement during the first trimester to identify congenital heart defects (Makrydimas et al., 2003; Wald et al., 2008). This test is often offered to pregnant women because it is an effective screening test for Down syndrome and other chromosomal abnormalities (NCCWCH, 2008). The most recent meta-analysis concluded that nuchal translucency measurement can detect 52% of fetuses with congenital heart defects for which diagnosis could affect management of a pregnancy (Wald et al., 2008).
Infectious disease

Pregnant women who have infectious diseases are at elevated risk for preterm delivery, low birth weight, and other poor birth outcomes. In addition, some infectious diseases can be transmitted from mother to child, which, if untreated, can cause blindness, liver disease (e.g. hepatitis), or death. Meta-analyses and systematic reviews have identified seven infectious diseases for which screening during pregnancy is beneficial for all women or women at elevated risk: asymptomatic bacteriuria, hepatitis B, human immunodeficiency virus, syphilis, chlamydia, gonorrhea, and group B streptococcus.

Asymptomatic bacteriuria. One meta-analysis and four systematic reviews of RCTs have examined the effectiveness of screening pregnant women for asymptomatic bacteriuria with urine culture, and prescribing antibiotics to those with positive urine cultures (ICSI, 2008; Lin and Fajardo, 2008; Lu et al., 2003; NCCWCH, 2008; Smaill and Vazquez, 2007). All five studies conclude that screening and treatment for asymptomatic bacteriuria reduce the risks that a pregnant woman will have a kidney infection, deliver preterm, or deliver a low–birth weight infant. The meta-analysis found that the risk of delivering a low–birth weight infant was 34% lower among women with asymptomatic bacteriuria who received antibiotics. The risk of having a kidney infection was 77% lower among pregnant women who were treated (Smaill and Vazquez, 2007). The USPSTF and ICSI recommend that pregnant women be screened for asymptomatic bacteriuria with a urine culture obtained at 12 to 16 weeks of pregnancy (ICSI, 2008; USPSTF, 2008). The NCCWCH recommends performing a urine culture early in pregnancy but does not specify a particular time interval (NCCWCH, 2008).

Hepatitis B. One meta-analysis and three systematic reviews of RCTs have examined the effectiveness of screening pregnant women for hepatitis B and administering hepatitis B vaccine and/or hepatitis B immune globulin to newborns whose mothers have hepatitis B (ICSI, 2008; Krishnaraj, 2004; Lee et al., 2006; NCCWCH, 2008). All four studies conclude that vaccination and/or prophylaxis with immune globulin reduces the risk that a child will develop chronic hepatitis B infection, which is associated with serious liver problems. The meta-analysis found that the risk of developing chronic hepatitis B was 50% lower for infants who received hepatitis B immune globulin, 72% lower for those who received hepatitis B vaccine, and 92% lower for infants who received both hepatitis B immune globulin and vaccine (Lee et al., 2006).

Human immunodeficiency virus (HIV). Three systematic reviews have evaluated the effectiveness of screening pregnant women for HIV, and providing treatment and harm reduction interventions to women who are HIV-positive and their infants (Chou et al., 2005; ICSI, 2008; NCCWCH, 2008). All three systematic reviews concluded that all pregnant women should be screened for HIV and that treatment and harm reduction interventions reduce the risk of mother-to-child transmission of HIV. A meta-analysis of RCTs cited in one of the systematic reviews reported that providing antiretroviral therapy to pregnant women with HIV substantially reduces the odds of mother-to-child transmission of HIV, stillbirth, and death within the first year of life (Chou et al., 2005). Individual studies cited in this systematic review found that HIV-positive women who delivered their babies by cesarean section were substantially less likely to transmit HIV to their babies than those who delivered vaginally (Chou et al., 2005). Other individual studies reported that mothers who fed their infants with formula were less likely to transmit HIV to their children than those who breastfed (Chou et al., 2005).
Sexually transmitted infections. Six systematic reviews have assessed the effectiveness of screening pregnant women for sexually transmitted infections (Glass et al., 2005; ICSI, 2008; Meyers et al., 2007; NCCWCH, 2008; Nelson et al., 2004; USPSTF, 1996). Findings from nonrandomized studies suggest that prescribing penicillin or other antibiotics to pregnant women with syphilis substantially reduces mother-to-child transmission of this disease (ICSI, 2008; NCCWCH, 2008; Nelson et al., 2004; USPSTF, 1996). Nonrandomized studies also indicate that providing prophylaxis to infants born to mothers with gonorrhea was associated with substantial decreases in the rate of conjunctivitis or blindness (ICSI, 2008; USPSTF, 1996). In addition, nonrandomized studies suggest that prescribing antibiotics to pregnant women who have chlamydia reduces the risk of preterm premature rupture of membranes, low birth weight, and infant mortality (ICSI, 2008; USPSTF, 1996). The effectiveness of screening for sexually transmitted infections depends on the prevalence of a disease in a population, as well as the accuracy of screening tests and the benefits of treatment. Based upon the systematic reviews it commissioned, the USPSTF recommends screening all pregnant women for syphilis, pregnant women at increased risk for gonorrhea, and women 25 years and older at increased risk, and all women aged 24 years or younger for chlamydia (USPSTF, 2008).

Group B streptococcus. Three systematic reviews conducted in conjunction with the development of evidence-based guidelines evaluated the effectiveness of screening pregnant women for group B streptococcus by culturing tissue sampled from the vaginal or perianal area during the third trimester and administering antibiotics during delivery to those who tested positive (ICSI, 2008; NCCWCH, 2008; Schrag et al., 2002). Based on these systematic reviews of nonrandomized studies with comparison groups, the authors of two of the evidence-based guidelines recommend screening all pregnant women for group B streptococcus (ICSI, 2007; Schrag et al., 2002). However, the authors of the other evidence-based guideline conclude that the evidence regarding effectiveness and cost-effectiveness of screening for group B streptococcus is inconclusive (NCCWCH, 2008).

Metabolic, nutritional, and endocrine conditions
There is less evidence of beneficial effects of screening and treatment for metabolic, nutritional, and endocrine conditions relative to infectious disease.

Gestational diabetes. Two systematic reviews assessed the evidence of the impact of screening pregnant women for high blood glucose (i.e., high blood sugar) and providing dietary advice to women with high blood sugar and insulin, if needed (ICSI, 2008; NCCWCH, 2008; USPSTF, 2008). One systematic review identified one study that found that controlling blood sugar was associated with small decreases (1% to 4%) in infant mortality, shoulder dystocia, bone fracture, and nerve palsy. The authors of two systematic reviews concluded that all pregnant women should be screened for gestational diabetes (ICSI, 2008; NCCWCH, 2008). However, the other systematic review determined that there was insufficient evidence to recommend for or against screening for this disorder (USPSTF, 2008).

Iron deficiency anemia. Three systematic reviews evaluated evidence of the impact of screening pregnant women for iron deficiency anemia and prescribing iron supplements to those who are anemic (Helfand et al., 2006; ICSI, 2008; NCCWCH, 2008). The majority of studies on iron supplementation have not found that it improves birth outcomes. However, a poorly
implemented RCT that was recently conducted in the United States reported that iron supplementation reduced the percentage of infants born to women with iron deficiency anemia who had low–birth weight infants (Helfand et al., 2006). Three organizations have issued evidence-based guidelines that recommend screening asymptomatic pregnant women for iron deficiency anemia (ICSI, 2008; NCCWCH, 2008; USPSTF, 2008).

Other medical conditions

There is also evidence of effectiveness for screening and treatment for hypertensive disorders and red blood cell antibody disorders.

Hypertensive disorders. Preeclampsia encompasses a variety of hypertensive disorders in pregnancy, including pregnancy-induced or gestational hypertension. These disorders occur in 2% to 8% of pregnancies (Duley et al., 2007). They can cause headaches, dizziness, nausea, vomiting, changes in vision, and upper abdominal pain. In severe cases, preeclampsia is associated with hemolysis, placental abruption, and lack of blood flow to the placenta, which can lead to preterm birth and small-for-gestational-age birth. To prevent or mitigate these complications, pregnant women with preeclampsia are often scheduled for preterm delivery. A small percentage of women with uncontrolled preeclampsia develop eclampsia, a condition that can cause coma, brain damage, and death for both mother and baby, if not treated.

Three organizations that issue evidence-based guidelines recommend screening all pregnant women for preeclampsia through blood pressure monitoring and urinalysis to detect proteinuria, although no controlled studies on this topic have been published (ICSI, 2008; NCCWCH, 2008; USPSTF, 1996). Controlled studies have not been undertaken because blood pressure monitoring for hypertension has been a standard practice for so long that it would be unethical to withhold it from pregnant women. In addition, both blood pressure monitoring and urine culture testing are inexpensive and noninvasive. However, RCTs have been conducted on three treatments to improve birth outcomes for women with preeclampsia.

One meta-analysis and three systematic reviews of RCTs have assessed the effects of providing calcium supplements to all pregnant women regardless of their risk of hypertensive disorders. (Hofmeyr et al., 2006; ICSI, 2008; Meads et al., 2008; NCCWCH, 2008). All three concluded that calcium supplements reduce the risk of preeclampsia and maternal death or serious morbidity. The meta-analysis concluded that pregnant women with preeclampsia who took calcium supplements had a 20% lower risk of death or serious morbidity (Hofmeyr et al., 2006).

Three meta-analyses and one systematic review of RCTs evaluated the impact of prescribing low doses of aspirin or other antiplatelet agents to pregnant women at risk for preeclampsia (Askie et al., 2007; Duley et al., 2007; Meads et al., 2008; Ruano et al., 2005). The authors of the most thorough meta-analysis reported that pregnant women who used antiplatelet agents were 17% less likely to develop preeclampsia than pregnant women who received a placebo or no treatment (Duley et al., 2007). This meta-analysis also found that use of antiplatelet agents was also

---

29 Randomization of pregnant women to the treatment and control groups was not successful. Women in the control group had higher weight pre-pregnancy and had higher levels of ferritin (the main iron storage protein) at the time they enrolled in the study. In addition, 23% of these women had to be excluded from the analysis because the researchers could not obtain birth weight data for their infants (previous study was cited in Helfand et al., 2006).
associated with reductions in the risk of preterm birth, small-for-gestational-age birth, and fetal or neonatal death. A meta-analysis of individual patient data from a subset of studies analyzed in the aforementioned meta-analysis reached the same conclusions regarding the impact of anti-platelet agents on the risks of preeclampsia and preterm birth but found no statistically significant difference in risks of small-for-gestational-age birth or fetal or neonatal death (Askie et al., 2007).

One meta-analysis of RCTs investigated the impact of administering magnesium sulfate to pregnant women to prevent seizures associated with eclampsia (Duley et al., 2003). The authors of one meta-analysis reported that women who received magnesium sulfate during delivery had a 59% lower risk of eclampsia and a 36% lower risk of placental abruption.

**Rh(D) incompatibility.** Three systematic reviews have addressed the impact of Rh(D) immune globulin for treatment of Rh(D) incompatibility (ICSI, 2008; NCCWCH, 2008; USPSTF, 1996). If Rh(D) incompatibility is not diagnosed and treated, children born to Rh(D) negative mothers are at high risk for hemolytic disease, a serious disease whose symptoms include anemia, body swelling, difficulty breathing, and jaundice. Based on controlled studies conducted in the 1960s, all three systematic reviews concluded that screening for Rh(D) incompatibility and administration of Rh(D) immune globulin is effective. One systematic review also recommends screening for other atypical red blood cell alloantibodies and referral of pregnant women with abnormalities to a maternal-fetal medicine subspecialist (NCCWCH, 2008).

**Pregnancy outcomes**

There is also evidence that some interventions that are targeted at preventing preterm birth are effective, as are some interventions for preventing complications at term.

**Progestational agents to prevent preterm delivery.** Four meta-analyses and two systematic reviews of RCTs have assessed studies of the effectiveness of progestational agents in preventing preterm delivery among women at risk for it (Dodd et al., 2006; Dodd et al., 2008; ICSI, 2008; Lu et al., 2003; Mackenzie et al., 2006; Sanchez-Ramos et al., 2005). Progesterone is a hormone that occurs naturally in the body. RCTs have assessed the effectiveness of administering either natural progesterone in the form of vaginal suppositories or intramuscular injection of synthetic progesterone (17 α-hydroxyprogesterone caproate). All six studies determined that prescribing progestational agents to pregnant women reduces the likelihood of preterm birth and/or delivering a low–birth weight infant. The authors of the most rigorous and inclusive meta-analysis found that prescribing progestational agents was associated with a 35% reduction in the risk of preterm birth at less than 37 weeks and with a 37% reduction in the risk of low birth weight (Dodd et al., 2006). This meta-analysis also found that taking progesterational agents was also associated with a statistically significant reduction in intraventricular hemorrhage, a risk factor for development of cerebral palsy.

**Corticosteroids to promote maturation of lungs in fetuses scheduled for preterm delivery.**

One systematic review and one meta-analysis of RCTs examined studies of the effect of prescribing corticosteroids to pregnant women to promote maturation of the lungs in fetuses scheduled for preterm delivery due to preeclampsia or other complications (Lu et al., 2003; Roberts and Dalziel, 2006). Both found that prescribing corticosteroids during pregnancy
improved birth outcomes for newborns. The meta-analysis reported that treatment with corticosteroids was associated with a 31% lower risk of neonatal mortality as well as with lower risks of respiratory distress syndrome, cerebrovascular hemorrhage, necrotizing enterocolitis (i.e., infection and inflammation that destroys the bowel or part of the bowel), and admission to neonatal intensive care units (Roberts and Dalziel, 2006).

**Magnesium sulfate to prevent neurological impairment in fetuses at risk for preterm delivery.** One meta-analysis has assessed whether prescribing magnesium sulfate to pregnant women at risk for preterm birth reduces the risk of bearing a child with a neurological impairment (Doyle et al., 2009). Infants who are born prematurely are at increased risk of having severe neurological impairments such as cerebral palsy, cognitive dysfunction, blindness, and deafness. The meta-analysis found that prescribing magnesium sulfate was associated with a 32% reduction in the risk that a newborn would have cerebral palsy and a 39% reduction in the risk of substantial gross motor dysfunction.

**Placenta previa.** Placenta previa is a condition under which the placenta covers the cervix, which can lead a pregnant woman to experience placental abruption or antenatal or postpartum hemorrhage. This condition can also lead to intrauterine growth restriction, which can cause a newborn to be small for his or her gestational age. One systematic review evaluated the use of ultrasound to detect and monitor placenta previa (NCCWCH, 2008). The authors concluded that ultrasound should be performed at 20 weeks, and again at 32 weeks if the scan at 20 weeks is positive. This practice accurately identifies most women for whom placenta previa will persist until term, enabling pregnant women and their physicians to anticipate and treat complications.

**Breech presentation at delivery.** In order for a fetus to move through the birth canal properly, the fetus must be able to precede head first. Most fetuses move into this position prior to term but some remain in a feet-first (breech) position, which places them at increased risk for poor birth outcomes unless they are delivered by elective cesarean section. While beneficial to babies in the breech position at term, cesarean section is a major abdominal surgery that has a greater risk of complications than vaginal delivery. Two systematic reviews have examined RCTs regarding the effectiveness of external cephalic version (application of pressure to the pregnant woman’s abdomen to encourage the fetus to turn to the head-first position) (Hutton and Hofmeyr, 2006; NCCWCH, 2008). Both found that external cephalic version was associated with lower risks of breech presentation at birth and delivery by cesarean section.

**Postterm delivery.** Once a pregnancy has reached term, continuation can be detrimental to the fetus and can lead to perinatal death. If a pregnancy continues beyond term, labor may be induced with pharmaceutical agents, but the risks of induction may outweigh benefits unless the fetus is truly past term (Baxley, 2003). Determining whether a pregnancy has continued past term is not simple. Identifying a fetus’s gestational age based on a pregnant woman’s recollection of the date of her last menstrual period is subject to significant recall bias. One

---

30 Risks associated with elective induction of labor include iatrogenic prematurity, uterine hyperstimulation, fetal heart rate abnormalities, shoulder dystocia, postpartum hemorrhage, and cesarean section. The risk that labor induction will result in an unplanned cesarean section is especially high for nulliparous women (i.e., women giving birth to their first child), who are also at increased risk for delivery with forceps and admission of their infants to neonatal intensive care units (Baxley, 2003).
systematic review of RCTs concluded that performing **ultrasound** between the 10\(^{th}\) and 14\(^{th}\) weeks of pregnancy is a reliable method for determining gestational age (NCCWCH, 2008). The authors compared rates of labor induction for postterm pregnancy between pregnant women who received ultrasound screening during the first trimester of pregnancy and pregnant women who received it during the second trimester. They found that first trimester ultrasound was associated with lower odds of labor induction due to postterm pregnancy (NCCWCH, 2008).

Two systematic reviews have assessed RCTs on **membrane sweeping** to encourage spontaneous labor to prevent postterm pregnancies (ICSI, 2008; NCCWCH, 2008). To sweep the membranes, a woman’s physician or nurse midwife inserts a finger into the cervix and moves it in a circular fashion to separate the membranes from the cervix. Both systematic reviews concluded that membrane sweeping reduces the probability that labor will have to be induced with pharmaceutical agents.

Two systematic reviews and two meta-analyses examined RCTs on the impact of **inducing labor with pharmaceutical agents** relative to monitoring and waiting for spontaneous labor (Gülmezoglu et al., 2006; ICSI, 2008; NCCWCH, 2008; Sanchez-Ramos et al., 2003). All four found that inducing labor with pharmaceutical agents reduces the risk of perinatal death. One meta-analysis reported that induction of labor was associated with a 70% lower risk of perinatal death that was statistically significant (Gülmezoglu et al., 2006) and the other reported a difference that was not statistically significant (Sanchez-Ramos et al., 2003). The meta-analyses also found that women whose labor was induced were at a lower risk of cesarean section (Gülmezoglu et al., 2006; Sanchez-Ramos et al., 2003).

**Summary of Findings**

Randomized controlled trials (RCTs) have consistently found no association between the numbers of prenatal visits pregnant women receive and birth outcomes for either infants or mothers.

However, there is clear and convincing evidence from multiple RCTs that the following prenatal care services are effective:

- Smoking cessation counseling
- Ultrasound to identify structural abnormalities determine gestational age
- Folic acid to prevent neural tube defects
- Screening and treatment for asymptomatic bacteriuria
- Screening for hepatitis B
- Screening and treatment for human immunodeficiency virus
- Calcium supplements, aspirin, and magnesium sulfate for treatment of hypertensive disorders
- Screening and prophylactic and therapeutic treatment for Rh(D) incompatibility
- Progestational agents to prevent preterm delivery
• Corticosteroids to promote maturation of lungs in fetuses scheduled for preterm delivery due to preeclampsia or other complications
• Magnesium sulfate to prevent neurological impairment in fetuses at risk for preterm delivery
• External cephalic version for breech presentation at term
• Membrane sweeping and induction of labor for prevention of postterm pregnancies

There is also a preponderance of evidence from nonrandomized studies and/or a small number of RCTs that the following prenatal care services are effective:

• Screening for domestic violence
• Screening for Down syndrome, hemoglobinopathies, and Tay-Sachs disease
• Screening and treatment for chlamydia, gonorrhea, and syphilis
• Screening for group B streptococcus
• Screening and treatment for gestational diabetes
• Iron supplements for treatment of iron deficiency anemia
• Blood pressure monitoring for hypertensive disorders
• Screening for atypical red blood cell alloantibodies other than Rh(D) incompatibility
• Ultrasound to diagnose placenta previa
<table>
<thead>
<tr>
<th>Risk Factor/Problem</th>
<th>Prenatal Screening Test</th>
<th>Treatment</th>
<th>Effect of Treatment on Health Outcomes</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Behavioral</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Domestic violence</td>
<td>Interview patient</td>
<td>Refer patient to specialized professionals and community resources</td>
<td>Reduction in risk of injury to mother and fetus</td>
<td>ICSI, 2008&lt;sup&gt;31&lt;/sup&gt;</td>
</tr>
<tr>
<td>Smoking</td>
<td>Ask patient whether she smokes</td>
<td>Provide brief advice, counseling, and/or written self-help materials to mother</td>
<td>Reduction in risk of preterm delivery and low birth weight</td>
<td>Lu et al., 2003; Lumley et al., 2004; NCCWCH, 2008&lt;sup&gt;32&lt;/sup&gt;; NZMOH, 2008; NZMOH, 2008; US DHHS, 2008&lt;sup&gt;34&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Genetic Disorders</strong></td>
<td>Ultrasound during 1&lt;sup&gt;st&lt;/sup&gt; trimester for nuchal translucency scan plus blood test for biochemical markers followed by diagnostic testing for mothers at high risk (amniocentesis or chorionic villus sampling)</td>
<td>None available</td>
<td>Not applicable</td>
<td>ICSI, 2008; NCCWCH, 2008</td>
</tr>
</tbody>
</table>

<sup>31</sup> ICSI = Institute for Clinical Systems Improvement. ICSI is an independent, not-for-profit organization that promotes quality improvement among health plans, hospitals, and medical groups in Minnesota. This citation is to an evidence-based guideline for routine prenatal care.

<sup>32</sup> NCCWCH = British National Collaborating Centre for Women’s and Children’s Health. This citation is to an evidence-based guideline for routine prenatal care that was prepared for the National Institute for Clinical Excellence.

<sup>33</sup> NZMOH = New Zealand Ministry of Health. This citation is to a systematic review that was commissioned for use in the development of an evidence-based guideline for smoking cessation.

<sup>34</sup> US DHHS = United States Department of Health and Human Services. This citation is to an evidence-based guideline for smoking cessation.
Table 2. Medically Effective Prenatal Care Services (Cont’d)

<table>
<thead>
<tr>
<th>Risk Factor/Problem</th>
<th>Prenatal Screening Test</th>
<th>Treatment</th>
<th>Effect of Treatment on Health Outcomes</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobinopathies(^{35})</td>
<td>Questionnaires regarding family history and blood tests for abnormal hemoglobinopathies followed by diagnostic testing for mothers at high risk (amniocentesis or chorionic villus sampling)(^{36})</td>
<td>None available</td>
<td>Not applicable</td>
<td>ICSI, 2008; NCCWCH, 2008</td>
</tr>
<tr>
<td>Tay-Sachs disease</td>
<td>Genetic testing for parents to determine whether they are Tay-Sachs carriers</td>
<td>No curative treatment available</td>
<td>Not applicable</td>
<td>ICSI, 2008</td>
</tr>
<tr>
<td>Neural tube defects(^{37})</td>
<td>Ultrasound to determine whether the fetus has a neural tube defect</td>
<td>No curative treatment available but risk can be reduced by mother’s consumption of adequate amounts of folic acid</td>
<td>Reduction in risk of giving birth to a child with a neural tube defect</td>
<td>ICSI, 2008; NCCWCH, 2008</td>
</tr>
<tr>
<td>Other structural anomalies(^{38})</td>
<td>Ultrasound during 1(^{st}) trimester for nuchal translucency scan or ultrasound during 2(^{nd}) trimester including fetal echocardiography</td>
<td>None available in most cases</td>
<td>Not applicable</td>
<td>Ultrasound during 1(^{st}) trimester: Makrydimas et al., 2003; Wald et al., 2008 Ultrasound during 2(^{nd}) trimester: NCCWCH, 2008</td>
</tr>
</tbody>
</table>

\(^{35}\) Hemoglobinopathies are disorders in the genes that control the expression of hemoglobin protein. These genetic disorders can result in anemia and abnormal hemoglobins. Sickle cell anemia and thalassemia are two of the most common types of hemoglobinopathies.

\(^{36}\) Blood tests are generally recommended only for mothers at risk for being a carrier of genetic traits associated with hemoglobinopathies.

\(^{37}\) Neural tube defects are birth defects that affect the spine and brain, such as spina bifida.

\(^{38}\) Structural anomalies are abnormalities in the development of the fetus. Congenital heart defects are the most common structural anomalies. Other structural anomalies that can be detected via ultrasound include anterior abdominal wall defects, congenital hydrocephalus, craniofacial abnormalities, dwarfism, neural tube defects, and renal defects (NCCWCH, 2008).
Table 2. Medically Effective Prenatal Care Services (Cont’d)

<table>
<thead>
<tr>
<th>Risk Factor/Problem</th>
<th>Prenatal Screening Test</th>
<th>Treatment</th>
<th>Effect of Treatment on Health Outcomes</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infectious Disease</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asymptomatic</td>
<td>Urine culture</td>
<td>Prescribe antibiotics to mother</td>
<td>Reduction in risk of kidney infection in mother, preterm delivery, and low birth weight</td>
<td>ICSI, 2008; Lin and Fajardo, 2008; Lu et al., 2003; NCCWH, 2008; Smaill and Vazquez, 2007</td>
</tr>
<tr>
<td>bacteriuria</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Chlamydia</strong></td>
<td>Nucleic acid amplification tests on specimens obtained from urine or vaginal swabs</td>
<td>Prescribe antibiotics to mother and prophylaxis to newborn</td>
<td>Reduction in risk of preterm premature rupture of membranes, preterm delivery, low birth weight, infant mortality, and conjunctivitis among newborns</td>
<td>ICSI, 2008; USPSTF, 1996</td>
</tr>
<tr>
<td><strong>Gonorrhea</strong></td>
<td>Tests on specimens obtained from urine or swabs of the vagina, rectum, urethra, or pharynx</td>
<td>Prescribe antibiotics to mother; provide ocular prophylaxis with silver nitrate, erythromycin, or tetracycline to newborn</td>
<td>Reduction in risk of conjunctivitis and blindness among newborns</td>
<td>ICSI, 2008; USPSTF, 1996</td>
</tr>
<tr>
<td><strong>Group B Streptococcus</strong></td>
<td>Culture sample from lower vagina or perianal area</td>
<td>Administer antibiotics during delivery</td>
<td>Reduction in incidence of meningitis, pneumonia, and sepsis among newborns</td>
<td>ICSI, 2008; Schrag et al., 2002</td>
</tr>
<tr>
<td><strong>Hepatitis B</strong></td>
<td>Blood test for detecting hepatitis B surface antigen</td>
<td>Administer hepatitis B vaccine and hepatitis B immune globulin to newborn</td>
<td>Reduction in risk of newborn developing chronic hepatitis B</td>
<td>ICSI, 2008; Krishnaraj, 2004; Lee et al., 2006; NCCWCH, 2008</td>
</tr>
</tbody>
</table>

---

39 The US Preventive Services Task Force (USPSTF) recommends only for pregnant women who are aged 24 years or younger and older pregnant women at increased risk of chlamydia infection (USPSTF, 2008).
40 USPSTF recommends only for pregnant women at increased risk of gonorrhea infection (USPSTF, 2008).
<table>
<thead>
<tr>
<th>Risk Factor/Problem</th>
<th>Prenatal Screening Test</th>
<th>Treatment</th>
<th>Effect of Treatment on Health Outcomes</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human Immunodeficiency Virus</td>
<td>HIV test (blood or oral fluid)</td>
<td>Prescribe antiretroviral therapy to mother, perform cesarean section, avoid breastfeeding</td>
<td>Reduction in risk of mother-to-child transmission of HIV</td>
<td>Chou et al., 2005; ICSI, 2008; NCCWCH, 2008</td>
</tr>
<tr>
<td>Syphilis</td>
<td>Blood test for syphilis</td>
<td>Prescribe penicillin to mother</td>
<td>Reduction in proportion of infants with syphilis and infant mortality</td>
<td>ICSI, 2008; NCCWCH, 2008; Nelson et al., 2004</td>
</tr>
<tr>
<td>Metabolic, Nutritional, and Endocrine Conditions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gestational diabetes</td>
<td>Assess risk factors, perform blood test for glucose tolerance</td>
<td>Dietary changes to control blood glucose, monitoring of blood glucose, insulin</td>
<td>Reduction in risk of infant death, shoulder dystocia, bone fracture, nerve palsy</td>
<td>ICSI, 2008; NCCWCH, 2008</td>
</tr>
<tr>
<td>Iron deficiency anemia</td>
<td>Hemoglobin or hematocrit test</td>
<td>Prescribe iron supplements to mother</td>
<td>Reduction in risk of low birth weight</td>
<td>Helfand et al., 2006; ICSI, 2008</td>
</tr>
<tr>
<td>Risk Factor/Problem</td>
<td>Prenatal Screening Test</td>
<td>Treatment</td>
<td>Effect of Treatment on Health Outcomes</td>
<td>Source</td>
</tr>
<tr>
<td>--------------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td><strong>Other Medical Conditions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Hypertensive disorders   | Assess risk of preeclampsia, monitor blood pressure, test urine for proteinuria         | Prescribe calcium supplements, antiplatelet agents (e.g., aspirin), and/or corticosteroids to mother; administer anti-convulsants (e.g., magnesium sulfate) during delivery | Calcium supplements: reduction in risk of preeclampsia and maternal death or serious morbidity (e.g., kidney failure)  
Antiplatelet agents: Reduction in risk of preeclampsia, preterm birth, small for gestational age birth, and fetal or neonatal death  
Calcium supplements: Hofmyer et al., 2006; ICSI, 2008; Meads et al., 2008; NCCWCH, 2008  
Antiplatelet agents: Askie et al., 2007; Duley et al., 2007; Meads et al., 2008; Ruano et al., 2005  
Anti-convulsants: Duley et al., 2003 |
| Rh(D) incompatibility    | Blood test for Rh typing and antibody screening                                         | Administer Rh(D) immune globulin to mother                                                      | Reduction in risk of hemolytic disease in neonates and newborns                                      | ICSI, 2008; NCCWCH, 2008; USPSTF, 1996 |
### Table 2. Medically Effective Prenatal Care Services (Cont’d)

<table>
<thead>
<tr>
<th>Risk Factor/Problem</th>
<th>Prenatal Screening Test</th>
<th>Treatment</th>
<th>Effect of Treatment on Health Outcomes</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other atypical red blood cell alloantibodies</td>
<td>Blood test for atypical red blood cell alloantibodies</td>
<td>Referral to specialist</td>
<td>Reduction in risk of hemolytic disease(^{41}) in neonates and newborns</td>
<td>NCCWCH, 2008</td>
</tr>
<tr>
<td>Pregnancy Outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placenta previa</td>
<td>Ultrasound in 2(^{nd}) trimester at 20 weeks to determine if placenta covers opening to vagina with follow-up scan at 32 weeks if the previous scan was positive</td>
<td>Hospitalization of mother if she becomes symptomatic</td>
<td>Reduction in risk of placental abruption, hemorrhage, intrauterine growth restriction</td>
<td>NCCWCH, 2008</td>
</tr>
<tr>
<td>Prevention of preterm delivery</td>
<td>Any test for a condition or behavior associated with increased risk of preterm delivery</td>
<td>Prescribe progestational agents to mother</td>
<td>Reduction in risk of preterm delivery and low birth weight</td>
<td>Progestational agents: Dodd et al., 2006; Dodd et al., 2008 ICSI, 2008; Lu et al., 2003; Mackenzie et al., 2006; Sanchez-Ramos et al., 2005</td>
</tr>
</tbody>
</table>

\(^{41}\) Symptoms of hemolytic disease include anemia, jaundice, body swelling, and difficulty breathing.
<table>
<thead>
<tr>
<th>Risk Factor/Problem</th>
<th>Prenatal Screening Test</th>
<th>Treatment</th>
<th>Effect of Treatment on Health Outcomes</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduce risk of severe neonatal morbidity in fetuses at risk for preterm delivery</td>
<td>Any test for a condition or behavior associated with increased risk of preterm delivery</td>
<td>Prescribe corticosteroids to promote maturation of fetal lungs, prescribe magnesium sulfate to prevent neurological impairment</td>
<td>Corticosteroids: Reduction in risk of neonatal death, respiratory distress syndrome, cerebroventricular hemorrhage, necrotising enterocolitis, systemic infection, and intensive care admissions among newborns</td>
<td>Corticosteroids: Lu et al., 2003; Roberts and Dalziel, 2006; Magnesium sulfate: Doyle et al., 2009</td>
</tr>
<tr>
<td>Breech presentation at term</td>
<td>Abdominal palpitations at 36 weeks or later</td>
<td>External cephalic version</td>
<td>Reduction in risk of baby being born in breech position and cesarean section</td>
<td>Hutton and Hofmeyr, 2006; NCCWCH, 2008</td>
</tr>
<tr>
<td>Postterm delivery (after 41 or 42 weeks)</td>
<td>Perform ultrasound during 1st trimester of pregnancy to determine the gestational age of the fetus</td>
<td>Membrane sweeping; induction of labor</td>
<td>Membrane sweeping: lower odds of induction of labor; Induction of labor: lower risk of perinatal death</td>
<td>Ultrasound screening for gestational age: NCCWCH, 2008; Membrane sweeping: ICSI, 2008; NCCWCH, 2008; Induction of labor: Gülmezoglu, et al., 2006; ICSI, 2008; NCCWCH, 2008; Sanchez-Ramos et al., 2003</td>
</tr>
</tbody>
</table>

\[42\] Health professional applies pressure to mother’s abdomen to encourage the fetus to turn from feet-first to head-first position.
AB 98 would apply only to health insurance products regulated by the CDI subject to the California Insurance Code. It would require all CDI-regulated policies to cover maternity services. Maternity services generally include prenatal care (office visits and screening tests), labor and delivery services (including hospitalization), and postnatal care. Since all CDI-regulated group policies currently cover maternity benefits, the effect of this bill would be primarily on the CDI-regulated individual market.

This section presents first the current, or baseline, costs and coverage related to maternity coverage and then details the estimated utilization, cost, and coverage impacts of AB 98. This analysis excluded complications of pregnancy because all health insurance plans provide coverage for such complications. For further details on the underlying data sources and methods, please see Appendix D at the end of this document.

Present Baseline Cost and Coverage

Current Coverage of Mandated Benefit

To estimate current coverage of maternity benefits, CHBRP surveyed the largest major health insurers in California. Responses to this survey represented 73.4% of the CDI-regulated market. Coverage for maternity services is almost universal, particularly in the public sector and for individuals and families who receive employment-based health insurance.

Public programs

All public programs include maternity benefits for eligible recipients. As discussed in the Introduction, pregnant women with incomes less than 200% of the Federal poverty level qualify for maternity benefits under the Medi-Cal program. In addition, women who have incomes between 200% and 300% of the Federal poverty level qualify for maternity benefits through the AIM program, even if they simultaneously have private insurance with maternity benefits but are subject to high deductibles or copayments.

Private insurance

Because maternity benefits are required to be provided by Knox-Keene licensed DMHC-regulated plans, AB 98 targets CDI-regulated policies. The distribution of enrollee coverage is summarized as follows:

- About 2,370,000 Californians, or 11.1% of enrollees in plans subject to state regulation, are in the CDI-regulated market.
- Within the CDI-regulated market, 100% of large- and small-groups policies cover maternity services, according to CHBRP’s survey of health insurers.
- Therefore, the proposed mandate would impact the 1,038,000 enrollees in individual (non-group) CDI-regulated policies.

 Health maintenance organizations in California are licensed under the Knox-Keene Health Care Services Plan Act, which is part of the California Health and Safety Code.
• Within the CDI-regulated individual market, 22% of enrollees or about 233,000 individuals have coverage for maternity services and 805,000 (78%) do not.

• Of those that do not currently have coverage for maternity services, about one-quarter, or 207,000, are women of childbearing age (19 to 44).

• In addition, about 149,700 Californians in CDI-licensed individual plans that include maternity benefits are in HDHPs (defined as deductibles of $1,050 or higher). HDHPs generally do not exempt maternity/prenatal services from the high deductibles (KFF, 2007), so a high level of cost sharing is required for maternity services.

As a result of the broad availability of maternity benefits within the private insurance markets and through public programs, only a small proportion of deliveries in California are not covered by some form of insurance (RAND Corporation, 2009). In 2007, 46.7% of deliveries were covered by Medi-Cal and 46.1% were covered by private insurance; self-pay accounted for only 2.3%. However, since 2004, when CHBRP conducted its analysis of SB 1555, the number of insured Californians (men and women) in CDI-regulated individual policies without maternity benefits has more than quadrupled, from an estimated 192,000 in 2004 to an estimated 805,000 in 2008.

Table 3 summarizes the rates of maternity coverage among those enrolled in CDI-regulated individual policies, by age and gender of the enrollee.

**Table 3. Percentage of Members Enrolled in Individual CDI-Regulated Policies with Maternity Coverage**

<table>
<thead>
<tr>
<th>Age of Covered Individual</th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>00-19</td>
<td>25%</td>
<td>25%</td>
<td>25%</td>
</tr>
<tr>
<td>20-24</td>
<td>12%</td>
<td>18%</td>
<td>15%</td>
</tr>
<tr>
<td>25-29</td>
<td>10%</td>
<td>21%</td>
<td>15%</td>
</tr>
<tr>
<td>30-34</td>
<td>14%</td>
<td>24%</td>
<td>19%</td>
</tr>
<tr>
<td>35-39</td>
<td>18%</td>
<td>25%</td>
<td>22%</td>
</tr>
<tr>
<td>40-44</td>
<td>21%</td>
<td>23%</td>
<td>22%</td>
</tr>
<tr>
<td>45-49</td>
<td>25%</td>
<td>25%</td>
<td>25%</td>
</tr>
<tr>
<td>50-54</td>
<td>28%</td>
<td>27%</td>
<td>27%</td>
</tr>
<tr>
<td>55-59</td>
<td>33%</td>
<td>33%</td>
<td>33%</td>
</tr>
<tr>
<td>60-64</td>
<td>46%</td>
<td>45%</td>
<td>45%</td>
</tr>
<tr>
<td><strong>Under 65 Total</strong></td>
<td>21%</td>
<td>24%</td>
<td>22%</td>
</tr>
</tbody>
</table>

*Source: California Health Benefits Review Program, 2009.*

**Current Utilization Levels and Costs of the Mandated Benefit**

*Current utilization levels, births*

CHBRP estimates that about 30,100 births would occur among women enrolled in CDI-regulated policies in 2009 (Table 1). Of those births, about 7,100 would be to women who did not have coverage for maternity services at the time of pregnancy. All of these 7,100 women would be individual policyholders. These estimates are based on the Milliman Health Cost Guidelines estimates of age/gender pregnancy rates among all privately insured female employees with
maternity coverage and the age and gender distribution of the 2,370,000 Californians enrolled in all CDI-regulated policies (i.e., group and individual). Birth rates among women with CDI-regulated individual policies were assumed to be comparable to those among privately insured female employees, because after weighting for age group, the aggregate birthrate calculated using Milliman’s estimates for female employees was very similar to the birthrates reported by the two carriers who provided us with this information. Milliman Health Cost Guidelines data were used instead of the data provided by the two carriers so that birthrates could be estimated by age group.

The estimated number of births to women with no maternity coverage assumes that age-adjusted birth rates are the same among women who have maternity benefits and women who do not have maternity benefits, or no “selection effects.” There are several reasons to support this assumption:

- **Richer benefits:** Although there is clearly good reason to believe that women who choose plans in the individual market without maternity benefits would have lower birth rates due to self-selection, CHBRP’s survey of health plan enrollment data by age and gender indicates that many women who are 50 years or older have plans with maternity benefits. This finding suggests that plans with maternity benefits are appealing for reasons other than the maternity benefit. For example, these plans usually provide a much richer mix of benefits beyond maternity benefits. Thus, women of childbearing age are also likely to find these plans valuable for reasons other than the maternity benefit.

- **Unplanned pregnancies:** A recent Centers for Disease Control and Prevention (CDC) study reports that 49% of pregnancies are unplanned, suggesting that even among women who self-select into policies without maternity benefits, birth rates may be higher than the women themselves intend (Finer and Henshaw, 2006).

- **Insuring against financial risk:** Women (and men) may be selecting plans without maternity benefits primarily to provide protection against large financial risks, and may view pregnancy as a reasonable financial risk against which they should self-insure.

Because the main CHBRP estimates assume that birth rates are the same for policies that currently do and do not offer maternity coverage (i.e., no selection effects), the estimates of total expenditures derived using this assumption should be considered an upper bound. In other words, if the women who purchase individual coverage without maternity benefits have lower pregnancy rates than women who purchase individual coverage with maternity benefits, even after adjusting for age, then CHBRP’s estimate of the impact of AB 98 on covered deliveries, total expenditures, and premiums will be too high.

As an alternative, CHBRP estimated the impact of AB 98 on premiums under a different set of assumptions that allow for self-selection into maternity coverage based on factors other than age and gender. Women who do not currently have maternity benefits were assumed to have age-specific pregnancy rates lower than those of women who currently have maternity benefits. The effect of the alternative assumptions about relative birthrates on the estimated premium increase is summarized in the subsection “Impacts for Each Category of Payer Resulting from the Benefit Mandate.”
Prenatal care utilization
Assessing the utilization of prenatal services requires analysis both of frequency of care (how many office visits) and when in the pregnancy a woman initiates care. Most estimates define adequate utilization of prenatal services as care that is initiated in the first trimester and a total of between 8 and 13 visits (Braveman et al., 2003). The combination of these two dimensions of care can be an indicator of the adequacy of prenatal care (Kotelchuck, 1994).

In 2006, there were 562,200 live births in California. The vast majority of those live births (86.1%) were preceded by at least 9 prenatal visits, and 85.2% were preceded by prenatal care initiated during the first trimester. However, about 0.6% of live births were preceded by no prenatal care, and about 2.1% of live births were preceded by only 1 to 4 prenatal visits (CDPH, 2009).

Unit price
CHBRP’s estimates of the utilization and cost for uncomplicated deliveries in California were based on age-specific rates of utilization for the following categories of services: hospital inpatient, hospital outpatient, lab, and physician care. When aggregated across all categories of service and age categories, CHBRP estimates that the average cost of an uncomplicated delivery in California is $11,300.

Expenditures
CHBRP estimates that within the CDI-regulated market, the current (pre-mandate) portion of the total per member per month (PMPM) expenditures attributable to maternity is $11.96, broken down as follows:
- $5.82 PMPM of the total is currently covered by insurance,
- $2.09 PMPM is paid by individuals in the form of copayments and deductibles for covered services,
- $2.85 is paid by individuals in the form of out-of-pocket expenditures for noncovered services, and
- $1.21 is paid for by Medi-Cal or AIM on behalf of women who qualify for maternity benefits because their insurance does not cover maternity or they face costs for maternity services exceeding $500.

The Extent to Which Costs Resulting From Lack of Coverage Are Shifted to Other Payers, Including Both Public and Private Entities

Cost-shifting to public programs
Uninsured women whose income is less than 200% of the Federal poverty level may qualify for Medi-Cal when they become pregnant, and receive coverage for maternity services through that program. In 2007, about 47% of California births were covered by Medi-Cal (RAND Corporation, 2009).

AIM provides coverage for both uninsured and underinsured women between 200% and 300% of the Federal poverty level. Data provided to CHBRP from the AIM program indicate that in
2008, about 17% of births covered by AIM were for women who either had insurance but no coverage for maternity services, or who had maternity benefits but faced costs for services greater than $500. Therefore, there is evidence that some cost-shifting occurs to these programs from the privately insured market.

Risk segmentation and adverse selection

The absence of a mandate allows CDI-regulated insurers to offer a greater number of lower-cost individual policies that exclude maternity services, resulting in greater risk segmentation. The net impact of this trend toward greater market segmentation is debatable. Advocates for greater segmentation argue that the current health insurance market generally provides an insufficient number of policies with basic benefits, effectively forcing individuals to purchase more generous benefits than they prefer. The underlying belief is that it is inequitable to charge individuals who are unlikely to need certain benefits to subsidize individuals who do. In contrast, opponents argue that the failure to spread risk across larger populations is inequitable and that segmentation drives up the cost of higher-cost policies (such as those that cover maternity services) for those most in need of insurance, because only higher-risk people purchase them, with lower-risk individuals self-selecting instead into lower-cost policies.

The continued growth of HDHPs, as well as plans without maternity benefits, in the individual market is evidence that risk segmentation has already had a substantial impact on the individual (non-group) insurance market. The number of insured Californians without maternity benefits has more than quadrupled, from an estimated 192,000 in 2004 (CHBRP, 2004) to the current estimate of 805,000. This risk segmentation produces adverse selection among plans that still offer maternity benefits. At least in theory, the premiums in those plans experiencing adverse selection could increase disproportionately, as low-risk individuals abandon those policies in search of lower-cost policies. However, it is an empirical question as to whether or not a premium spiral has occurred. Although this is an issue worthy of further, systematic evaluation and research, it is not feasible to assess this within the 60-day timeframe CHBRP has to conduct this analysis.

Public Demand for Coverage

While coverage for maternity benefits is widely available and essentially universal in the group insurance market, there is clearly a growing demand for lower-premium insurance policies in the individual market, including those without maternity services. As discussed above, the number of enrollees in plans that do not cover maternity services has quadrupled during the last five years.

44 Personal communication with Legislative Coordinator, Managed Risk Medical Insurance Board (MRMIB), March 4, 2009.
45 Based on criteria specified under SB 1704 (2007), CHBRP is to report on the extent to which collective bargaining entities negotiate for, and the extent to which self-insured plans currently have, coverage for the benefits specified under the proposed mandate to determine “public demand.” However, given that all group policies cover maternity services, including those that are self-insured, the standard criteria for evaluating public demand is not relevant.
Impacts of Mandated Coverage

How Would Changes in Coverage Related to the Mandate Affect the Benefit of the Newly Covered Service and the Per-Unit Cost?

Changes in coverage
The enactment of AB 98 would require all CDI-regulated individual policies that do not cover maternity service to do so, thus expanding maternity services coverage to 805,000 enrollees, including 207,000 women aged 19 to 44 years. However, most women are likely to continue to face large out-of-pocket expenditures for maternity services regardless of whether or not their insurance policy includes maternity benefits. This is because almost two-thirds of the women in CDI-regulated individual policies are currently in HDHPs and prenatal care is usually subject to the HDHP deductible. Even the women currently enrolled in non-HDHPs frequently face high cost-sharing requirements in the CDI-regulated individual market, and some might also choose to switch to HDHPs post-mandate in order to save on premiums.

The changes in premiums resulting from AB 98 will impact the number of individuals who maintain health insurance coverage. This is discussed in further detail in the subsection, “Changes in Coverage as a Result of Premium Increases.”

Impact on supply and on the health benefit
There is no evidence that the proposed mandate would change the effectiveness of maternity services. It is conceivable that if there is currently self-selection of the highest-risk women into insurance policies with maternity benefits, then the average effectiveness of prenatal care and screening tests could be lower for the newly covered women than for those who already have maternity benefits.

Impact on per-unit cost
There is no evidence that the proposed mandate would change the per-unit cost of individual services (e.g., prenatal screenings) or the package of maternity services.

How Would Utilization Change As a Result of the Mandate?
CHBRP estimates that approximately 7,100 pregnancies would be newly covered under CDI-regulated insurance polices post-mandate. The impact of expanded coverage on utilization is summarized below:

- Overall, the mandate is estimated to have no impact on the number of deliveries, since the birth rate is not expected to change post-mandate.
- Most women are likely to continue to face large out-of-pocket expenditures for maternity services regardless of whether or not their insurance policy includes maternity benefits. This is because almost two-thirds of the women in CDI-regulated individual policies are currently in HDHPs and prenatal care is usually subject to the HDHP deductible. Even the women currently enrolled in non-HDHPs frequently face high cost-sharing requirements in the CDI-regulated individual market, and some might also choose to switch to HDHPs post-mandate in order to save on premiums.
• Standard prenatal care is almost always bundled with delivery services and paid for as a single lump-sum fee to physicians. As women need the obstetrician’s services for delivery, they are likely to pay this fee eventually even if they must pay out of pocket. Thus, their only pre-mandate incentive to delay or avoid receipt of prenatal care is to postpone payment. To the extent that prenatal care and delivery services are bundled as a fixed charge and women are aware of this fee structure, it is unlikely that AB 98 would have a large impact on utilization of standard prenatal care services. Furthermore, even if use of these services increased, it would not affect expenditures because the fee does not depend on the number of prenatal care visits made.

• Certain types of screening tests are not included in the standard prenatal care fee and might be used more frequently post-mandate if they are part of the maternity benefit, thereby affecting costs. The amount of the increase is difficult to estimate, as these tests would be subject to HDHP deductibles and women may treat them as out-of-pocket costs.

• Length of stay is likely to be shorter for mothers who are self-pay or for those women whose obstetricians are paid a fixed fee for postpartum care (Galbraith et al., 2003; Malkin et al., 2003). However, the latter would not change as a result of the mandate, and women in HDHPs are likely to pay the obstetrician fee out of their deductible anyway, implying that the mandate would have little impact on the number of women who self-pay. For this reason, CHBRP estimates the overall impact on length of stay to be negligible.

To What Extent Would the Mandate Affect Administrative and Other Expenses?

Health care plans include a component for administration and profit in their premiums. In estimating the impact of this mandate on premiums, CHBRP assumes that health plans would apply their existing administration and profit loads to the marginal increase in health care costs produced by the mandate. The mandate would therefore increase the administrative expenses for health plans proportionate to the increase in health care costs. Claims administration costs may go up slightly due to an increase in maternity claims. It is also conceivable that claims administration costs could decline slightly, by eliminating the need to distinguish different benefit structures in claims processing.

Plans would have to modify some insurance contracts and member materials. Plans would probably not have to re-contract with providers to define reimbursement for these services because they already offer other plans that cover maternity services.

Impact of the Mandate on Total Health Care Costs

Changes in total expenditures

Among all enrollees in state-regulated policies (both CDI-regulated and DMHC-regulated), total health expenditures are estimated to increase by $29.7 million, or 0.04%, as a result of this mandate (see row labeled “Total Annual Expenditures” in Table 1). As the total number of deliveries and average cost associated with each delivery is not expected to increase, the mandate primarily shifts costs from individuals to insurers. CHBRP assumes that the administrative expenses for health plans will increase in proportion to the increase in their covered health care
costs, leading to an estimated increase in overall expenditures. Note that the increase in total expenditures is a total of:

- the increase in premium expenditures in the individual market: $89.3 million (see row labeled “Premium expenditures for individually purchased insurance” in Table 1).

- the increase in out-of-pocket expenditures for maternity benefits covered by insurance (e.g., copayments and deductibles): $21.5 million (see row labeled “Individual out-of-pocket expenditures for covered benefits”).

- the reduction in out-of-pocket expenditures for maternity benefits not currently covered by insurance: $81.1 million (see row labeled, “Out-of-pocket expenditures for noncovered benefits”).

**Impact on long-term costs**

If women with maternity benefits were more likely to receive adequate prenatal care, and a lack of prenatal care were clearly shown to have an adverse effect on neonatal outcomes and downstream health care costs, then the long-term beneficial cost consequences could be considerable. Although there is evidence that some prenatal care services are associated with improvements in birth outcomes, AB 98 does not stipulate which services health plans must provide as part of prenatal care. The analyses summarized in the *Medical Effectiveness* section found no significant association between the number of prenatal care visits and birth outcomes. Furthermore, as noted above, HDHPs have become the predominant form of insurance in the individual market. As a result, the majority of pregnant women in this market face financial barriers to receiving prenatal care that are not addressed by this mandate. Therefore, to the extent that HDHPs reduce or delay access to prenatal care—leading to negative neonatal outcomes and thus higher long-term costs—these negative consequences would not be ameliorated by this mandate, which does nothing to address the growth or limits of such plans. For these reasons, the mandate is likely to have minimal impact on long-term costs.

**Impacts for Each Category of Payer Resulting from the Benefit Mandate**

**Changes in expenditures and PMPM amounts by payer category**

Mandating maternity coverage is expected to increase the per member per month (PMPM) premiums for CDI-regulated individual policies by $7.17, or 4.24%, on average (Table 5). Premium impacts are summarized as follows:

- CHBRP estimates that for the majority (78%) of individuals in the CDI-regulated individual market who do not currently have maternity benefits, AB 98 would *increase* average premiums by 2.01% to 27.47% among those 19 to 44 years old, depending on the age of the enrollee (see Table 6).

- Among the minority (22%) of individuals who currently have maternity benefits, AB 98 is expected to *decrease* average premiums by 1.30% to 19.46%, depending on the age of the enrollee (see Table 6).
The actual premium increase of those policies depends on a number of market factors, including, but not limited to, the changes in actuarial costs. CHBRP uses the actuarial value of the maternity benefit as the best estimate of the change in premiums that would occur under the mandate. The alternative is to use the observed differences in premiums between products with and without maternity coverage. However, these differences might yield a misleading estimate of the impact of adding maternity benefits to a health insurance product that currently has none, since products that currently include maternity benefits also include other benefits not typically found in products without maternity benefits and may also attract adverse selection based on those additional benefits. Premium differences between health insurance products with and without maternity benefits, controlling for other differences in benefits, would be an issue worthy of further and systematic review.

Impact of Gender Rating and Self-Selection

Most of the premium changes estimated by CHBRP would be concentrated among those aged 19 to 39 years, because insurance premiums in the individual market are stratified by age bands. To the extent that insurance premiums are gender-rated, women would also experience relatively higher premium increases than men if the bill were to become law. Gender-rating of premiums is legal in almost all states, including California, and is frequently used nationwide (NWLC, 2008). Based on CHBRP’s survey of health insurers, currently premiums are gender-rated for 59% of individually purchased CDI-regulated health insurance products in California. It is also possible that plans might use gender-rating for more of their insurance products if the mandate passed. CHBRP therefore conducted a hypothetical analysis of an alternative scenario in which premiums are gender-rated for all individual CDI-regulated policies. The analysis yielded estimated average PMPM premium decreases ranging from –0.87% to –8.16% among women who had maternity coverage pre-mandate and average PMPM premium increases ranging from 2.93% to 40.58% among those who did not, depending on age. Premiums of male enrollees would remain constant.

Essentially, gender rating spreads the cost of the newly covered pregnancies over a smaller population, so premium increases are higher among that group than in the absence of gender rating. Within each age group, the estimated average premium increases among women who currently have no maternity benefits are greater than the average increases estimated in the absence of gender rating, and the estimated average premium decreases among women who currently have maternity benefits are smaller than the average decreases estimated in the absence of gender rating. With gender-rating for only a subset of policies, the premium changes for women would likely be somewhere between the original and alternative estimates. To the extent that gender-rating of premiums segments the market and leads to the cost of new maternity coverage being borne entirely by female policyholders, AB 98 will be less able to fulfill its goal of spreading the risk of maternity costs over a broader patient population.

Impact of self-selection

In addition to varying with age and gender, premium changes resulting from the mandate could vary substantially across plans, depending on how women self-select into different plans in the pre- versus post-mandate period. Women with individual CDI-regulated policies who currently have maternity coverage may have a higher likelihood of getting pregnant in the future than women of the same age who are in policies without maternity coverage. If so, the cost of
extending maternity benefits to previously uncovered women could be overstated by the CHBRP model assumptions. For example, if women who currently do not have maternity benefits have only half the birth rate of the women who do have maternity benefits (rather than the same birthrate, as assumed in the tables), then the estimated percent premium increase across all enrollees in the CDI-regulated individual market would be only about 1.90% on average (vs. the estimated 4.24% increase when birth rates are assumed to be the same for women who currently do and do not have maternity benefits).

However, the impact of AB 98 on the premiums for any particular insurance product could be quite different from that suggested by the average premium increase. For example, a “bare-bones” policy that previously attracted only healthy young males might attract a number of otherwise healthy young women with a disproportionately high likelihood of pregnancy if the mandate were implemented. Under that scenario, it is conceivable that premiums in the policy attracting adverse selection could go up substantially. At the same time, however, these women would be switching out of other policies (presumably those with maternity coverage prior to the mandate) whose premiums would then decline more than the average. Thus, equalization of the maternity risk across policies could result in a commensurate narrowing of premium differentials in the individual CDI-regulated market, with some policies experiencing disproportionate increases and others experiencing disproportionate decreases.

Changes in coverage as a result of premium increases

CHBRP estimates the impact on the number of insured when the premium increase (or decrease) faced by any segment of the population is at least a 1% increase.46 Using CHBRP’s standard methodology, premium changes associated with AB 98 are projected to lead to a net increase of approximately 7,600 uninsured Californians. CHBRP estimates that these newly uninsured would disproportionately consist of younger individuals (e.g., those aged 19 to 29 years) since premiums are age-stratified and premium increases are concentrated among this population. To the extent that plans gender-rate premiums (either currently or if AB 98 passes), women may also experience greater premium increases and hence disproportionate loss of coverage.

Impact of changes in private coverage on public programs

Although all insured women would have maternity benefits after enactment of AB 98, it is likely that women who qualify for Medi-Cal after pregnancy would still shift to Medi-Cal post-mandate, due to their low income levels and desire to avoid the premiums associated with private insurance. National data from the Medical Expenditure Panel Survey (MEPS) showed that only 0.20% of female Medicaid beneficiaries aged 18 to 45 have any month in which they had both individually purchased private insurance and have Medicaid coverage. Even some of that apparent overlap may have been switching insurance coverage mid-month. These data suggest that women in California will not pay to retain their private coverage if they become eligible for Medi-Cal as a result of their pregnancy. Conversely, however, it seems unlikely that many of the individuals projected to drop private insurance coverage as a result of the premium increases associated with AB 98 would qualify for Medi-Cal, since they probably would have enrolled in Medi-Cal prior to the mandate, had they been eligible.

46 See http://www.chbrp.org/documents/uninsured_020707.pdf for more information on CHBRP’s methods for calculating the number of uninsured as a result of premium changes.
The extent to which AB 98 would impact the shift of maternity costs from private plans onto AIM depends on whether pregnant CDI-regulated individual policyholders who currently have no maternity coverage and qualify for AIM would continue to qualify and enroll in AIM after they are given maternity coverage through their health plan. HDHPs typically do not exempt prenatal care services from the high deductible and have high cost-sharing levels to reduce monthly premiums, so HDHPs with maternity benefits may still be viewed as inadequate coverage by low-income women. Since the cost of maternity services in HDHPs would likely still be greater than $500 (adding up deductibles and copayments), women enrolled in HDHPs would still qualify for AIM post-mandate.

About two-thirds of enrollees in CDI-regulated individual policies are already in HDHPs and it seems likely that even more low-income women who currently do not have maternity coverage would enroll in HDHPs after enactment of AB 98. Because individuals currently choosing plans without maternity services are doing so to save on monthly premiums, those who can afford to (and do not drop insurance entirely) may purchase the next “cheapest” option post-mandate—HDHPs. If low-income women who are currently enrolled in plans that do not cover maternity services would enroll in HDHPs that do cover maternity services post-mandate, then either way they are likely to qualify for, and enroll in, AIM. Thus, it is not likely that AB 98 would reduce enrollment in AIM.

The other consideration, however, is the extent to which AIM plans seek reimbursement from the private plans for the maternity costs of dual enrollees. AIM is a secondary payer, with the private insurer paying first if the enrollee’s coverage includes maternity benefits. This suggests that AIM’s costs could decrease since all enrollees would have maternity coverage. Thus, for the approximately 700 enrollees in CDI-regulated individual policies who would simultaneously enroll in the AIM program based on CHBRP’s model, the enrollee’s private insurance would pay for maternity services first and AIM would be the secondary payer.

Impact on Access and Health Service Availability
As discussed previously, the mandate is estimated to have a minimal impact on access to and availability of maternity services, primarily because the benefit is currently so widely available.
<table>
<thead>
<tr>
<th>Market Segment</th>
<th>DMHC-Regulated</th>
<th>CDI-Regulated</th>
<th>Total Annual</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Large Group</td>
<td>Small Group</td>
<td>Individual</td>
</tr>
<tr>
<td>Total Population in Plans Subject to State Regulation (a)</td>
<td>11,100,000</td>
<td>2,844,000</td>
<td>966,000</td>
</tr>
<tr>
<td>Total Enrolled in Plans Subject to AB 98</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Average portion of premium paid by employer</td>
<td>$279.83</td>
<td>$246.48</td>
<td>$0.00</td>
</tr>
<tr>
<td>Average portion of premium paid by employee</td>
<td>$69.94</td>
<td>$71.52</td>
<td>$330.89</td>
</tr>
<tr>
<td>Total Premium</td>
<td>$349.77</td>
<td>$318.00</td>
<td>$330.89</td>
</tr>
<tr>
<td>Member expenses for covered benefits (deductibles, copays, etc.)</td>
<td>$18.90</td>
<td>$24.61</td>
<td>$54.10</td>
</tr>
<tr>
<td>Member expenses for benefits not covered</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Total Expenditures</td>
<td>$368.67</td>
<td>$342.62</td>
<td>$385.00</td>
</tr>
</tbody>
</table>


Notes: (a) This population includes privately insured (group and individual) and publicly insured (e.g., CalPERS, Medi-Cal, Healthy Families, AIM, MRMIP) individuals enrolled in health insurance products regulated by DMHC or CDI. Population includes enrollees aged 0 to 64 years and enrollees 65 years or older covered by employment-sponsored insurance. (b) Of these CalPERS members, about 59% or 483,800 are state employees. (c) Medi-Cal state expenditures for members under 65 years of age include expenditures for the Major Risk Medical Insurance Program (MRMIP) and the Access for Infants and Mothers (AIM) program. Medi-Cal state expenditures for members over 65 years of age include those with Medicare coverage.
Table 5. Impacts of the Mandate on Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2009

<table>
<thead>
<tr>
<th></th>
<th>DMHC-Regulated</th>
<th></th>
<th>CDI-Regulated</th>
<th></th>
<th>Total Annual</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Large Group</td>
<td>Small Group</td>
<td>Individual</td>
<td>HMO</td>
<td>Managed Care 65 and Over</td>
</tr>
<tr>
<td>Total Population in Plans Subject to State Regulation (a)</td>
<td>11,100,000</td>
<td>2,844,00</td>
<td>966,00</td>
<td>820,00</td>
<td>159,000</td>
</tr>
<tr>
<td>Total Population in Plans Subject to AB 98</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Average portion of premium paid by employer</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Average portion of premium paid by employee</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Total Premium</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Member expenses for covered benefits (deductibles, copays, etc.)</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Member expenses for benefits not covered</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Total Expenditures</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
<td>$0.00</td>
</tr>
<tr>
<td>Percentage Impact of Mandate</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>Insured Premiums</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>Total Expenditures</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
</tbody>
</table>


Notes: (a) This population includes privately insured (group and individual) and publicly insured (e.g., CalPERS, Medi-Cal, Healthy Families, AIM, MRMIP) individuals enrolled in health insurance products regulated by DMHC or CDI. This population includes enrollees aged 0 to 64 years and enrollees 65 years or older covered by employment-sponsored insurance. (b) Of these CalPERS members, about 59% or 483,800 are state employees. (c) Medi-Cal state expenditures for members under 65 years of age include expenditures for the Major Risk Medical Insurance Program (MRMIP) and the Access for Infants and Mothers (AIM) program. Medi-Cal state expenditures for members over 65 years of age include those with Medicare coverage.
Table 6. Estimated Impact on Individual Premiums by Age Group

<table>
<thead>
<tr>
<th>Age</th>
<th>Estimated Premiums</th>
<th>Pre-Mandate</th>
<th>Post-Mandate</th>
<th>% Impact on Premium (a)</th>
<th>Covered w/ Maternity Pre-Mandate</th>
<th>Covered w/o Maternity Pre-Mandate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Covered w/ Maternity</td>
<td>Covered w/o Maternity</td>
<td>Covered w/ Maternity</td>
<td>Covered w/o Maternity</td>
<td>Covered w/ Maternity Pre-Mandate</td>
<td>Covered w/o Maternity Pre-Mandate</td>
</tr>
<tr>
<td>Child 0-1</td>
<td>$257</td>
<td>$257</td>
<td>$257</td>
<td>$257</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>Child 2-6</td>
<td>$60</td>
<td>$60</td>
<td>$60</td>
<td>$60</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>Child 7-18</td>
<td>$71</td>
<td>$70</td>
<td>$70</td>
<td>$70</td>
<td>-0.18%</td>
<td>0.63%</td>
</tr>
<tr>
<td>Child (b) 19-22</td>
<td>$100</td>
<td>$98</td>
<td>$100</td>
<td>$100</td>
<td>-0.41%</td>
<td>1.46%</td>
</tr>
<tr>
<td>Adult (c) To 25</td>
<td>$140</td>
<td>$101</td>
<td>$122</td>
<td>$122</td>
<td>-12.92%</td>
<td>21.27%</td>
</tr>
<tr>
<td>Adult 25-29</td>
<td>$182</td>
<td>$115</td>
<td>$147</td>
<td>$147</td>
<td>-19.46%</td>
<td>27.47%</td>
</tr>
<tr>
<td>Adult 30-34</td>
<td>$195</td>
<td>$134</td>
<td>$167</td>
<td>$167</td>
<td>-14.48%</td>
<td>24.21%</td>
</tr>
<tr>
<td>Adult 35-39</td>
<td>$188</td>
<td>$157</td>
<td>$175</td>
<td>$175</td>
<td>-6.82%</td>
<td>11.45%</td>
</tr>
<tr>
<td>Adult 40-44</td>
<td>$191</td>
<td>$184</td>
<td>$188</td>
<td>$188</td>
<td>-1.30%</td>
<td>2.01%</td>
</tr>
<tr>
<td>Adult 45-49</td>
<td>$224</td>
<td>$224</td>
<td>$224</td>
<td>$224</td>
<td>-0.03%</td>
<td>0.11%</td>
</tr>
<tr>
<td>Adult 50-54</td>
<td>$285</td>
<td>$285</td>
<td>$285</td>
<td>$285</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>Adult 55-59</td>
<td>$360</td>
<td>$360</td>
<td>$360</td>
<td>$360</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>Adult 60-64</td>
<td>$451</td>
<td>$451</td>
<td>$451</td>
<td>$451</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
</tbody>
</table>


Notes: (a) Percent impact on premiums may not correspond to ratio of pre- vs. post-mandate premiums shown in table, due to rounding.
(b) This analysis is based on Milliman’s claims analysis and the claims database identifies “Child 19-22” as those young adults who are dependent on another individual enrollee.
(c) “Adult, To 25” means those young adults who are individual enrollees.
PUBLIC HEALTH IMPACTS

The Impact of the Proposed Mandate on the Health of the Community

As presented in the Medical Effectiveness section, the prenatal care services that are effective in improving health outcomes are counseling on behavioral risks such as smoking and domestic violence; screening and counseling for genetic disorders; screening for and treating infectious diseases such as asymptomatic bacteriuria, hepatitis B, HIV, STIs, and group B streptococcus; screening and management of hypertensive disorders, gestational diabetes, anemia, and Rh(D) incompatibility; and screening and management of women at risk for preterm deliveries.

The Utilization, Cost, and Coverage Impacts section estimates that 7,100 pregnancies would be newly covered as a result of AB 98. Although the previously mentioned specific prenatal care services are effective, the extent to which AB 98 would increase the utilization of these services is unknown. This section will present both the lower bound and upper bound estimates of the change in utilization of effective prenatal care services and the resulting public health impact of this mandate to illustrate the range in potential public health impacts.

Lower Bound Estimate

A lower bound estimate of the public health impact of AB 98 assumes that utilization of effective prenatal care services would not increase post-mandate. The justification for this assumption is that the women enrolled in the CDI-regulated policies without maternity benefits chose this health insurance option due to its low cost. We assume that as insurers comply with AB 98, these women would still enroll in the lower cost plans, which would still have high levels of cost sharing. Therefore, in this lower bound estimate, it is assumed that there is no increase in the utilization of effective prenatal care services and thus no impact on public health as a result of AB 98 would be expected.

Upper Bound Estimate

To estimate the upper bound of the public health impact of AB 98, it is assumed that pregnant women previously enrolled in CDI-regulated policies without maternity benefits would switch to insurance plans without substantial cost sharing for prenatal care post-mandate. In this scenario, we are assuming that we would expect to see an increase in utilization of effective prenatal services by all 7,100 newly covered pregnant women.

As an example of how AB 98 could impact health outcomes, Table 7 presents the upper bound estimates of potential public health impacts of receipt of effective prenatal care services. The impact is estimated assuming that pre-mandate, none of these 7,100 women would receive prenatal care and that post-mandate 100% of these women would receive effective prenatal care services. In an average population of women, we would expect to have 8.7% of the population smoking during their pregnancy, between 2% and 10% of pregnancies screen positive for asymptomatic bacteriuria, 5.6% of women test positive for hepatitis B, 0.2% of women test positive for HIV, 5% of pregnant women are diagnosed with a hypertensive disorder, and 1.9% of women are at risk for respiratory distress syndrome (RDS) as a result of preterm delivery. Assuming that as a result of AB 98, all newly covered pregnant women received the necessary prenatal service, it is estimated that AB 98 could result in 37 pregnant women quitting smoking,
the reduction of 145 low–birth weight births, the prevention of 199 hepatitis B transmissions, the prevention of 14 HIV transmissions, the prevention of 185 cases of preeclampsia, and the prevention of 46 cases of RDS (Table 7).

**Table 7. Upper Bound Estimates of Public Health Impacts of AB 98**

<table>
<thead>
<tr>
<th>Prenatal care service</th>
<th>Prevalence of Condition</th>
<th>Medical Effectiveness of Intervention</th>
<th>Public Health Impact (a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking cessation counseling (b)</td>
<td>8.7% smoke during pregnancy</td>
<td>RR = 0.94</td>
<td>37 pregnant women quit smoking</td>
</tr>
<tr>
<td>Screening and treatment for asymptomatic bacteriuria (c)</td>
<td>2%-10% of pregnancies</td>
<td>RR = 0.66</td>
<td>Prevent 145 low–birth weight babies</td>
</tr>
<tr>
<td>Screening and treatment for hepatitis B (d)</td>
<td>5.6%</td>
<td>RR = 0.50</td>
<td>Prevented 199 hepatitis B transmissions</td>
</tr>
<tr>
<td>Screening and treatment for HIV (e)</td>
<td>0.2%</td>
<td>RR = 0.13</td>
<td>Prevented 14 HIV transmissions</td>
</tr>
<tr>
<td>Prophylaxis for hypertensive disorders (f)</td>
<td>5%</td>
<td>RR = 0.48</td>
<td>Prevented 185 cases of preeclampsia</td>
</tr>
<tr>
<td>Corticosteroids and progestational agents for women at increased risk for preterm delivery (g)</td>
<td>1.9%</td>
<td>RR = 0.66 (Corticosteroids) RR = 0.65 (Progestational agents)</td>
<td>Reduction in RDS by 46 cases</td>
</tr>
</tbody>
</table>

*Source: California Health Benefits Review Program, 2009.*

*Notes: (a) Calculations used the estimated 7,100 pregnancies newly covered under AB 98 as presented in the Utilization, Cost, and Coverage Impacts section. (b) Data taken from Lumley et al., 2004, and CDPH, 2006. (c) Data taken from Smaill and Vazquez, 2007. (d) Prevalence data taken from McQuillan et al., 2004; RR taken from Lee et al., 2006. (e) Prevalence data taken from CDC, 2008; OR taken from Chou et al., 2005. The OR is labeled as the RR for consistency. In cases where the prevalence of the condition is <1%, the OR and the RR are virtually identical. (f) Data taken from Hofmeyr et al., 2006. (g) Data taken from Roberts and Dalziel, 2006; Dodd et al., 2006; and March of Dimes, Peristats. RR = Risk ratio*

CHBRP is unable to estimate what the impact of AB 98 would be on the utilization of prenatal care. A lower bound estimate would assume that there would be no increase in the utilization of effective prenatal care services because these pregnant women would likely still face high levels of cost sharing found in the cheapest insurance plans. As presented in Table 7, an upper bound estimate would assume that all 7,100 newly covered pregnancies would have financial barriers to prenatal care removed and thus an increase in the utilization of effective prenatal care services, and an improvement in corresponding health outcomes would be expected. Most likely, the overall public health impact lies somewhere between the lower and upper bounds presented in this section.
The Impact on the Health of the Community Where Gender and Racial Disparities Exist

Of the more than 562,000 live births each year in California, over half (52.2%) are to Hispanic women (CDPH, 2009). Among non-Hispanic women, the largest number of births are to non-Hispanic white women (27.4%), followed by Asian women (11.2%), black women (5.3%), and Native American women (0.4%) (CDPH, 2009). The birth rates across these groups differ dramatically, with the rate of births to Hispanic women of childbearing age almost double those of other race/ethnic groups (Table 8).

Table 8. Births in California by Race/Ethnicity of Mother, 2006

<table>
<thead>
<tr>
<th>Race/Ethnicity of Mother</th>
<th>Number of Live Births (a)</th>
<th>Percent of Live Births (b)</th>
<th>General Fertility Rate (c)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>562,157</td>
<td>100%</td>
<td>71.3</td>
</tr>
<tr>
<td>Hispanic</td>
<td>293,276</td>
<td>52.2%</td>
<td>96.9</td>
</tr>
<tr>
<td>Non-Hispanic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>154,227</td>
<td>27.4%</td>
<td>52.7</td>
</tr>
<tr>
<td>Asian</td>
<td>62,949</td>
<td>11.2%</td>
<td>62.2</td>
</tr>
<tr>
<td>Black</td>
<td>30,016</td>
<td>5.3%</td>
<td>57.6</td>
</tr>
<tr>
<td>Native American</td>
<td>2,136</td>
<td>0.4%</td>
<td>42.6</td>
</tr>
</tbody>
</table>

Sources and Notes:
(a) Data taken from CDPH, 2009, Table 2-4, based on 2006 California birth certificate information.
(b) Data calculated from the birth data presented in Table 2-4. The sum does not equal 100% because women of other or unknown race/ethnicity are not included.
(c) Data taken from CDPH, 2009, Table 2-2. The general fertility rate is the number of live births per 1,000 women of childbearing age (15-44).

Overall, 2.8% of births in California are to women receiving late or no prenatal care (CDPH, 2009). This varies by race/ethnicity with Pacific Islanders and Native Americans having the highest rates of receiving late or no prenatal care (8.7% and 7.2%, respectively), and Asians and non-Hispanic whites having the lowest rates (1.8% and 2.1%, respectively) (Table 9). The rate of low–birth weight babies varies significantly by race/ethnicity, with babies born to black women classified as low birth weight or very low birth weight twice as often as babies born to other racial/ethnic groups. In addition, black women have the highest rates of preterm births (15.7% of births). Accordingly, infant mortality rates are also more than twice as high for babies born to black women compared to other racial/ethnic groups (11.4 per 1,000 live births to black women compared to 5.2 per 1,000 live births overall).

As discussed in the Medical Effectiveness section, there are specific prenatal services that are effective in reducing low–birth weight births, preterm births, and infant mortality. To the extent that the utilization of these services could increase among black women as a result of the mandate, there is potential to reduce the health disparities associated with births in this population. There is no evidence that, as a result of AB 98, utilization of effective prenatal care services would increase specifically among black women thus leading to better health outcomes for pregnant black women and their babies.
Table 9. Birth Characteristics in California by Race/Ethnicity of Mother, 2006

<table>
<thead>
<tr>
<th>Race/Ethnicity of Mother</th>
<th>Late or No Prenatal Care (a)</th>
<th>Low–Birth Weight Births (b)</th>
<th>Preterm Births (c)</th>
<th>Infant Mortality Rates (d)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.8%</td>
<td>6.9%</td>
<td>10.9%</td>
<td>5.2</td>
</tr>
<tr>
<td>Hispanic</td>
<td>3.2%</td>
<td>6.3%</td>
<td>11.0%</td>
<td>5.0</td>
</tr>
<tr>
<td>Non-Hispanic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>2.1%</td>
<td>6.3%</td>
<td>10.0%</td>
<td>4.6</td>
</tr>
<tr>
<td>Asian</td>
<td>1.8%</td>
<td>7.7%</td>
<td>10.3%</td>
<td>4.1</td>
</tr>
<tr>
<td>Pacific Islander</td>
<td>8.7%</td>
<td>7.5%</td>
<td>12.9%</td>
<td>Included in Asian Data</td>
</tr>
<tr>
<td>Black</td>
<td>3.9%</td>
<td>12.3%</td>
<td>15.7%</td>
<td>11.4</td>
</tr>
<tr>
<td>Native American</td>
<td>7.2%</td>
<td>6.7%</td>
<td>12.6%</td>
<td>6.9</td>
</tr>
</tbody>
</table>

Sources and Notes:
(a) Data taken from CDPH, 2009, Table 2-6. Late prenatal care is defined as prenatal care starting in the third trimester.
(b) Data taken from CDPH, 2009, Table 2-6. Low birth weight is defined as less than 2,500 grams (5.5 pounds).
(c) Data taken from CDPH, 2009, Table 2-6. Preterm births are births prior to 37 weeks of gestation.
(d) Data taken from MOD, 2003-2005. An infant death is a death occurring within the first year of life. Rates are expressed as the number of deaths per 1,000 live births.

Gender Disparities

The passage of AB 98 could disproportionately impact women in that, to the extent that insurance premiums are gender-rated, women would also experience relatively higher premium increases than men. As presented in the Utilization, Cost, and Coverage Impacts section, it is estimated that AB 98 could lead to an increase in gender-rating of premiums. On average, premiums of female enrollees purchasing in the individual CDI-regulated health insurance market would go up by 7.7%, while premiums of male enrollees would remain constant.

The Extent to Which the Proposed Service Reduces Premature Death and the Economic Loss Associated with Disease

Premature Death

Overall in California, the rate of maternal pregnancy-related mortality is 13.6 deaths per 100,000 live births (CDPH, 2007), while infant mortality rates are much higher with approximately 520 deaths per 100,000 live births (MOD, 2003-2005). As presented in the Medical Effectiveness section, there are specific prenatal care services that are effective in reducing the risk of preterm deliveries, low–birth weight babies, and other causes of infant and maternal mortality. To the extent that pregnant women gain access to health insurance plans that reduce out-of-pocket costs for prenatal care, it is possible that utilization of effective prenatal care services could increase, resulting in a reduction in premature death.
Economic Loss

The economic loss associated with poor pregnancy health outcomes consists of the direct costs of providing medical care and the indirect costs related to lost productivity and other special services needed to treat infants with additional health care needs. It has been estimated that the annual societal economic burden associated with preterm births is $51,600 per infant born preterm (IOM, 2006). More than one-fifth of this cost ($11,200 per preterm infant) is associated with lost household and labor market productivity (IOM, 2006). In California, 10.9% of babies are born prematurely, translating to more than 770 births and an economic burden of nearly $40 million in the population of 7,100 pregnancies covered as a result of AB 98. To the extent to which AB 98 increases the utilization of effective prenatal care that can reduce outcomes such as preterm births and related infant mortality, there is a potential to reduce morbidity and mortality and the associated societal costs.

Long-Term Public Health Impacts

As a result of AB 98, premiums in the individual market are expected to increase by approximately 1.5%, thus increasing the number of uninsured by more than 7,600 people. Losing one’s health insurance has many harmful consequences. Compared to those who remain insured, persons who lose their insurance coverage report reduced access to needed health care and receive fewer services (Kasper et al., 2000). Hadley’s review of the literature on insurance status and health found that compared to the insured, uninsured individuals obtain less preventive, diagnostic, and therapeutic care, are diagnosed at more advanced stages of illness, and have a higher risk of death (Hadley, 2003). In addition to the issues of health and health care access, the loss of health insurance can also cause substantial stress and worry due to lack of coverage as well as financial instability if health problems emerge (Lave et al., 1998).
APPENDICES

Appendix A: Text of Bill Analyzed

BILL NUMBER: AB 98 INTRODUCED

BILL TEXT

INTRODUCED BY Assembly Member De La Torre
(Coauthors: Assembly Members Brownley, Caballero, Carter, Chesbro, Ma, Monning, Ruskin, Salas, Skinner, Torlakson, Torres, and Yamada)
(Coauthors: Senators Hancock, Negrete McLeod, and Wolk)

JANUARY 6, 2009

An act to add Section 10123.865 to the Insurance Code, relating to health care coverage.

LEGISLATIVE COUNSEL’S DIGEST

AB 98, as introduced, De La Torre. Maternity services.
Existing law provides for the regulation of health insurers by the Department of Insurance. Under existing law, a health insurer that provides maternity coverage may not restrict inpatient hospital benefits, as specified, and is required to provide notice of the maternity services coverage.
This bill would require specified health insurance policies to provide coverage for maternity services, as defined.

THE PEOPLE OF THE STATE OF CALIFORNIA DO ENACT AS FOLLOWS:

SECTION 1. The Legislature finds and declares the following:
(a) In actual practice, health care service plans have been required by the Knox-Keene Health Care Service Plan Act of 1975 (Chapter 2.2 (commencing with Section 1340) of Division 2 of the Health and Safety Code) to provide maternity services as a basic health care benefit.
(b) At the same time, existing law does not require health insurers to provide designated basic health care services and, therefore, health insurers are not required to provide coverage for maternity services.
Therefore, it is essential to clarify that all health coverage made available to California consumers, whether issued by health care service plans regulated by the Department of Managed Health Care or by health insurers regulated by the Department of Insurance, must include maternity services.

SEC. 2. Section 10123.865 is added to the Insurance Code, to read:

10123.865. (a) Every individual or group policy of health insurance that covers hospital, medical, or surgical expenses and that is issued, amended, renewed, or delivered on or after January 1, 2010, shall provide coverage for maternity services. For the purposes of this section, "maternity services" include prenatal care, ambulatory care maternity services, involuntary complications of pregnancy, neonatal care, and inpatient hospital maternity care, including labor and delivery and postpartum care.

(b) This section shall not apply to Medicare supplement, short-term limited duration health insurance, vision-only, or CHAMPUS-supplement insurance, or to hospital indemnity, hospital-only, accident-only, or specified disease insurance that does not pay benefits on a fixed benefit, cash payment only basis.
Appendix B: Literature Review Methods

Appendix B describes methods used in the medical effectiveness literature review for AB 98, a bill that would require health insurance policies issued by insurance companies regulated by the CDI to provide coverage for maternity services.

As noted in the Introduction, AB 98 defines maternity services to include prenatal care, ambulatory care maternity services, involuntary complications of pregnancy, neonatal care, and inpatient hospital maternity care including labor and delivery and postpartum care. Each of these categories of maternity services in turn encompasses multiple screening tests, diagnostic tests, monitoring services, and treatments. Conducting a medical effectiveness analysis on the full range of maternity services was not feasible during the timeframe within which this report had to be completed. Because AB 98 is most likely to affect utilization of prenatal care, CHBRP focuses its review of the medical effectiveness literature on studies of the effectiveness of prenatal care services. Regardless of health insurance status, the vast majority of women in the United States deliver their babies in hospitals. In addition, AB 98 would not affect coverage for infants.

Due to the large amount of literature on prenatal care services, CHBRP limited its literature search to meta-analyses, systematic reviews, and evidence-based guidelines. Such syntheses of multiple studies are the strongest forms of evidence of the effectiveness of medical interventions. The medical librarian’s search encompassed both studies of the impact of receiving more or fewer prenatal care services, and studies of the effectiveness of screening tests, diagnostic tests, monitoring services, and treatments provided during or in conjunction with prenatal care visits. CHBRP also searched for literature on the impact of cost sharing for prenatal care and other preventive services, because AB 98 could result in lower out-of-pocket costs for prenatal care among women of childbearing age who previously had health insurance policies that did not cover maternity services.

The search was limited primarily to studies published in English from January 2008 to present. The timeframe for the search was truncated because CHBRP conducted a search of the literature on the effectiveness of prenatal care services published from 1995 through 2007 for a report it issued in 2008 on AB 1962, an identical bill regarding coverage for maternity services. Older literature was searched only for certain topics that were not adequately addressed in the previous literature search, such as screening for congenital disorders and interventions to prevent preeclampsia and preterm birth. Pertinent studies retrieved during the previous literature search are discussed in this report along with studies obtained from the new search.

The following databases that index peer-reviewed literature were searched: PubMed, the Web of Science, EconLit, the Cochrane Library (including the Cochrane Database of Systematic Reviews and the Cochrane Register of Controlled Clinical Trials). Web sites maintained by the following organizations that publish systematic reviews and evidence-based guidelines were searched: Agency for Healthcare Research and Quality (including the U.S. Preventive Services Task Force), American College of Obstetricians and Gynecologists, Centers for Disease Control and Prevention, Institute for Clinical Systems Improvement, International Network of Agencies for Health Technology Assessment, National Guideline Clearinghouse, National Health Service...
The literature search yielded a total of 206 studies regarding the effectiveness of maternity services or the impact of cost sharing on the use of prenatal care or other preventive services. At least two reviewers screened the title and abstract of each citation returned by the literature search to determine eligibility for inclusion. The reviewers obtained the full text of articles that appeared to be eligible for inclusion in the review and reapplied the initial eligibility criteria. Sixteen studies met the inclusion criteria and were included in the medical effectiveness review. These studies included updated editions of three of the evidence-based guidelines cited in CHRP’s report on AB 1962.

In making a “call” for each outcome measure, the team and the content expert consider the number of studies as well the strength of the evidence. To grade the evidence for each outcome measured, the team uses a grading system that has the following categories:

- Research design
- Statistical significance
- Direction of effect
- Size of effect
- Generalizability of findings

The grading system also contains an overall conclusion that encompasses findings in these five domains. The conclusion is a statement that captures the strength and consistency of the evidence of an intervention’s effect on an outcome. The following terms are used to characterize the body of evidence regarding an outcome.

- Clear and convincing evidence
- Preponderance of evidence
- Ambiguous/conflicting evidence
- Insufficient evidence

The conclusion states that there is “clear and convincing” evidence that an intervention has a favorable effect on an outcome, if most of the studies included in a review are well-implemented randomized controlled trials and report statistically significant and clinically meaningful findings that favor the intervention.

The conclusion characterizes the evidence as “preponderance of evidence” that an intervention has a favorable effect if most but not all five criteria are met. For example, for some interventions the only evidence available is from nonrandomized studies or from small RCTs with weak research designs. If most such studies that assess an outcome have statistically and clinically significant findings that are in a favorable direction and enroll populations similar to those covered by a mandate, the evidence would be classified as a “preponderance of evidence favoring the intervention.” In some cases, the preponderance of evidence may indicate that an intervention has no effect or has an unfavorable effect.
The evidence is presented as “ambiguous/conflicting if their findings vary widely with regard to the direction, statistical significance, and clinical significance/size of the effect.

The category “insufficient evidence” of an intervention’s effect is used where there is little if any evidence of an intervention’s effect.

Search Terms

The search terms used to locate studies relevant to the AB 98 were as follows:

*MeSH Terms Used to Search PubMed*

Calcium, Dietary
Cost-Benefit Analysis
Cost Savings
Cost Sharing
Counseling
Deductibles and Coinsurance
Delivery, Obstetric
Diabetes, Gestational/prevention & control
Dietary Supplements
Disease Transmission, Infectious/prevention & control
Domestic Violence/prevention & control
Eclampsia
Evidence-Based Medicine
Genetic Screening/economics
Health Benefit Plans, Employee
Health Services Accessibility
Hepatitis B/prevention & control/transmission
Hypertension/ prevention & control
Infant, Low Birth Weight
Infant Mortality
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases/ prevention & control
Infant, Very Low Birth Weight
Insurance Coverage
Labor, Induced
Length of Stay
Managed Care Programs/economics/utilization
Mass Screening
Maternal Mortality
Medical Savings Accounts/economics/ utilization
Neonatal Screening/economics/ methods
Perinatal Care
Postnatal Care/economics/utilization
Preeclampsia/prevention & control
Pregnancy
Pregnancy Complications/prevention & control
Pregnancy in Diabetics
Pregnancy Outcome
Pregnancy, Prolonged
Premature Birth
Prenatal Care/economics/utilization
Prenatal Diagnosis
Program Evaluation
Prospective Studies
Sexually Transmitted Diseases/prevention & control
Smoking Cessation
Treatment Outcome
Ultrasonography, prenatal
Uterine hemorrhage
Vaginosis, Bacterial/prevention & control

Publication Types:
Meta-Analysis
Multicenter Study
Practice Guideline
Randomized Control Trial
Systematic Reviews

Keywords used to search PubMed, Cochrane Library, EconLit, Web of Science and relevant web sites

Appendix C: Summary of Studies on Medical Effectiveness of Prenatal Care Services

Appendix C describes the studies on prenatal care services that were analyzed by the medical effectiveness team. Tables C-1a through C-1c present information regarding the citation, type of study, intervention and comparison groups, population studied, and the location at which a study was conducted. Tables C-2a through C-2b summarize findings from the studies reviewed. These tables include studies that were reviewed for the report CHBRP issued on AB 1962, an identical bill introduced in 2008, and new studies, indicated in bold in the tables below, which have been added for the medical effectiveness review for AB 98.

Table C-1. Description of Published Studies on Effectiveness of Prenatal Care Services

Table C-1a. Studies that Examined the Effectiveness of Different Numbers of Prenatal Visits

<table>
<thead>
<tr>
<th>Citation</th>
<th>Type of Trial</th>
<th>Intervention vs. Comparison Group</th>
<th>Population Studied</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fiscella, 1995</td>
<td>Systematic review</td>
<td>Multiple intervention and comparison groups</td>
<td>Pregnant women</td>
<td>N/A</td>
</tr>
<tr>
<td>Villar et al., 2001</td>
<td>Meta-analysis</td>
<td>Reduced number of prenatal visits vs. standard number of prenatal visits</td>
<td>Pregnant women at low risk of developing complications during pregnancy or labor</td>
<td>N/A</td>
</tr>
</tbody>
</table>

47 Level I = Well-implemented RCTs and cluster RCTs, Level II = RCTs and cluster RCTs with major weaknesses, Level III = Nonrandomized studies that include an intervention group and one or more comparison group, time series analyses, and cross-sectional surveys, Level IV = Case series and case reports, Level V = Clinical/practice guidelines based on consensus or opinion.
<table>
<thead>
<tr>
<th>Citation</th>
<th>Type of Trial</th>
<th>Intervention vs. Comparison Group</th>
<th>Population Studied</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICSI, 2008*48</td>
<td>Evidence-based guideline</td>
<td>Multiple intervention and comparison groups</td>
<td>Pregnant women</td>
<td>N/A</td>
</tr>
<tr>
<td>Lu et al., 2003</td>
<td>Systematic review</td>
<td>Multiple intervention and comparison groups</td>
<td>Pregnant women</td>
<td>N/A</td>
</tr>
<tr>
<td>NCCWCH, 2008*49</td>
<td>Evidence-based guideline</td>
<td>Multiple intervention and comparison groups</td>
<td>Pregnant women</td>
<td>N/A</td>
</tr>
<tr>
<td>USPSTF, 1996*50</td>
<td>Evidence-based guideline</td>
<td>Multiple intervention and comparison groups</td>
<td>All persons—reviewed sections that address pregnant women</td>
<td>N/A</td>
</tr>
<tr>
<td>USPSTF, 2008*51</td>
<td>Evidence-based guideline</td>
<td>Multiple intervention and comparison groups</td>
<td>All persons—reviewed sections that address preventive services for pregnant women</td>
<td>N/A</td>
</tr>
</tbody>
</table>

48 ICSI = Institute for Clinical Systems Improvement. ICSI is an independent, not-for-profit organization that promotes quality improvement among health plans, hospitals, and medical groups in Minnesota. This citation is to an evidence-based guideline for routine prenatal care. For this new report on AB 98, the 2008 edition of this guideline was used in place of the 2007 edition cited in CHBRP’s report on AB 1962.
49 NCCWCH = British National Collaborating Centre for Women’s and Children’s Health. This citation is to an evidence-based guideline for routine prenatal care that was prepared for the National Institute for Clinical Excellence. For this new report on AB 98, the 2008 edition of this guideline was used in place of the 2003 edition cited in CHBRP’s report on AB 1962.
50 USPSTF = United States Preventive Services Task Force.
51 For this new report on AB 98, the 2008 edition of this guideline was used in place of the 2007 edition cited in CHBRP’s report on AB 1962.
Table C-1c. Studies that Examined the Effectiveness of Specific Interventions

<table>
<thead>
<tr>
<th>Type of Risk Factor/Problem and Service</th>
<th>Citation</th>
<th>Type of Trial</th>
<th>Intervention vs. Comparison Group</th>
<th>Population Studied</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Behavioral</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tobacco cessation counseling</td>
<td>Lumley et al., 2004</td>
<td>Meta-analysis</td>
<td>Brief advice vs. usual care</td>
<td>Pregnant women who smoke</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Individual counseling vs. usual care</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Group counseling vs. usual care</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NZMOH, 2008</td>
<td>Systematic review</td>
<td>Brief advice vs. usual care</td>
<td>Pregnant women who smoke</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Individual counseling vs. usual care</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Group counseling vs. usual care</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>US DHHS, 2008</td>
<td>Meta-analysis</td>
<td>Individual counseling vs. usual care</td>
<td>Pregnant women who smoke</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Genetic Disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congenital heart defects</td>
<td>Makrydimas et al., 2003</td>
<td>Meta-analysis</td>
<td>Accuracy of nuchal translucency ultrasound scan for detecting major congenital heart defects—no control group</td>
<td>Pregnant women with chromosomally normal fetuses (i.e., did not have Down syndrome or other chromosomal disorder)</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>Wald et al., 2008</td>
<td>Meta-analysis</td>
<td>Accuracy of nuchal translucency ultrasound scan for detecting major congenital heart defects—no control group</td>
<td>Pregnant women with chromosomally normal fetuses</td>
<td>N/A</td>
</tr>
</tbody>
</table>

52 NZMOH = New Zealand Ministry of Health.
53 US DHHS = United States Department of Health and Human Services. This citation is to an evidence-based guideline for smoking cessation. For this new report on AB 98, the 2008 edition of this guideline was used in place of the 2000 edition cited in CHBRP’s report on AB 1962.
<table>
<thead>
<tr>
<th>Type of Risk Factor/Problem and Service</th>
<th>Citation</th>
<th>Type of Trial</th>
<th>Intervention vs. Comparison Group</th>
<th>Population Studied</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infectious Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antibiotics for treatment of asymptomatic bacteriuria</td>
<td>Lin and Fajardo, 2008</td>
<td>Systematic review</td>
<td>Antibiotics vs. placebo or no treatment</td>
<td>Pregnant women with asymptomatic bacteriuria</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>Smaill and Vazquez, 2007</td>
<td>Meta-analysis</td>
<td>Antibiotics vs. placebo or no treatment</td>
<td>Pregnant women with asymptomatic bacteriuria</td>
<td>N/A</td>
</tr>
<tr>
<td>Screening for chlamydia</td>
<td>Meyers et al., 2007</td>
<td>Systematic review</td>
<td>Screening for chlamydia vs. not screening</td>
<td>Women at increased risk for chlamydia</td>
<td>N/A</td>
</tr>
<tr>
<td>Screening for gonorrhea</td>
<td>Glass et al., 2005</td>
<td>Systematic review</td>
<td>Screening for gonorrhea vs. not screening</td>
<td>N/A – no new studies found since literature review completed for USPSTF, 1996</td>
<td>N/A</td>
</tr>
<tr>
<td>Screening for group b streptococcus</td>
<td>Schrag et al., 2002</td>
<td>Evidence-based guideline</td>
<td>Universal screening for group b streptococcus vs. assessment of clinical risk factors</td>
<td>Pregnant women</td>
<td></td>
</tr>
<tr>
<td>Vaccination for hepatitis B</td>
<td>Krishnaraj, 2004</td>
<td>Systematic review</td>
<td>Vaccination for hepatitis b vs. placebo or no treatment</td>
<td>Infants born to women with hepatitis B</td>
<td>N/A</td>
</tr>
<tr>
<td>Vaccination and/or immune globulin for hepatitis B</td>
<td>Lee et al., 2006</td>
<td>Meta-analysis</td>
<td>Hepatitis B vaccine vs. placebo or no treatment; Hepatitis B immune globulin vs. placebo or no treatment; Hepatitis B vaccine and immune globulin vs. placebo or no treatment</td>
<td>Infants born to women who have hepatitis B</td>
<td>N/A</td>
</tr>
<tr>
<td>Type of Risk Factor/Problem and Service</td>
<td>Citation</td>
<td>Type of Trial</td>
<td>Intervention vs. Comparison Group</td>
<td>Population Studied</td>
<td>Location</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>----------</td>
<td>---------------</td>
<td>-----------------------------------</td>
<td>--------------------</td>
<td>----------</td>
</tr>
<tr>
<td><strong>Infectious Disease (cont’d.)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiretroviral therapy and other interventions to prevent transmission of HIV$^{54}$ to newborns</td>
<td>Chou et al., 2005</td>
<td>Systematic review</td>
<td>Antiretroviral therapy vs. placebo or no treatment; Elective cesarean section vs. vaginal delivery; Formula feeding vs. breastfeeding</td>
<td>Pregnant women with HIV</td>
<td>N/A</td>
</tr>
<tr>
<td>Screening for syphilis</td>
<td>Nelson et al., 2004</td>
<td>Systematic review</td>
<td>Screening for syphilis vs. not screening</td>
<td>Pregnant women</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Metabolic, Nutritional, and Endocrine Conditions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gestational diabetes</td>
<td>Hillier et al., 2008</td>
<td>Systematic review</td>
<td>Dietary advice, training in self-monitoring of blood glucose, and insulin vs. no treatment; Insulin vs. no treatment</td>
<td>Pregnant women with gestational diabetes</td>
<td>N/A</td>
</tr>
<tr>
<td>Iron supplementation for anemia</td>
<td>Helfand et al., 2006</td>
<td>Systematic review</td>
<td>Iron supplements vs. placebo</td>
<td>Pregnant women with iron deficiency anemia</td>
<td>N/A</td>
</tr>
</tbody>
</table>

---

$^{54}$ HIV = Human Immunodeficiency Virus
<table>
<thead>
<tr>
<th>Type of Risk Factor/Problem and Service</th>
<th>Citation</th>
<th>Type of Trial</th>
<th>Intervention vs. Comparison Group</th>
<th>Population Studied</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertensive Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium supplementation to prevent hypertensive disorders</td>
<td>Hofmeyr et al., 2006</td>
<td>Meta-analysis</td>
<td>Calcium supplementation vs. placebo</td>
<td>Pregnant women regardless of risk of hypertensive disorders</td>
<td>N/A</td>
</tr>
<tr>
<td>Antiplatelet agents to prevent preeclampsia and associated complications</td>
<td>Askie et al., 2007</td>
<td>Meta-analysis</td>
<td>Antiplatelet agents (e.g., low-dose aspirin) vs. placebo or no medication</td>
<td>Pregnant women at risk for preeclampsia</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>Duley et al., 2007</td>
<td>Meta-analysis</td>
<td>Antiplatelet agents vs. placebo or no treatment</td>
<td>Pregnant women at risk for preeclampsia</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>Ruano et al., 2005</td>
<td>Meta-analysis</td>
<td>Low-dose aspirin vs. placebo</td>
<td>Pregnant women at low risk for preeclampsia</td>
<td>N/A</td>
</tr>
<tr>
<td>Anti-convulsants for treatment of preeclampsia</td>
<td>Duley et al., 2003</td>
<td>Meta-analysis</td>
<td>Anti-convulsant drugs vs. placebo</td>
<td>Women with preeclampsia before or after delivery</td>
<td>N/A</td>
</tr>
<tr>
<td>Multiple interventions to prevent preeclampsia</td>
<td>Meads et al., 2008</td>
<td>Meta-analysis</td>
<td>Intervention vs. placebo, no treatment, or usual care</td>
<td>Pregnant women at risk for preeclampsia</td>
<td>N/A</td>
</tr>
<tr>
<td>Type of Risk Factor/Problem and Service</td>
<td>Citation</td>
<td>Type of Trial</td>
<td>Intervention vs. Comparison Group</td>
<td>Population Studied</td>
<td>Location</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>----------</td>
<td>--------------</td>
<td>-----------------------------------</td>
<td>--------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Pregnancy Outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Progestational agents to prevent preterm birth</td>
<td>Dodd et al., 2006</td>
<td>Meta-analysis</td>
<td>Progestational agents vs. placebo</td>
<td>Pregnant women at risk for preterm delivery</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>Dodd et al., 2008</td>
<td>Meta-analysis</td>
<td>Progestational agents vs. placebo</td>
<td>Pregnant women at risk for preterm delivery</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>Mackenzie et al., 2006</td>
<td>Meta-analysis</td>
<td>Progestational agents administered during 2\textsuperscript{nd} trimester vs. placebo</td>
<td>Pregnant women at risk for preterm delivery</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>Sanchez-Ramos et al., 2005</td>
<td>Meta-analysis</td>
<td>Progestational agents vs. placebo</td>
<td>Pregnant women at risk for preterm delivery</td>
<td>N/A</td>
</tr>
<tr>
<td>Corticosteroids to accelerate maturation of lungs in fetuses scheduled for preterm birth</td>
<td>Roberts and Dalziel, 2006</td>
<td>Meta-analysis</td>
<td>Corticosteroid drug capable of crossing the placenta vs. placebo or no treatment</td>
<td>Pregnant women expected to deliver their babies preterm due to spontaneous preterm labor, preterm prelabor rupture of membranes, or elective preterm labor</td>
<td>N/A</td>
</tr>
<tr>
<td>Magnesium sulfate to prevent neurological impairment in fetuses at risk for preterm delivery</td>
<td>Doyle et al., 2009</td>
<td>Meta-analysis</td>
<td>Anti-convulsant drugs (e.g., magnesium sulfate) vs. placebo or no treatment</td>
<td>Pregnant women at risk for preterm birth</td>
<td>N/A</td>
</tr>
<tr>
<td>External cephalic version for breech presentation before term</td>
<td>Hutton and Hofmeyr, 2006</td>
<td>Systematic review</td>
<td>External cephalic version vs. no intervention</td>
<td>Pregnant women whose fetuses are in breech position before term (i.e., before 37 weeks)</td>
<td>N/A</td>
</tr>
<tr>
<td>Type of Risk Factor/Problem and Service</td>
<td>Citation</td>
<td>Type of Trial</td>
<td>Intervention vs. Comparison Group</td>
<td>Population Studied</td>
<td>Location</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>----------</td>
<td>---------------</td>
<td>-----------------------------------</td>
<td>--------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Pregnancy Outcomes (cont’d.)</td>
<td>Gülmezoglu, et al., 2006</td>
<td>Meta-analysis</td>
<td>Induction of labor vs. waiting for spontaneous onset of labor</td>
<td>Pregnant women whose pregnancies continued beyond term</td>
<td>N/A</td>
</tr>
<tr>
<td>Induction of labor at or beyond term</td>
<td>Sanchez-Ramos et al., 2003</td>
<td>Meta-analysis</td>
<td>Induction of labor vs. waiting for spontaneous onset of labor</td>
<td>Pregnant women whose pregnancies continued beyond term</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Table C-2. Summary of Findings from Studies of the Effectiveness of Prenatal Care Services

Table C-2a. Studies that Examined the Effectiveness of Different Numbers of Prenatal Visits

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Research Design 55</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low birth weight</td>
<td>1 meta-analysis and 1 systematic review of Level II studies</td>
<td>• No statistically significant difference</td>
<td>• No effect</td>
<td>• No effect</td>
<td>• Somewhat generalizable—includes pregnant women from both developed and developing countries</td>
<td>• Changing the number of prenatal visits does not affect the odds of having a low–birth weight infant</td>
</tr>
<tr>
<td>Preterm birth</td>
<td>1 meta-analysis and 1 systematic review of Level II studies</td>
<td>• No statistically significant difference</td>
<td>• No effect</td>
<td>• No effect</td>
<td>• Somewhat generalizable—includes pregnant women from both developed and developing countries</td>
<td>• Changing the number of prenatal visits does not affect the odds of giving birth preterm</td>
</tr>
<tr>
<td>Admission to neonatal intensive care unit</td>
<td>1 meta-analysis and 1 systematic review of Level II studies</td>
<td>• No statistically significant difference</td>
<td>• No effect</td>
<td>• No effect</td>
<td>• Somewhat generalizable—includes pregnant women from both developed and developing countries</td>
<td>• Changing the number of prenatal visits does not affect the odds that a newborn will be admitted to a neonatal intensive care unit</td>
</tr>
<tr>
<td>Maternal mortality</td>
<td>1 meta-analysis and 1 systematic review of Level II studies</td>
<td>• No statistically significant difference</td>
<td>• No effect</td>
<td>• No effect</td>
<td>• Generalizable—includes pregnant women from developed countries</td>
<td>• Changing the number of prenatal visits does not affect the odds of maternal death</td>
</tr>
<tr>
<td>Antepartum or postpartum hemorrhage</td>
<td>1 meta-analysis and 1 systematic review of Level II studies</td>
<td>• No statistically significant difference</td>
<td>• No effect</td>
<td>• No effect</td>
<td>• Somewhat generalizable—includes pregnant women from both developed and developing countries</td>
<td>• Changing the number of prenatal visits does not affect the odds of antepartum or postpartum hemorrhage</td>
</tr>
</tbody>
</table>

55 Level I = Well-implemented RCTs and cluster RCTs; Level II = RCTs and cluster RCTs with major weaknesses; Level III = Nonrandomized studies that include an intervention group and one or more comparison group, time series analyses, and cross-sectional surveys; Level IV = Case series and case reports; Level V = Clinical/practice guidelines based on consensus or opinion.
<table>
<thead>
<tr>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preeclampsia</td>
<td>1 meta-analysis and 1 systematic review of Level II studies</td>
<td>• No statistically significant difference</td>
<td>• No effect</td>
<td>• No effect</td>
<td>• Somewhat generalizable —includes pregnant women from both developed and developing countries</td>
<td>• Changing the number of prenatal visits does not affect the odds of having preeclampsia</td>
</tr>
<tr>
<td>Risk Factor/Intervention</td>
<td>Outcome</td>
<td>Research Design</td>
<td>Statistical Significance</td>
<td>Direction of Effect</td>
<td>Size of Effect</td>
<td>Generalizability</td>
</tr>
<tr>
<td>--------------------------</td>
<td>----------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>---------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Behavioral</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking cessation</td>
<td>Abstinence from smoking</td>
<td>2 meta-analyses and 1 systematic review of Level I-II studies</td>
<td>• Statistically significant</td>
<td>• Favors smoking cessation counseling</td>
<td>• OR(^56) = 1.8 (95% CI(^57) = 1.4, 2.3)(^58)</td>
<td>• Somewhat generalizable</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reduction in risk of</td>
<td>1 meta-analysis and 3 systematic reviews of Level I-II studies</td>
<td>• Statistically significant</td>
<td>• Favors smoking cessation counseling</td>
<td>• RR(^59) = 0.81 (95% CI = 0.70, 0.94)(^60)</td>
<td>• Somewhat generalizable</td>
</tr>
<tr>
<td></td>
<td>low birth weight</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reduction in risk of</td>
<td>1 meta-analysis and 3 systematic reviews of Level I-II studies</td>
<td>• Statistically significant</td>
<td>• Favors smoking cessation counseling</td>
<td>• RR = 0.84 (95% CI = 0.72, 0.98)</td>
<td>• Somewhat generalizable</td>
</tr>
<tr>
<td></td>
<td>preterm birth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening for</td>
<td>Reduction in risk of</td>
<td>1 systematic review of Level III studies</td>
<td>• Results of formal test of</td>
<td>• Favors screening</td>
<td>• Not reported</td>
<td>• Somewhat generalizable</td>
</tr>
<tr>
<td>domestic violence</td>
<td>injury to mother and fetus</td>
<td></td>
<td>statistical significance not</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^{56}\) OR = Odds ratio  
\(^{57}\) CI = Confidence interval  
\(^{58}\) Results for the effect of smoking cessation counseling on abstinence from smoking were reported in US DHHS (2008). This meta-analysis compared the effectiveness of providing counseling and other psychosocial interventions relative to brief advice, self-help materials, or referral to a smoking cessation program.  
\(^{59}\) RR = Risk ratio  
\(^{60}\) Results for the impact of smoking cessation counseling on the risks of low birth weight and preterm birth were reported in Lumley et al. (2004).
<table>
<thead>
<tr>
<th>Risk Factor/Intervention</th>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Congenital Disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening for Down syndrome with ultrasound and/or blood tests for biochemical markers</td>
<td>Accurate diagnosis</td>
<td>2 systematic reviews of Level III-IV studies</td>
<td>N/A—studies of test accuracy</td>
<td>N/A—studies of test accuracy</td>
<td>Detection rates ranged from 80% to 96%; false positive rate ranged from 3% to 9%&lt;sup&gt;61&lt;/sup&gt;</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td>Screening for hemoglobinopathies&lt;sup&gt;62&lt;/sup&gt;</td>
<td>Accurate diagnosis</td>
<td>2 systematic reviews</td>
<td>N/A—studies of test accuracy</td>
<td>N/A—studies of test accuracy</td>
<td>Not stated</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td>Screening for Tay-Sachs disease</td>
<td>Accurate diagnosis</td>
<td>1 systematic review</td>
<td>N/A—studies of test accuracy</td>
<td>N/A—studies of test accuracy</td>
<td>Not stated</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td>Screening for structural anomalies&lt;sup&gt;63&lt;/sup&gt;</td>
<td>Accurate diagnosis</td>
<td>2 meta-analyses and 1 systematic review</td>
<td>N/A—studies of test accuracy</td>
<td>N/A—studies of test accuracy</td>
<td>For congenital heart defects, detection rate of 52% (95% CI = 42%, 71%) with a false positive rate of 5%&lt;sup&gt;64&lt;/sup&gt;</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td>Folic acid to prevent neural tube defects</td>
<td>Prevention of neural tube defects</td>
<td>2 systematic reviews</td>
<td>Statistically significant</td>
<td>Favors folic acid</td>
<td>RR = 0.28 (95% CI = 0.13, 0.58)</td>
<td>Somewhat generalizable</td>
</tr>
</tbody>
</table>

<sup>61</sup> Detection rates and false positive rates are from previous studies cited in NCCWCH (2008) and are for the screening strategy recommended by NCCWCH (i.e., combined ultrasound and maternal serum biochemistry tests).

<sup>62</sup> Hemoglobinopathies are genetic disorders in the genes that control the expression of hemoglobin protein. Disorders of these genes can result in anemia and abnormal hemoglobins. Sickle cell anemia and thalassemia are two of the most common types of hemoglobinopathies.

<sup>63</sup> Structural anomalies are abnormalities in the development of the fetus. Congenital heart defects are the most common structural anomalies. Other structural anomalies that can be detected via ultrasound include anterior abdominal wall defects, congenital hydrocephalus, craniofacial abnormalities, Dwarfism, neural tube defects, and renal defects (NCCWCH, 2008).

<sup>64</sup> Detection rate and false positive rate for congenital heart defects are reported in Wald (2008) and apply only to congenital heart defects for which diagnosis could affect management of a pregnancy.
## Table C-2-b. Studies that Examined the Effectiveness of Specific Interventions (Cont’d)

<table>
<thead>
<tr>
<th>Risk Factor/ Intervention</th>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infectious Disease</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screening with urine culture and antibiotics for treatment of asymptomatic bacteriuria</td>
<td>Reduction in risk of kidney infection in mother</td>
<td>1 meta-analysis and 4 systematic reviews of Level II studies</td>
<td>Statistically significant</td>
<td>Favors antibiotics</td>
<td>RR = 0.23 (95% CI = 0.13, 0.41)</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td>Reduction in risk of low birth weight</td>
<td>1 meta-analysis and 4 systematic reviews of Level II studies</td>
<td>Statistically significant</td>
<td>Favors antibiotics</td>
<td>RR = 0.66 (95% CI = 0.49, 0.89)</td>
<td>Somewhat generalizable</td>
<td></td>
</tr>
<tr>
<td>Reduction in odds of preterm birth</td>
<td>1 meta-analysis and 2 systematic reviews? (at least 1) of Level II studies</td>
<td>Statistically significant</td>
<td>Favors antibiotics</td>
<td>OR = 0.60 (95% CI = 0.45, 0.80)</td>
<td>Somewhat generalizable</td>
<td></td>
</tr>
<tr>
<td><strong>Antibiotics for chlamydia</strong></td>
<td>Reduction in risk of premature rupture of membranes</td>
<td>2 systematic reviews of Level III studies</td>
<td>Statistically significant Approaches statistical significance (p = 0.08)</td>
<td>Favors antibiotics</td>
<td>Treated = 3%; untreated = 5%</td>
<td>Generalizable —studies conducted in Ohio and Tennessee</td>
</tr>
<tr>
<td>Reduction in risk of low birth weight</td>
<td>2 systematic reviews of Level III studies</td>
<td>Statistically significant</td>
<td>Favors antibiotics</td>
<td>Treated = 11%; untreated = 20%</td>
<td>Generalizable —studies conducted in Ohio and Tennessee</td>
<td></td>
</tr>
</tbody>
</table>

---

65 Results for outcomes of antibiotics for treatment of asymptomatic bacteriuria on risk of kidney infection and low birth weight were reported in Smaill and Vazquez, 2007.

66 Lu et al. (2003) reported results from a previous meta-analysis.

67 Results for all three outcomes of treating chlamydia with antibiotics are from a previous study cited in USPSTF (1996).
Table C-2-b. Studies that Examined the Effectiveness of Specific Interventions (Cont’d)

<table>
<thead>
<tr>
<th>Risk Factor/Intervention</th>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prophylaxis for infants born to mothers with gonorrhea</td>
<td>Reduction in rates of conjunctivitis and blindness in newborns</td>
<td>2 systematic reviews of Level III studies</td>
<td>• Approaches statistical significance (p = 0.08)</td>
<td>• Favors antibiotics</td>
<td>• Treated = 1%; untreated = 2%</td>
<td>• Generalizable—studies conducted in Ohio and Tennessee</td>
</tr>
<tr>
<td>Antibiotics for group B streptococcus</td>
<td>Reduction in incidence of group B streptococcus in newborns and associated conditions</td>
<td>2 systematic reviews of Level III studies</td>
<td>• No formal tests of statistical significance</td>
<td>• Favors prophylaxis</td>
<td>• 83% decrease in infants treated with silver nitrate</td>
<td>• Somewhat generalizable—studies conducted in Africa</td>
</tr>
<tr>
<td>Hepatitis B vaccination and/or hepatitis B immune globulin for hepatitis B</td>
<td>Reduction in risk of infant developing chronic hepatitis B</td>
<td>1 meta-analysis and 3 systematic reviews of Level I-II studies</td>
<td>• Statistically significant</td>
<td>• Favors vaccination and/or immune globulin</td>
<td>• RR = 0.08 (95% CI = 0.03, 0.17) for vaccine plus immune globulin</td>
<td>• Generalizable—most studies conducted in developing countries</td>
</tr>
</tbody>
</table>

68 USPSTF (1996) reported results from previous studies.
69 Lee et al., 2006
### Table C-2-b. Studies that Examined the Effectiveness of Specific Interventions (Cont’d)

<table>
<thead>
<tr>
<th>Risk Factor/ Intervention</th>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screening for human immunodeficiency virus (HIV) and antiretroviral therapy</td>
<td>Reduction in risk of mother-to-child transmission of HIV</td>
<td>3 systematic reviews of Level I-III studies</td>
<td>• Statistically significant</td>
<td>• Favors antiretroviral therapy</td>
<td>• OR = 0.13 (95% CI = 0.06, 0.27)(^{70})</td>
<td>• Somewhat generalizable—some studies conducted in developing countries</td>
</tr>
<tr>
<td>Elective cesarean section for mothers with HIV</td>
<td>Reduction in risk of mother-to-child transmission of HIV</td>
<td>2 systematic reviews of Level I-III studies</td>
<td>• Statistically significant</td>
<td>• Favors cesarean section</td>
<td>• Transmission rate: cesarean section = 2%; Vaginal delivery = 11%(^{71})</td>
<td>• Somewhat generalizable</td>
</tr>
<tr>
<td>Avoiding breastfeeding infants whose mothers have HIV</td>
<td>Reduction in risk of mother-to-child transmission of HIV</td>
<td>3 systematic reviews of Level I-III studies</td>
<td>• Statistically significant</td>
<td>• Favors formula</td>
<td>• Transmission rate: Formula = 21%; Breast-feeding = 37%(^{72})</td>
<td>• Somewhat generalizable—some studies conducted in developing countries</td>
</tr>
<tr>
<td>Antibiotics for syphilis</td>
<td>Reduction in mother-to-child transmission of syphilis</td>
<td>4 systematic reviews of Level III-IV studies</td>
<td>• No formal test of statistical significance</td>
<td>• Favors penicillin</td>
<td>• Prevented transmission in 98.2% of infants(^{73})</td>
<td>• Generalizable—conducted in Texas</td>
</tr>
</tbody>
</table>

\(^{70}\) All results for outcomes of treatments to prevent mother-to-child transmission of HIV are from previous studies that are cited in Chou et al. (2005).

\(^{71}\) Some women in both the cesarean section and vaginal delivery groups took an antiretroviral drug (zidovudine) during pregnancy. Among women who took zidovudine and had an elective cesarean section had a transmission rate of 1% (Chou et al., 2005).

\(^{72}\) Chou et al. (2005) reported results from previous study. Mothers enrolled in the study cited had not taken antiretroviral drugs during pregnancy. Taking these drugs would probably attenuate the effect of feeding infants formula instead of breast milk.

\(^{73}\) NCCWCH (2008) reported results from a previous study.
<table>
<thead>
<tr>
<th>Risk Factor/Intervention</th>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Metabolic, Nutritional, and Endocrine Conditions</strong></td>
<td>Reduction in risk of infant mortality, shoulder dystocia, bone fracture, and nerve palsy</td>
<td>1 systematic review of Level I-III studies</td>
<td>• Statistically significant</td>
<td>• Favors treatment</td>
<td>• Rates of reduction in infant mortality, shoulder dystocia, bone fracture, and nerve palsy ranged from 1% to 4%&lt;sup&gt;74&lt;/sup&gt;</td>
<td>• Somewhat generalizable</td>
</tr>
<tr>
<td>Dietary advice regarding gestational diabetes (and insulin if necessary)</td>
<td>Reduction in risk of infant mortality, shoulder dystocia, bone fracture, and nerve palsy</td>
<td>1 systematic review of Level I-III studies</td>
<td>• Statistically significant</td>
<td>• Favors treatment</td>
<td>• Rates of reduction in infant mortality, shoulder dystocia, bone fracture, and nerve palsy ranged from 1% to 4%&lt;sup&gt;74&lt;/sup&gt;</td>
<td>• Somewhat generalizable</td>
</tr>
<tr>
<td><strong>Iron supplements for iron deficiency anemia</strong></td>
<td>Reduction in risk of low birth weight</td>
<td>2 systematic reviews of Level I-II studies</td>
<td>• Statistically significant</td>
<td>• Favors iron supplements</td>
<td>• Intervention = 4% of infants had birth weight &lt;2,500 grams, Control = 17% of infants had birth weight less &lt; 2,500 grams&lt;sup&gt;75&lt;/sup&gt;</td>
<td>• Generalizable—conducted in Ohio</td>
</tr>
<tr>
<td><strong>Hypertensive Disorders</strong></td>
<td>Early identification of preeclampsia</td>
<td>No direct evidence because unethical to withhold blood pressure monitoring</td>
<td>• No formal tests of statistical significance</td>
<td>• Favors monitoring blood pressure</td>
<td>• No direct evidence</td>
<td>• Somewhat generalizable</td>
</tr>
<tr>
<td>Blood pressure monitoring and urine culture to detect preeclampsia</td>
<td>Early identification of preeclampsia</td>
<td>No direct evidence because unethical to withhold blood pressure monitoring</td>
<td>• No formal tests of statistical significance</td>
<td>• Favors monitoring blood pressure</td>
<td>• No direct evidence</td>
<td>• Somewhat generalizable</td>
</tr>
</tbody>
</table>

<sup>74</sup> Crowther et al., 2005, as referenced in ICSI, 2008.
<sup>75</sup> Helfand et al. (2006) reported results from a previous study.
<table>
<thead>
<tr>
<th>Risk Factor/Intervention</th>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium supplements for hypertensive disorders</td>
<td>Reduction in risk of preeclampsia</td>
<td>1 meta-analyses and 3 systematic reviews of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors calcium supplements</td>
<td>RR = 0.48 (95% CI = 0.33, 0.69)</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td>Calcium supplements for hypertensive disorders</td>
<td>Reduction in risk of maternal death and serious morbidity</td>
<td>2 meta-analyses and 2 systematic reviews of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors calcium supplements</td>
<td>RR = 0.80 (95% CI = 0.65, 0.97)</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td>Antiplatelet agents for women at risk for preeclampsia</td>
<td>Reduction in risk of preeclampsia</td>
<td>34 meta-analyses and 1 systematic review of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors antiplatelet agents</td>
<td>RR = 0.83 (95% CI = 0.77, 0.89)</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td>Antiplatelet agents for women at risk for preeclampsia</td>
<td>Reduction in risk of preterm birth</td>
<td>4 meta-analyses of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors antiplatelet agents</td>
<td>RR = 0.92 (95% CI = 0.88, 0.97)</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td>Antiplatelet agents for women at risk for preeclampsia</td>
<td>Reduction in risk of small for gestational age birth</td>
<td>4 meta-analyses of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors antiplatelet agents</td>
<td>RR = 0.90 (95% CI = 0.83, 0.98)</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td>Antiplatelet agents for women at risk for preeclampsia</td>
<td>Reduction in risk of fetal or neonatal death</td>
<td>4 meta-analyses of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors antiplatelet agents</td>
<td>RR = 0.86 (95% CI = 0.76, 0.98)</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td>Magnesium sulfate to prevent eclampsia</td>
<td>Reduction in risk of eclampsia</td>
<td>1 meta-analysis of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors magnesium sulfate</td>
<td>RR = 0.41 (95% CI = 0.29, 0.58)</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td>Magnesium sulfate to prevent eclampsia</td>
<td>Reduction in risk of placental abruption</td>
<td>1 meta-analysis of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors magnesium sulfate</td>
<td>RR = 0.64 (95% CI = 0.50, 0.83)</td>
<td>Somewhat generalizable</td>
</tr>
</tbody>
</table>

---

76 Both results for outcomes of prescribing calcium supplements during pregnancy were reported in Hofmeyr et al. (2006).

77 All results for outcomes of prescribing antiplatelet agents were reported in Duley et al. (2007).

78 All results for outcomes of administering magnesium sulfate during delivery were reported in Duley et al. (2003).
<table>
<thead>
<tr>
<th>Risk Factor/ Intervention</th>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Other Medical Conditions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immune globulin for Rh(D) incompatibility</td>
<td>Reduction in risk of hemolytic disease in newborns</td>
<td>3 systematic reviews of Level I-II studies</td>
<td>• Formal test of statistical significance not reported</td>
<td>• Favors screening</td>
<td>• Not stated</td>
<td>• Somewhat generalizable</td>
</tr>
<tr>
<td>Referral to specialist for other atypical red blood cell alloantibodies</td>
<td>Reduction in risk of hemolytic disease in newborns</td>
<td>1 systematic review of Level III-IV studies</td>
<td>• No formal test of statistical significance</td>
<td>• Favors screening</td>
<td>• Not stated</td>
<td>• Somewhat generalizable</td>
</tr>
<tr>
<td><strong>Pregnancy Outcomes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ultrasound to diagnose placenta previa</td>
<td>Accurate diagnosis</td>
<td>1 systematic review of Level II-IV studies</td>
<td>N/A—studies of test accuracy</td>
<td>N/A—studies of test accuracy</td>
<td>• In 73% of women diagnosed with placenta previa at 32-35 weeks, condition persisted to delivery</td>
<td>• Somewhat generalizable</td>
</tr>
<tr>
<td>Progestational agents to prevent preterm delivery</td>
<td>Reduction in risk of preterm delivery</td>
<td>4 meta-analysis and 2 systematic reviews of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors progestational agents</td>
<td>• RR = 0.65 (95% CI = 0.54, 0.79)</td>
<td>• Somewhat generalizable</td>
</tr>
</tbody>
</table>

---

79 Symptoms of hemolytic disease include anemia, jaundice, body swelling, and difficulty breathing.
80 A diagnosis of placenta previa indicates that the placenta covers the opening to the vagina, which is associated with placental abruption, hemorrhage, intrauterine growth restriction.
81 All results for outcomes of prescribing progestational agents were reported in Dodd et al. (2006).
Table C-2-b. Studies that Examined the Effectiveness of Specific Interventions (Cont’d)

<table>
<thead>
<tr>
<th>Risk Factor/Intervention</th>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Reduction in risk of low birth weight</td>
<td>4 meta-analysis and 2 systematic reviews of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors progesteronal agents</td>
<td>RR = 0.63 (95% CI = 0.49, 0.81)</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td></td>
<td>Reduction in risk of intraventricular hemorrhage</td>
<td>4 meta-analysis and 2 systematic reviews of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors progesteronal agents</td>
<td>RR = 0.25 (95% CI = 0.08, 0.82)</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td>Corticosteroids to accelerate fetal lung maturation</td>
<td>Reduction in risk of neonatal mortality</td>
<td>1 meta-analysis and 1 systematic review of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors corticosteroids</td>
<td>RR = 0.69 (95% CI = 0.58, 0.81)²</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td></td>
<td>Reduction in risk of respiratory distress syndrome</td>
<td>1 meta-analysis and 1 systematic review of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors corticosteroids</td>
<td>RR = 0.66 (95% CI = 0.59, 0.73)</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td></td>
<td>Reduction in risk of cerebroventricular hemorrhage</td>
<td>1 meta-analysis and 1 systematic review of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors corticosteroids</td>
<td>RR = 0.54 (95% CI = 0.43, 0.69)</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td></td>
<td>Reduction in risk of necrotizing enterocolitis</td>
<td>1 meta-analysis of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors corticosteroids</td>
<td>RR = 0.46 (95% CI = 0.29, 0.74)</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td></td>
<td>Reduction in risk of intensive care admission</td>
<td>1 meta-analysis of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors corticosteroids</td>
<td>RR = 0.80 (95% CI = 0.65, 0.99)</td>
<td>Somewhat generalizable</td>
</tr>
</tbody>
</table>

² All results for outcomes of prescribing antenatal corticosteroids were reported in Roberts and Dalziel (2006).
Table C-2-b. Studies that Examined the Effectiveness of Specific Interventions (Cont’d)

<table>
<thead>
<tr>
<th>Risk Factor/Intervention</th>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnesium sulfate to prevent neurological impairment in fetuses of women at risk for preterm delivery</td>
<td>Reduction in risk of cerebral palsy</td>
<td>1 meta-analysis of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors magnesium sulfate</td>
<td>RR = 0.68 (95% CI = 0.54, 0.87)&lt;sup&gt;83&lt;/sup&gt;</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td></td>
<td>Reduction in risk of substantial gross motor dysfunction</td>
<td>1 meta-analysis of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors magnesium sulfate</td>
<td>RR = 0.61 (95% CI = 0.44, 0.85)</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td>External cephalic version&lt;sup&gt;84&lt;/sup&gt; for breech presentation at term</td>
<td>Reduction in risk of baby being born in breech position</td>
<td>1 meta-analysis and 1 systematic review of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors external cephalic version</td>
<td>RR = 0.59 to 1.0 if performed preterm&lt;sup&gt;85&lt;/sup&gt;</td>
<td>Somewhat generalizable</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RR = 0.42 (95% CI = 0.35, 0.50) if performed at term&lt;sup&gt;86&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Reduction in risk of cesarean section</td>
<td>1 meta-analysis and 1 systematic review of Level I-II studies</td>
<td>Statistically significant</td>
<td>Favors external cephalic version</td>
<td>RR = 0.52 (95% CI = 0.39, 0.71) if performed at term</td>
<td>Somewhat generalizable</td>
</tr>
</tbody>
</table>

<sup>83</sup> Both results for the outcomes of prescribing magnesium sulfate to prevent neurological impairment were reported in Doyle et al. (2009).

<sup>84</sup> Health professional applies pressure to the mother’s abdomen to encourage the fetus to turn from feet first to head first.

<sup>85</sup> Effect of external cephalic version performed preterm on risk of baby being born in breech position was reported in Hutton and Hofmeyr (2006).

<sup>86</sup> NCCWCH (2008) reported results of a previously published meta-analysis for both outcomes of external cephalic version performed at term for breech presentation.
### Table C-2-b. Studies that Examined the Effectiveness of Specific Interventions (Cont’d)

<table>
<thead>
<tr>
<th>Risk Factor/ Intervention</th>
<th>Outcome</th>
<th>Research Design</th>
<th>Statistical Significance</th>
<th>Direction of Effect</th>
<th>Size of Effect</th>
<th>Generalizability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ultrasound to determine gestational age</td>
<td>Reduction in odds of inducing labor</td>
<td>1 systematic review of Level I-II studies</td>
<td>• Statistically significant</td>
<td>• Favors routine ultrasound</td>
<td>• OR = 0.61 (95% CI = 0.52, 0.72)⁸⁷</td>
<td>• Somewhat generalizable</td>
</tr>
<tr>
<td>Membrane sweeping to induce labor in postterm pregnancies</td>
<td>Reduction in odds of inducing labor</td>
<td>2 systematic reviews of Level II studies</td>
<td>• Statistically significant</td>
<td>• Favors membrane sweeping</td>
<td>• RR = 0.59 (95% CI = 0.50, 0.70)⁸⁸</td>
<td>• Somewhat generalizable</td>
</tr>
<tr>
<td>Routine induction of labor with pharmaceuticals in postterm pregnancies</td>
<td>Reduction in odds of cesarean section</td>
<td>1 meta-analysis of Level I-II studies</td>
<td>• Statistically significant</td>
<td>• Favors induction of labor</td>
<td>• OR = 0.88 (95% CI = 0.78, 0.99)⁸⁹</td>
<td>• Somewhat generalizable</td>
</tr>
<tr>
<td></td>
<td>Reduction in odds of perinatal death</td>
<td>2 meta-analyses and 2 systematic reviews of Level I-II studies</td>
<td>• Statistically significant</td>
<td>• Favors induction of labor</td>
<td>• RR = 0.30 (95% CI = 0.09, 0.99)⁹⁰</td>
<td>• Somewhat generalizable</td>
</tr>
</tbody>
</table>

⁸⁷ NCCWCH (2008) reported results of a previously published meta-analysis.
⁸⁸ NCCWCH (2008) reported results from a previous meta-analysis.
⁸⁹ Sanchez-Ramos et al., 2003
⁹⁰ Gülmezoglu et al., 2006
Appendix D: Cost Impact Analysis: Data Sources, Caveats, and Assumptions

This appendix describes data sources, as well as general and mandate-specific caveats and assumptions used in conducting the cost impact analysis. For additional information on the cost model and underlying methodology, please refer to the CHBRP Web site at www.chbrp.org/costimpact.html.

The cost analysis in this report was prepared by the Cost Team, which consists of CHBRP task force members and staff, specifically from the University of California, Los Angeles, and Milliman Inc. (Milliman). Milliman is an actuarial firm, and it provides data and analyses per the provisions of CHBRP authorizing legislation.

Data Sources

In preparing cost estimates, the Cost Team relies on a variety of data sources as described below.

Private Health Insurance

1. The latest (2005) California Health Interview Survey (CHIS), which is utilized to estimate insurance coverage for California’s population and distribution by payer (i.e., employment-based, privately purchased, or publicly financed). The biannual CHIS is the largest state health survey conducted in the United States, collecting information from over 40,000 households. More information on CHIS is available at www.chis.ucla.edu/.

2. The latest (2007) California Employer Health Benefits Survey is utilized to estimate:
   - size of firm,
   - percentage of firms that are purchased/underwritten (versus self-insured),
   - premiums for plans regulated by the Department of Managed Health Care (DMHC) (primarily health maintenance organizations [HMOs]),
   - premiums for policies regulated by the California Department of Insurance (CDI) (primarily preferred provider organizations [PPOs]), and
   - premiums for high-deductible health plans (HDHPs) for the California population covered under employment-based health insurance.

   This annual survey is released by the California Health Care Foundation/National Opinion Research Center (CHCF/NORC) and is similar to the national employer survey released annually by the Kaiser Family Foundation and the Health Research and Educational Trust. Information on the CHCF/NORC data is available at www.chcf.org/topics/healthinsurance/index.cfm?itemID=133543.

3. Milliman data sources are relied on to estimate the premium impact of mandates. Milliman’s projections derive from the Milliman Health Cost Guidelines (HCGs). The HCGs are a health care pricing tool used by many of the major health plans in the United States. See www.milliman.com/expertise/healthcare/products-tools/milliman-care-guidelines/index.php. Most of the data sources underlying the HCGs are claims databases.
from commercial health insurance plans. The data are supplied by health insurance companies, Blues plans, HMOs, self-funded employers, and private data vendors. The data are mostly from loosely managed health care plans, generally those characterized as preferred provider plans or PPOs. The HCGs currently include claims drawn from plans covering 4.6 million members. In addition to the Milliman HCGs, CHBRP’s utilization and cost estimates draw on other data, including the following:

- The MEDSTAT MarketScan Database, which includes demographic information and claim detail data for approximately 13 million members of self-insured and insured group health plans.
- An annual survey of HMO and PPO pricing and claim experience. The most recent survey (2006 Group Health Insurance Survey) contains data from seven major California health plans regarding their 2005 experience.
- Ingenix MDR Charge Payment System, which includes information about professional fees paid for health care services, based upon approximately 800 million claims from commercial insurance companies, HMOs, and self-insured health plans.

These data are reviewed for applicability by an extended group of experts within Milliman but are not audited externally.

4. An annual survey by CHBRP of the seven largest providers of health insurance in California (Aetna, Blue Cross of California, Blue Shield of California, CIGNA, Health Net, Kaiser Foundation Health Plan, and PacifiCare) to obtain estimates of baseline enrollment by purchaser (i.e., large and small group and individual), type of plan (i.e., DMHC- or CDI-regulated), cost-sharing arrangements with enrollees, and average premiums. Enrollment in these seven firms represents 94.6% of privately insured enrollees in full-service health plans regulated by DMHC and 85.4% of those privately insured by comprehensive health insurance products regulated by CDI.

Public Health Insurance

5. Premiums and enrollment in DMHC- and CDI-regulated plans by self-insured status and firm size are obtained annually from CalPERS for active state and local government public employees and their family members who receive their benefits through CalPERS. Enrollment information is provided for fully funded, Knox-Keene licensed health care service plans covering non-Medicare beneficiaries, which is about 75% of CalPERS total enrollment. CalPERS self-funded plans—approximately 25% of enrollment—are not subject to state mandates. In addition, CHBRP obtains information on current scope of benefits from health plans’ evidence of coverage (EOCs) publicly available at www.calpers.ca.gov.

6. Enrollment in Medi-Cal Managed Care (Knox-Keene licensed plans regulated by DMHC) is estimated based on CHIS and data maintained by the Department of Health Care Services (DHCS). DHCS supplies CHBRP with the statewide average premiums negotiated for the Two-Plan Model, as well as generic contracts that summarize the current scope of benefits. CHBRP assesses enrollment information online at http://www.dhcs.ca.gov/dataandstats/statistics/Pages/BeneficiaryDataFiles.aspx.
7. Enrollment data for other public programs—Healthy Families, Access for Infants and Mothers (AIM), and the Major Risk Medical Insurance Program (MRMIP)—are estimated based on CHIS and data maintained by the Major Risk Medical Insurance Board (MRMIB). The basic minimum scope of benefits offered by participating plans under these programs must comply with all requirements of the Knox-Keene Act, and thus these plans are affected by changes in coverage for Knox-Keene licensed plans. CHBRP does not include enrollment in the Post-MRMIB Guaranteed-Issue Coverage Products as these individuals are already included in the enrollment for individual health insurance products offered by private carriers. Enrollment figures for AIM and MRMIP are included with enrollment for Medi-Cal in presentation of premium impacts. Enrollment information is obtained online at www.mrmib.ca.gov/. Average statewide premium information is provided to CHBRP by MRMIB staff.

General Caveats and Assumptions

The projected cost estimates are estimates of the costs that would result if a certain set of assumptions were exactly realized. Actual costs will differ from these estimates for a wide variety of reasons, including:

- Prevalence of mandated benefits before and after the mandate may be different from CHBRP assumptions.
- Utilization of mandated services before and after the mandate may be different from CHBRP assumptions.
- Random fluctuations in the utilization and cost of health care services may occur.

Additional assumptions that underlie the cost estimates presented in this report are:

- Cost impacts are shown only for people with insurance and only for the first year after enactment of the proposed mandate.
- The projections do not include people covered under self-insured employer plans because those plans are not subject to state-mandated minimum benefit requirements.
- Employers and employees would share proportionately (on a percentage basis) in premium rate increases resulting from the mandate. In other words, the distribution of premium paid by the subscriber (or employee) and the employer would be unaffected by the mandate.
- For state-sponsored programs for the uninsured, the state share would continue to be equal to the absolute dollar amount of funds dedicated to the program.
- When cost savings are estimated, they reflect savings realized for one year. Potential long-term cost savings or impacts are estimated if existing data and literature sources are available and provide adequate detail for estimating long-term impacts. For more information on CHBRP’s criteria for estimating long-term impacts please see www.chbrp.org/documents/longterm_impacts_final011007.pdf.
- Several recent studies have examined the effect of private insurance premium increases on the number of uninsured (Chernew et al., 2005; Hadley, 2006; Glied and Jack, 2003). Chernew et al., estimate that a 10% increase in private premiums results in a 0.74 to 0.92
percentage point decrease in the number of insured, while Hadley (2006) and Glied and Jack (2003) estimate that a 10% increase in private premiums produces a 0.88 and 0.84 percentage point decrease in the number of insured, respectively. The price elasticity of demand for insurance can be calculated from these studies in the following way. First, take the average percentage point decrease in the number of insured reported in these studies in response to a 1% increase in premiums (about -0.088), divided by the average percentage of insured individuals (about 80%), multiplied by 100%, i.e., \([\left[-0.088/80\right] \times 100\) = -0.11). This elasticity converts the percentage point decrease in the number of insured into a percentage decrease in the number of insured for every 1% increase in premiums. Because each of these studies reported results for the large-group, small-group, and individual insurance markets combined, CHBRP employs the simplifying assumption that the elasticity is the same across different types of markets. For more information on CHBRP’s criteria for estimating impacts on the uninsured please see www.chbrp.org/documents/uninsured_020707.pdf.

There are other variables that may affect costs, but which CHBRP did not consider in the cost projections presented in this report. Such variables include, but are not limited to:

- **Population shifts by type of health insurance coverage:** If a mandate increases health insurance costs, then some employer groups and individuals may elect to drop their coverage. Employers may also switch to self-funding to avoid having to comply with the mandate.

- **Changes in benefit plans:** To help offset the premium increase resulting from a mandate, health plan members may elect to increase their overall plan deductibles or copayments. Such changes would have a direct impact on the distribution of costs between the health plan and the insured person, and may also result in utilization reductions (i.e., high levels of patient cost sharing result in lower utilization of health care services). CHBRP did not include the effects of such potential benefit changes in its analysis.

- **Theoretically, individuals or employer groups who had previously foregone insurance may now elect to enroll in an insurance plan post-mandate because they perceive that it is to their economic benefit to do so.**

- **Health plans may react to the mandate by tightening their medical management of the mandated benefit.** This would tend to dampen the CHBRP cost estimates. The dampening would be more pronounced on the plan types that previously had the least effective medical management (i.e., PPO plans).

- **Variation in existing utilization and costs, and in the impact of the mandate, by geographic area and delivery system models:** Even within the plan types CHBRP modeled (HMO—including HMO and point of service [POS] plans—and non-HMO—including PPO and fee for service [FFS] policies), there are likely variations in utilization and costs by these plan types. Utilization also differs within California due to differences in the health status of the local commercial population, provider practice patterns, and the level of managed care available in each community. The average cost per service would also vary due to different underlying cost levels experienced by providers throughout California and the market dynamic in negotiations between health plans and providers. Both the baseline costs prior to the mandate and the estimated cost impact of the mandate...
Mandate-Specific Caveats and Assumptions

This section highlights specific caveats and assumptions that are not already discussed in the Utilization, Cost and Coverage section of the report.

- CHBRP estimates that in the absence of the mandate, there would be approximately 10,400 births in 2009 among women with no maternity benefits when they become pregnant. This estimate was based on birth rates in the privately-insured population drawing from Milliman claims data, combined with data on the number of enrollees by plan type, gender and age group provided to CHBRP by the insurance carriers.

- According to CHIS 2008, approximately 22% of women ages 18 to 45 with individual insurance are in households with incomes less than 200% of the FPL, making them eligible for Medi-Cal. Based on the previously described data from the Medical Expenditure Panel Survey (MEPS), CHBRP assumes that women will drop their private coverage entirely when they become eligible for Medi-Cal.

- Based on AIM data on dually enrolled women (having both private coverage and AIM) and CHBRP estimates of the number of women without maternity coverage at the time of pregnancy, CHBRP estimates that another 7% of privately insured women without maternity benefits would enroll in the AIM program.

- Thus, of the 10,400 women without maternity coverage at the time of pregnancy, about 2,300 may qualify for Medi-Cal and 700 may be covered by AIM. Based on the carrier survey, CHBRP estimates that about another 300 of these women would switch to plans with maternity benefits offered by their existing carrier prior to delivery.

- CHBRP estimates that the remaining 7,100 expected births among women who currently have no maternity benefits would not be covered by insurance pre-mandate. This is the population that would directly be impacted by AB 98 and be newly covered for maternity services post-mandate.

- CHBRP assumes that the women who already have maternity coverage pre-mandate are unlikely to get maternity coverage from Medi-Cal or AIM if they become pregnant. Women with incomes low enough to qualify for these public programs are unlikely to be willing to pay the higher premiums for policies with maternity coverage if lower-cost policies without maternity coverage are available.

- CHBRP assumes that post-mandate, men and women within the same age group would be equally distributed across policies that did and did not offer maternity coverage pre-mandate.

- Note that because the main CHBRP estimates (Table 5) assume that birth rates are the same for women who do and do not have maternity coverage pre-mandate, the post-mandate decrease in average premiums among women who already had maternity coverage (Table 6) is attributable entirely to the last two assumptions.

---

91 AIM enrollment data indicates that there are a proportion of AIM enrollees that currently have private insurance coverage and have maternity coverage. However, a proportion of that population is likely to be enrolled in group plans and it would be more likely that women in the individual market, who are in households that qualify for AIM, seek low-cost high deductible policies without maternity coverage.
Appendix E: Information Submitted by Outside Parties

In accordance with CHBRP policy to analyze information submitted by outside parties during the first two weeks of the CHBRP review, the following parties chose to submit information.

*No information was submitted directly by interested parties for this analysis.*

For information on the processes for submitting information to CHBRP for review and consideration please visit [www.chbrp.org/requests.html](http://www.chbrp.org/requests.html).
REFERENCES


Hadley J. Sicker and poorer—The consequences of being uninsured: A review of the research on the relationship between health insurance, medical care use, health, work and income. *Medical Care Research and Review*. 2003;60(3):3S-75S.


Hofmeyr GJ, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database of Systematic Reviews. 2006(3);CD001059.

Hutton EK, Hofmeyr GJ. External cephalic version for breech presentation before term. Cochrane Database of Systematic Reviews. 2006(1);CD000084.


Kasper JD, Giovannini TA, Hoffman C. Gaining and losing health insurance: Strengthening the evidence for effects on access to care and health outcomes. Medical Care Research and Review. 2000;57(3):298-318.


California Health Benefits Review Program Committees and Staff

A group of faculty and staff undertakes most of the analysis that informs reports by the California Health Benefits Review Program (CHBRP). The CHBRP Faculty Task Force comprises rotating representatives from six University of California (UC) campuses and three private universities in California. In addition to these representatives, there are other ongoing contributors to CHBRP from UC. This larger group provides advice to the CHBRP staff on the overall administration of the program and conducts much of the analysis. The CHBRP staff coordinates the efforts of the Faculty Task Force, works with Task Force members in preparing parts of the analysis, and coordinates all external communications, including those with the California Legislature. The level of involvement of members of the CHBRP Faculty Task Force and staff varies on each report, with individual participants more closely involved in the preparation of some reports and less involved in others.

As required by the CHBRP authorizing legislation, UC contracts with a certified actuary, Milliman Inc. (Milliman), to assist in assessing the financial impact of each benefit mandate bill. Milliman also helped with the initial development of CHBRP methods for assessing that impact.

The National Advisory Council provides expert reviews of draft analyses and offers general guidance on the program to CHBRP staff and the Faculty Task Force. CHBRP is grateful for the valuable assistance and thoughtful critiques provided by the members of the National Advisory Council. However, the Council does not necessarily approve or disapprove of or endorse this report. CHBRP assumes full responsibility for the report and the accuracy of its contents.

Faculty Task Force

Helen Halpin, PhD, *Vice Chair for Public Health Impacts*, University of California, Berkeley  
Gerald Kominski, PhD, *Vice Chair for Financial Impacts*, University of California, Los Angeles  
Ed Yelin, PhD, *Vice Chair for Medical Effectiveness*, University of California, San Francisco  
Wayne S. Dysinger, MD, MPH, Loma Linda University Medical Center  
Susan Ettner, PhD, University of California, Los Angeles  
Theodore Ganiats, MD, University of California, San Diego  
Sheldon Greenfield, MD, University of California, Irvine  
Kathleen Johnson, PharmD, MPH, PhD, University of Southern California  
Richard Kravitz, MD, University of California, Davis  
Thomas MaCurdy, PhD, Stanford University

Task Force Contributors

Wade Aubry, MD, University of California, San Francisco  
Nicole Bellows, MHSA, PhD, University of California, Berkeley  
Tanya G. K. Bentley, PhD, University of California, Los Angeles  
Meghan Cameron, MPH, University of California, Los Angeles  
Janet Coffman, MPP, PhD, University of California, San Francisco  
Mi-Kyung Hong, MPH, University of California, San Francisco  
Harold Luft, PhD, University of California, San Francisco  
Stephen McCurdy, MD, MPH, University of California, Davis  
Sara McMenamin, PhD, University of California, Berkeley  
Ying-Ying Meng, DrPH, University of California, Los Angeles  
Nadererh Pourat, PhD, University of California, Los Angeles  
Dominique Ritley, MPH, University of California, Davis
National Advisory Council

Lauren LeRoy, PhD, President and CEO, Grantmakers In Health, Washington, DC, Chair

John Bertko, FSA, MAAA, Vice President and Chief Actuary, Humana, Inc., Flagstaff, AZ
Troyen A. Brennan, MD, MPH, Executive Vice President, Chief Medical Officer, CVS Caremark, Woonsocket, RI
Deborah Chollet, PhD, Senior Fellow, Mathematica Policy Research, Washington, DC
Michael Connelly, JD, President and CEO, Catholic Healthcare Partners, Cincinnati, OH
Maureen Cotter, ASA, Founder and Owner, Maureen Cotter & Associates, Inc., Dearborn, MI
Susan Dentzer, Editor-in-Chief of Health Affairs, Washington, DC
Joseph Ditre, JD, Executive Director, Consumers for Affordable Health Care, Augusta, ME
Allen D. Feezor, Deputy Secretary for Health Services, North Carolina Department of Health and Human Services, Raleigh, NC
Charles “Chip” Kahn, MPH, President and CEO, Federation of American Hospitals, Washington, DC
Trudy Lieberman, Director, Health and Medicine Reporting Program, Graduate School of Journalism, City University of New York, New York City, NY
Marilyn Moon, PhD, Vice President and Director, Health Program, American Institutes for Research, Silver Spring, MD
Michael Pollard, JD, MPH, Consultant, Federal Policy and Regulation, Medco Health Solutions, Washington, DC
Karen Pollitz, MPP, Project Director, Georgetown University Health Policy Institute, Washington, DC
Christopher Queram, President and CEO, Wisconsin Collaborative for Healthcare Quality, Madison, WI
Richard Roberts, MD, JD, Professor of Family Medicine, University of Wisconsin-Madison, Madison, WI
Frank Samuel, LLB, Former Science and Technology Advisor, State of Ohio, Columbus, OH
Patricia Smith, President and CEO, Alliance of Community Health Plans, Washington, DC
Prentiss Taylor, MD, Regional Center Medical Director, Advocate Health Centers, Advocate Health Care, Chicago, IL

CHBRP Staff

Susan Philip, MPP, Director
John Lewis, MPA, Principal Analyst
Cynthia Robinson, MPP, Principal Analyst
Jackie Shelton, Program Assistant

California Health Benefits Review Program
1111 Franklin Street, 11th Floor
Oakland, CA 94607
Tel: 510-287-3876 Fax: 510-763-4253
info@chbrp.org www.chbrp.org

The California Health Benefits Review Program is administered by the Division of Health Sciences and Services at the University of California Office of the President, John D. Stobo, M.D., Senior Vice President – Health Sciences and Services.